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Abstract
Osteoarthritis (OA) is a multifactorial disease involving different tissues that form an articular
joint. As cartilage destruction is one of the major problems in OA, cartilage is the main target
for therapeutic approach. Growth factors have been proposed as a tool to stimulate chondrocytes
to repair the damaged cartilage matrix. One growth factor that has great potential in cartilage
repair is Transforming Growth Factor–β (TGF-β). In this review, we will focus on the role of TGF-β
in OA, potential therapeutic intervention in OA with TGF-β, application of the growth factor
TGF-β in cartilage repair and on the side-effects of TGF-β treatment that can occur.
Normal Osteoarthritis
Figure 1
Schematic representation of osteoarthritis in a synovial joint. The left part of the figure displays a normal joint whereas
in the right part of the figure, an osteoarthritic joint is depicted. The latter shows cartilage degradation and loss, synovial
fibrosis, osteophyte formation and a change in angle of the opposing bones.
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Osteoarthritis
OA is the most common form of arthritis, involving cartilage, synovium and bone. (Figure 1) The
main characteristics are cartilage damage, synovial fibrosis, sclerosis of the subchondral bone
and osteophyte formation at the joint margins (1). Clinically OA is characterized by joint pain,
tenderness, occasional effusions and eventually loss of joint function.
The etiology of OA is still unknown although certain risk factors have been established. Systemic
risk factors include genetic susceptibility, race, gender, age and nutrition. Besides systemic factors,
local joint environment is important. Previous damage to the joint as well as muscle weakness
and joint deformation that can cause alteration in joint loading heighten the risk of OA devel-
opment. In addition, elevated loading caused by obesity or injurious physical activity increases
the probability of OA development (2). Although several risk factors are known, in general the
cause of OA remains to be discovered. Traditionally OA was assessed with articular cartilage
damage as the main pathological event, but lately it has become clear that OA is a whole organ
disease in which the role of bone and synovial tissue have come up in relation to OA onset and
progression.
It is highly feasible that there is not one main initiating event of OA, but that several different
triggers can lead to a common disease pathway eventually leading to the same disease. Regardless
of the initiating trigger cartilage damage is the main event in OA. Cartilage has a very limited
intrinsic reparative capacity. As a consequence, cartilage damage results in progressive disease.
This makes it crucial to target cartilage damage at an early stage to prevent further progression.
Cartilage
Cartilage is non-vascular and nutrients are provided by the synovial fluid. On a weight base it is
mainly composed of collagens and proteoglycans. Collagens provide tensile strength and proteo-
glycans retain water molecules in the matrix. In humans, cartilage is composed of three zones:
superficial, middle and deep zone, each with a distinct composition. (Figure 2) The superficial
zone includes disc-shaped chondrocytes and the collagen fibers are aligned along the surface.
The middle zone has a higher proteoglycan content than the superficial zone, cells are more
spherical and the collagen fibers are orientated isotropically. The deep zone contains spherical
cells and collagens have a perpendicular orientation (1).
Cartilage damage in OA has several hallmarks. Initially, in contrast to what is expected during
damage, an increased synthesis of matrix molecules is observed. However, in time cartilage matrix
degradation exceeds matrix deposition resulting in net matrix loss. In early OA the cartilage surface
is still intact, but shows some focal oedema or even minor fibrillations. The chondrocytes then
start to proliferate and form cell clusters. In addition, chondrocyte hypertrophy can be observed.
muscle bone angulation
synovial lining
meniscus
cartilage
bone cartilage damage
osteophyte
fibrosis
cartilage loss
superficial zone
middle zone
deep zone
bone
Figure 2.
Graphical representation of human car-
tilage. Three distinct zones can be iden-
tified: a superficial zone containing
flattened, disc-shaped cells and collagen
fibers that are aligned almost horizon-
tally, a deep zone with more spherical
cells and isotropically orientated collagen
fibers and a deep zone with spherical
cells and peripendicular orientated
collagen fibers. The deep zone contains
more proteoglycans than the superficial
zone (indicated by the dark colour).
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Subsequently, the superficial zone shows fibrillations and loss of chondrocytes. The fibrillations
then progress into fissures that extend into the mid zone, followed by cartilage erosion, denu-
dation of bone and finally deformation (3).
Chondrocytes can be stimulated by catabolic cytokines to release cartilage degradation products,
ultimately leading to damage. In the 1980’s catabolin, now termed IL-1 (Interleukin-1), was
suggested to play a role in OA. Several groups described its capacity to induce metalloproteinases
in cartilage and its ability to stimulate chondrocytes to degrade both proteoglycan and collagen
(4;5). The exact nature of the major mediator of chondrocyte activation in in OA is not identified
yet, but Interleukin-1β (IL-1β) is considered to be a principle mediator of joint damage in OA (6).
It causes destruction of cartilage by increasing enzyme activity and inflammation while inhibiting
synthesis of enzyme-inhibitors (7). IL-1 and TNFα can stimulate chondrocytes to produce nitric
oxide (NO) (8), matrix metalloproteinases (MMPs) (9), aggrecanases (ADAMTS) (10) and suppress
the synthesis of aggrecan and collagen type II (11-15).
In normal cartilage there is constant degradation as well as synthesis of cartilage matrix molecules,
controlled by the chondrocytes. A high degradation rate does not necessarily implicate OA as
long as there is enough compensation by synthesis. Besides catabolic factors OA chondrocytes
also express anabolic factors, like insulin-like growth factor-1 (IGF-1) and TGF-β that stimulate ex-
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tracellular matrix (ECM) production (16-19). Increased synthetic activity in early OA has been
found accompanied with an up regulation of TGF-β expression (20;21). The initial increase in
production of ECM that is found in OA, shows that OA is more than just accelerated cartilage
degradation. Unfortunately the increased anabolic impulse is only a temporary state characteristic
for early OA and therefore cannot compensate for the overall catabolic insult to cartilage.
Chondrocytes in OA cartilage are different from normal cartilage in their cytokine and growth
factor expression patterns. For instance, chondrocytes from fibrillated OA cartilage display higher
levels of intracellular IL-1α and β and up regulated plasma membrane-bound IL-1RI, whereas the
decoy receptor IL-1RII is down regulated in OA chondrocytes (22;23). Thus, not only are there
higher levels of IL-1 present in OA joints, but OA-chondrocytes are also more sensitive to IL-1,
thereby increasing susceptibility to IL-1 induced cartilage damage. Not only fibrillated areas show
different expression patterns, also cartilage proximal to macroscopic OA lesions show a higher
binding of TNF-α and IL-1β compared to chondrocytes from morphologically normal cartilage
from the same joint (24). In normal cartilage chondrocytes are able to counteract IL-1 with TGF-β,
however, with age, this ability is lost (25).
Synovium
The role of the synovium in OA pathology is becoming more important than initially anticipated.
Commonly, hyperplasia and extensive fibrosis are observed in OA joints (26). In addition, inflam-
mation of the synovium, which was thought to be primarily a feature of rheumatoid arthritis,
has been found in OA. Mainly in early OA mononuclear infiltration, proinflammatory cytokines
and mediators of joint damage are found (27;28). There is a correlation between severity of
inflammation and severity of chondropathy, indicating that inflammation may be a predictive
factor in OA (29). In patients with early OA, the inflamed synovium releases catabolic cytokines
like IL-1α, IL-1β and TNF-α (28;29). The correlation of synovitis with chondropathy as well as the
release of catabolic cytokines suggests that synovitis contributes to the pathology seen in OA,
including cartilage damage.
Osteophytes
Besides cartilage damage and synovial fibrosis, OA often displays osteophytes. They develop at
the joint margins starting with chondrogenesis and eventually developing into bone. Osteophytes
are thought to result from mesenchymal cells in the periosteum activated to undergo chondro-
genesis by mechanical or biochemical stimuli. Gelse et al have divided osteophyte development
into four stages. Stage I starts with condensation of mesenchymal cells, collagen type II and
aggrecan expression. Stage II is characterized by addition of fibrous tissue and collagen type I
14
expression. In stage III a zonal organization is observed and chondrocyte hypertrophy is seen, in
which bone is formed leading to stage IV: the mature osteophyte with largely hyaline articular
cartilage and mainly collagen type II, aggrecan and collagen type XI expression (30). Whether
osteophyte formation is a good or a bad thing is still under discussion. Osteophytes are associated
with malalignment of the joint, limit movement and increased risk of structural progression of
OA (2). On the other hand, patients with varus limbs have larger medial osteophytes. Pottenger
et al demonstrated that removal of osteophytes in patients with osteoarthritis increased varus-
valgus motion, indicating that marginal osteophytes help to stabilize the joint (31). However,
development of osteophytes result in severe joint-deformation, sometimes joint fixation. Overall
it is unclear whether the osteophytes are formed as a compensatory mechanism for stabilization
or a side-effect of joint pathology. Another possibility is a combination of both options: they
start out as a means of stabilization but the process eventually runs amok.
TGF-β
The TGF-β family consists of over 35 members and includes, besides TGF-βs, activins and bone
morphogenetic proteins (BMPs) (32). They play vital roles in development and homeostasis of
various tissues. They regulate cell proliferation, differentiation, apoptosis and migration, as well
as control ECM synthesis and degradation. Moreover, these factors mediate cell and tissue res-
ponses to injury and modulate immune functions (33). In mammals there are three isotypes of
TGF-β, called β1, β2 and β3. All isoforms show a high degree of homology of 84-92%. The expression
of the three isoforms is differently regulated at the transcriptional level due to different promotor
sequences (34-36). TGF-β is secreted as an inactive complex comprised of a TGF-β dimer, its
propeptide LAP (Latency Associated Peptide) and LTBP (Latent TGF-β Binding Proteins) (37;38).
Therefore, the secreted TGF-β requires activation before it can bind to its receptor. Activated
TGF-β binds to the TGF-β type II receptor to form a complex that recruits the TGF-β type I
receptor, which is activated by phosphorylating the serine/threonine residues. There is an addi-
tional third TGF-β receptor, also known as betaglycan, which allows high-affinity binding of
mainly TGF-β 2 to the TGF-β receptor type II (33).
Upon receptor phosphorylation, R-Smads (Smad2 or 3) are presented to the receptor by SARA
(Smad-Anchored for Receptor Activation) and phosphorylated. Then the phosphorylated
R-Smads form a complex with the Co-Smad (Smad4), and translocate to the nucleus where they
can act either as, or in orchestrate with, transcription factors. (33;39;40) I-Smads (Smad6 and 7)
can inhibit TGF-β signaling by interfering with R-Smad phosphorylation, thereby functioning as
a negative feedback system. (Figure 3)
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Figure 3
Simplified representation of the TGF-β signaling cascade. TGF-β is secreted in a latent form attached to LAP. When released
from LAP, TGF-β can bind to the type II receptor. The type I receptor is then recruited and phosphorylated upon binding.
Thereafter Smad2 or 3 can bind to the complex and is phosphorylated as well. Smad2/3P then binds to Co-Smad, Smad4 and
shuttles to the nucleaus where it can induce transcriptional activation. Smad2 or 3 phosphorylation can be
inhibited by inhibitory Smads: Smad6 or 7, thereby preventing signaling.
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TGF-β can also activate Erk, JNK and p38MAPK pathways (41). Cross talk between the Smad-
pathway and other TGF-β signaling pathways have also been reported (40;41). They can interact
by Smad phosphorylation by ERK or JNK, by controlling Smad7 expression and by nuclear inter-
action between Smad complexes and MAPK-activated transcription factors. The latter depends
on the structure of the target promotors (42). MAPK activation is not TGF-β signaling specific and
can be triggered by various extracellular stimuli, such as IL-1 and TNF-α. Therefore, the Smad-
MAPK interactions are not solely the result of multifaceted TGF-β signaling downstream of the
receptors, but are a result of interacting cytokines that together modulate the Smad/MAPK
signals (42). The mechanism of alternative TGF-β signaling pathways and their biological
consequences are poorly understood since there are many factors that can activate the MAPK
pathways at various levels, most of which are able to interact.
Genetic aspects of osteoarthritis and TGF-β
Family studies can indicate a relation between genetically determined factors and the develop-
ment of osteoarthritis. In humans a relationship between TGF-β and osteoarthritis symptoms
has been shown in Japanese women. A polymorphism of TGF-β1 on position 29 (T to C, amino
acid 10) positioned in the signal sequence region of TGF-β1 is related to an elevated prevalence
of spinal osteophytosis and ossification of the posterior longitudinal ligament (43;44). This TGF-β
polymorphism was also associated with decreased Bone Mineral Density (BMD) and increased
fracture risk in postemenopausal Chinese women (45). The same polymorphism appears to
protect Japanese women from osteoporosis (44;46). However, in a sample of post-menopausal
German women a relationship between increased BMD and the C29 polymorphism was not
found (47).
Other studies showing a relationship between TGF-β1 activity and bone mass are reports of the
rare autosomal dominant disorder, Camurati-Engelmann disease. The long bones of patients
with Camurati-Engelmann disease show osteosclerosis. The osteosclerosis is associated with a
number of mutations in the TGF-β1 gene. All of these observed mutations result in an elevated
activity of TGF-β1 in these patients (48;49). Since an inverse relationship between osteoporosis
and osteoarthritis has been suggested in the literature (50;51) elevated bone mass due to increased
TGF-β activity might be related to the development of osteoarthritis.
Asporin, which is abundantly expressed in cartilage of OA patients, inhibits TGF-β mediated
expression of cartilage matrix genes like collagen type II and aggrecan and reduces accumulation
of proteoglycans (52). Kizawa et al have found a asporin polymorphism that showed a signifi-
cantly higher frequency in OA (52). They found that this particular (D-14) polymorphism has a
stronger inhibitory effect on TGF-β than the common D-13 repeat. This indicates that in OA there
is a higher frequency D-14, resulting in strong TGF-β inhibition, which can result in reduction of
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ECM of cartilage. This suggests that reduced TGF-β action might be correlated with increased
susceptibility to OA. However, the study performed by Kizawa et al included only Japanese
patients. When repeated in a Spanish Caucasian population, by Rodriguez-Lopez et al, the higher
susceptibility to OA in patients with the D-14 polymorphism was no longer found (53). In UK
Caucasians a trend was seen towards a higher degree of D-14 polymorphism in OA patients, but
this was only significant in a specific subset of patients (54). However, in a different ethnic group,
Han Chinese, the OA susceptibility was found again (55). The susceptibility was not limited to OA,
Torres et al also found that patients with rheumatoid arthritis (RA) that carried the D-14 poly-
morphism more frequently produced rheumatoid factor and had an earlier onset of the disease.
Although the repeat might not be the major influence in RA, it was concluded to influence the
outcome of the disease (56). The studies mentioned above show that TGF-β inhibition can aggra-
vate OA and RA.
Mice deficient for TGF-β1 show 50% embryonic lethality and animals that are born alive develop
severe inflammatory disorders and die within 1 month (57;58). Mice with a knockout gene for
TGF-β2 and TGF-β3 show numerous developmental defects and perinatal death. Mice lacking
TGF-β2 have numerous structural defects in the skeletal elements and show joint laxity (59). This
indicates that TGF-β2 is involved in skeletal development. Animals with a non-functional gene
for the type I receptors ALK1 or ALK5 or the Smad proteins 2 and 4 are embryonic lethal (60-63).
Null mice for Smad3 developed degenerative joint disease resembling human osteoarthritis, as
characterized by progressive loss of articular cartilage, formation of osteophytes and increased
expression of type X collagen. These data indicate that Smad3 signaling is essential for repressing
chondrocyte terminal differentiation, a hallmark of human OA (64). This observation is supported
by studies in mice that overexpress a dominant negative TGF-β type II receptor in skeletal tissues
(65). These mice developed progressive skeletal degeneration that strongly resembles human
osteoarthritis.
In addition, mice that lack the latent TGF-β binding protein (LTBP-3) also show altered chondrocyte
differentiation and early osteoarthritis development (64;66;67). These observations show that
interference with TGF-β signaling in chondrocytes results in abnormalities in chondrocyte diffe-
rentiation and the development of osteoarthritis.
TGF-β and cartilage
Lack of TGF-β or an abnormality in TGF-β signaling apparently results in a cartilage phenotype
that resembles cartilage pathology in OA. TGF-β has been shown to be very beneficial for carti-
lage as it stimulates chondrocytes in vitro to elevate proteoglycan and collagen type II production
(16-18;64;68). Also in vivo TGF-β proved to have beneficial effects on cartilage such as stimulation
of proteoglycan synthesis in cartilage (69).
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Not only does TGF-β stimulate ECM production, it also counteracts the main catabolic players in
OA. Our group has shown that TGF-β counteracts 38% of the genes that are regulated by IL-1.
For example, TGF-β counteracts IL-1 up regulation of MMP-13 and –14, which have been found
important mediators of cartilage damage. In addition, IL-1 down regulation of collagen and
ECM-related genes are counteracted by TGF-β (10). Hui et al show that TNF-α promotes MMP
dependent collagen breakdown, which can be prevented by TGF-β1 in bovine cartilage explant
cultures. In addition, TGF-β1 reduced expression and secretion of collagenases and induced TIMP
production (70). In addition, IL-1β has been shown to inhibit proteoglycan biosynthesis in a dose-
dependent manner in porcine articular cartilage and increase the rate of degradation in
proteoglycans. TGF-β was able to recover the IL-1 induced proteoglycan reduction (71;72). TGF-β
is not only able to counteract the effects of IL-1, but can also reduce IL-1 signaling by down
regulation of its receptors and increasing the expression of the decoy receptor IL-1Ra, thereby
counteracting at several levels (73-77).
Overall, IL-1 and TNF-α produce matrix proteases and suppress the synthesis of collagen and
proteoglycan. TGF-β is able to counteract the net effect of catabolic cytokines by stimulating
the synthesis of matrix components, of protease inhibitors and down regulating the expression
of cytokine receptors and cartilage degrading enzymes (78). These studies show that TGF-β can
potently counteract catabolic effects in cartilage and stimulate ECM production and can be used
as a potential treatment for cartilage destruction in OA.
TGF-β supplementation
Lack of TGF-β signaling results in susceptibility to cartilage damage, therefore TGF-β supplemen-
tation should aid in cartilage maintenance or repair. For years many researchers have focused
on this TGF-β quality. We have shown that multiple injections of TGF-β induce strong and long-
lasting stimulation of proteoglycan synthesis and increase the GAG content in patellar cartilage
in mice under arthritic conditions (69;74). TGF-β stimulation of proteoglycans is a long-lasting
effect. A single injection of 200 ng TGF-β into a murine knee joint stimulated proteoglycan
synthesis for 3 weeks and elevated proteoglycan content for 2 weeks. Triple injections prolonged
the increase in proteoglycan content for 3 weeks (79). In a survey, Grimaud et al concluded that
TGF-β expression and the use of gene transfer might provide an approach for treatment of OA
lesions in cartilage (80).
Unfortunately, the effects of injecting TGF-β into a joint are not limited to cartilage. Chondrocytes
are embedded in the cartilage without direct contact with other cells. The non-vascular properties
make chondrocytes dependent on their direct environment for signals. This makes it very hard
to target cartilage without involvement of other tissues. This implies that TGF-β supplementation
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in a joint also results in responses of other tissues that are in contact with the synovial fluid.
TGF-β is implicated in fibrosis in many organs like eye, lung, heart, liver, kidney, pancreas and
skin (81). The synovial tissue in articular joints is susceptible to TGF-β induced fibroplasias and
fibrosis. As a consequence multiple injections of TGF-β induce synovial fibrosis in murine knee
joints (69). In contrast to the lack of sufficient TGF-β expression in cartilage in progressive OA,
it is abundantly present in synovial tissue. Therefore, TGF-β might also be involved in the synovial
hyperplasia that is observed in OA. Besides being a potent inducer of synovial fibrosis, TGF-β is
also able to induce osteophytes similar to those found in OA (69;82). TGF-β expression as well
as active TGF-β signaling is found highly expressed in osteophytes in OA, suggesting a role for
TGF-β in OA-induced osteophytes. Because of the role of TGF-β in fibrosis and osteophyte
formation, the use of TGF-β as a therapeutic agent for cartilage repair should be evaluated
thoroughly as side effects will likely occur or aggravate already existing pathology if TGF-β
exposure is not confined to the articular cartilage.
TGF-β inhibition
The experiments discussed above are all circumstantial evidence of TGF-β involvement in the
OA-changes like fibrosis and osteophyte formation. The only real proof of a protective role for
TGF-β in OA and a role in induction of fibrosis and osteophytes can be obtained by blocking
endogenous TGF-β during OA to see whether cartilage damage is aggravated by the lack of
TGF-β and if fibrosis and osteophyte formation can be prevented.
Our group has shown that inhibition of TGF-β with a soluble receptor enhanced proteoglycan
loss and reduced cartilage thickness (83). Serra et al overexpressed a dominant negative TGF-β
receptor resulting in terminal chondrocyte differentiation and OA (65). This proves that endo-
genous TGF-β is important for maintaining cartilage integrity.
Inhibition of endogenous TGF-β in a murine model for OA revealed that indeed TGF-β plays a
role in OA-induced synovial fibrosis and osteophyte formation as both were reduced by blocking
TGF-β by adenoviral overexpression of different TGF-β inhibitors: Smad6, Smad7 or LAP (84). As
TGF-β seems to be important for cartilage, blocking of TGF-β has to be compartementalized to
the locations where it is needed, excluding sites where side-effects occur. Although utilization
of Smad6, -7 and LAP works in mice, for human transfection of the synovial lining would mean
introducing modifications that are not directly usable as a treatment. Therefore, it would be
very beneficial if we could find secondary mediators for the unwanted side-effects of TGF-β.
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Potential secondary pathways
A potential solution to abolishing TGF-β side-effects is application of local inhibitors like Smad7.
But this is not the only possibility to overcome the problem of having to compartmentalize TGF-β
effects in a single tissue of the joint. Another potentially fruitful approach of abolishing TGF-β
side-effects, while preserving the beneficial effects of TGF-β, is to evaluate the secondary
pathways that might be involved in the side-effects. To enhance cartilage ECM formation with
TGF-β while preventing synovial fibrosis, the putative TGF-β-induced secondary mediator that
induces fibrosis should be identified. Connective Tissue Growth Factor (CTGF/CCN2) is a good
candidate as it is directly induced by TGF-β through a TGF-β response element in the CTGF-
promotor. Moreover, CTGF is an established player in various fibrotic disorders including
nephropathy, Crohn’s disease, liver fibrosis, scleroderma, systemic sclerosis, lung fibrosis and
heart fibrosis (85-92). Wahab et al established that CTGF augments TGF-β signaling by reducing
the negative feedback through Smad7 and enhancing Smad2 phosphorylation (93). These data
suggest that CTGF might be a candidate secondary mediator of TGF-β induced synovial fibrosis
and therefore a potential therapeutic target.
In addition to fibrosis, TGF-β induces osteophytes. Secondary mediators might play essential
roles in TGF-β induced osteophyte formation. A potent inducer of osteophytes is Bone Morpho-
genetic Protein 2 (BMP-2). BMP belongs to the TGF-β superfamily and shares some of the TGF-β
functions. BMP has been shown to compensate for TGF-β in Smad3 deficiency. Chondrocytes
that are Smad3 deficient, therefore partially lacking TGF-β signaling, have a high up regulation
of BMP-signaling indicating a compensatory mechanism (94). Therefore, it is possible that BMPs
share some of the TGF-β functions in osteophyte formation, making it a potential candidate for
mediating TGF-β induced osteophyte formation.
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Outline of the thesis
Osteoarthritis is a common joint disease affecting mainly the elderly in the population, but can
also be a result of joint trauma. Although risk factors have been established, the actual cause of
OA is still unknown. OA is characterized by cartilage damage, synovial fibrosis and osteophyte
formation.
TGF-β is a growth factor that is an important inducer of cartilage extracellular matrix production
and is therefore suggested as a potential tool to enhance cartilage repair upon damage. Defi-
ciencies in the TGF-β signal lead to OA-like phenotypes. (64-67) Thus TGF-β is potentially not
only a reparative factor, but might also be important for cartilage integrity. This led to the
hypothesis that during OA TGF-β function might be compromised. Therefore, we investigated
whether the presence and function of TGF-β was deficient during OA. We studied expression of
TGF-β and the TGF-β signaling molecules in cartilage during experimental OA (Chapter 2). We
found that indeed during OA there is a decrease in expression of the TGF-β isoforms 2 and 3
(not 1), the TGF-β receptors and the phosphorylated form of Smad2. The reduction in TGF-β was
not a common reduction of growth factor expression as we found elevated expression of BMP-2.
In addition, the reduction of the TGF-β signal was confined to the cartilage as the osteophytes
that had developed during OA showed very high expression of TGF-β and Smad2P. The decreased
TGF-β signaling was more pronounced with more progressive OA, suggesting an association
between decreased TGF-β signaling and cartilage damage.
The potential importance of TGF-β for cartilage maintenance or repair is its strong ability to
counteract the major cartilage degrader IL-1 (95). However, with age, which is a risk factor for
OA, this counteracting ability is lost (96). This could be due to an age related reduction in TGF-β
signaling or to an age related altered response to IL-1. Therefore, we evaluated the expression
of various TGF-β signaling molecules in aged mice versus young mice as well as the potential
influence of IL-1 on their expression (Chapter 3). We found that with age, similar to our findings
in OA, the TGF-β signaling cascade was down regulated. As age is a risk factor for OA, this might
be preceding the damage that we see during OA. To investigate what the implications were of
a reduced TGF-β signal, we blocked endogenous TGF-β while inflicting cartilage damage with
IL-1 (Chapter 3). Lack of TGF-β resulted in a more severe damage in response to IL-1. This showed
that TGF-β presence is important for preserving cartilage.
Our data showed that lack of TGF-β in cartilage induced a condition that favors damage, but
does supplementation of TGF-β compensate for this flaw? We set out to investigate whether
TGF-β supplementation had an anabolic effect on damaged cartilage (Chapter 4). But since we
know that TGF-β supplementation results in side-effects like synovial fibrosis, we investigated
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whether it was possible to compartmentalize the positive and negative effects by locally blocking
TGF-β signaling in the synovium (Chapter 4). We found that indeed it was possible to stimulate
cartilage repair with TGF-β while preventing synovial fibrosis by local inhibition of TGF-β in
synovial tissue with Smad7. Moreover, we transferred this system to our murine models for OA
and found that in this setting we were also able to boost proteoglycan synthesis in OA cartilage,
while preventing synovial fibrosis (Chapter 4).
Although this was a adequate proof of principle, it is not directly applicable in the clinic. It would
be very beneficial if we could identify specific secondary mediators for the negative side effects
induced by TGF-β. As CTGF is strongly induced by TGF-β and seen as a potential target for fibrosis,
we evaluated its effects in murine knee joints (Chapter 5). This showed that CTGF was able to
induce fibrosis, but only transient. In addition, CTGF induced cartilage damage, which was in
contrast to findings in literature. This might be due to the indirect effects via the CTGF-induced
fibrosis. As CTGF-induced fibrosis was only transient in contrast to the more persistent fibrosis
that was induced by TGF-β, we wanted to find out what caused the differences in fibrosis
induced by either TGF-β or CTGF (Chapter 6). We found that TGF-β induced expression of lysyl
hydroxylase 2 splice variant B (LH2B). Expression of LH2B will result in collagen cross-linking
which is harder to degrade than LH2A, thereby contributing to persistence of fibrosis (97).
In addition, TGF-β induced high levels of TIMP1, which has been found associated with matrix
accumulation in fibrosis (98-101).
CTGF is strongly up regulated by TGF-β, but despite the fact that TGF-β is drastically
reduced in OA cartilage, CTGF is one of the most highly up regulated factors in OA cartilage.
Besides CTGF we found that BMP2 was expressed strongly in areas surrounding OA lesions,
whereas in normal cartilage it was hardly present (Chapter 2). The functional consequence of its
presence during OA was unknown. Hence, we investigated what the role for BMP-2 was in
cartilage (Chapter 7). We found that BMP-2 induced both anabolic and catabolic effects, but
overall led to an increase in proteoglycan content. This suggested that BMP-2 might be important
for cartilage repair. Therefore we investigated the role of BMP during damage repair (Chapter 7).
Upon IL-1 induced cartilage damage BMP-2 boosted the proteoglycan synthesis, whereas blocking
BMP during this process aggravated cartilage damage. This implies that the presence of BMP
during OA is functional and probably serves as a cartilage-remodeling factor.
BMP-2 itself is able to induce de novo osteophyte formation. Therefore BMP-2 could serve as a
secondary mediator of TGF-β induced osteophyte formation. To investigate whether it played a
role during TGF-β-induced osteophyte formation or during OA-induced osteophyte formation
we compared the patterns of osteophytes in all these conditions (Chapter 8). We found that
BMP-2-induced osteophytes initially developed at different locations when compared to the
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osteophytes induced by TGF-β and experimental OA. TGF-β induced osteophytes developed at
similar locations as during OA, indicating that perhaps TGF-β is more important during OA-
induced osteophyte development when compared to BMP-2. By blocking BMP during the onset
of TGF-β-induced or OA-induced osteophyte formation we could show that BMP is not important
for the onset of osteophyte formation in these processes.
Overall, we show that TGF-β is an important factor to maintain cartilage integrity, but also to
repair cartilage. The unwanted TGF-β induced fibrosis can be abrogated by local inhibition of
TGF-β activity. The secondary mediators that we identified did not dominate the side-effects
enough to serve as targets for therapeutic intervention. However, they have contributed to
better understanding of the processes underlying TGF-β side-effects.
Figure 4
Graphical representation of the general scope of this thesis. The arrows show the chapters in which each aspect is
discussed.
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Chapter 2
Expression of TGF-β and the TGF-β
signaling molecule Smad-2P in spontaneous
and instability-induced osteoarthritis. Role
in cartilage degradation, chondrogenesis
and osteophyte formation.
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Introduction
Osteoarthritis (OA) is a degenerative joint disease with a high prevalence in the elderly population.
Although OA is a complex disease, the primary feature in all OA affected joints is focal cartilage
destruction. This can vary from cartilage fibrillation, to fissures, or total loss of cartilage exposing
the bone underneath. Within certain limits, chondrocytes are capable of repairing cartilage (1).
In contrast to degradation, frequently excess tissue production is observed elsewhere in the
joint. This might be a remodeling process initiated as a response to injury, resulting in osteo-
phytes at the joint margins. TGF-β is involved in protection against cartilage destruction and in
formation of new cartilage as can be found during osteophyte formation (2-6). TGF-β stimulates
production of ECM components by chondrocytes and has the ability to counteract catabolic
cytokines like Interleukin-1 (IL-1) (5,7-10). Blocking TGF-β during papain-induced experimental
OA enhances articular cartilage proteoglycan loss (4). TGF-β injection or adenoviral overexpression
induces osteophyte formation in naive knee joints (3,5,11), while inhibition of endogenous TGF-β
prevented osteophyte formation during experimental OA (4). In addition, blocking osteophyte
formation in the rat anterior cruciate ligament transsection model with alendronate was asso-
ciated with a reduced release of active TGF-β (12). TGF-β expression has also been found in
human femoral head osteophytes, but in very variable amounts (13). These studies indicate a
role for TGF-β in protection against cartilage destruction and in osteophyte formation.
In OA joints both cartilage degradation and cartilage formation occur simultaneously in the
same joint. To elucidate the role for TGF-β in these processes during OA, we investigated TGF-β
expression and signaling during cartilage degradation and osteophyte development in two
murine models of OA with a different etiology: a spontaneous OA model and an instability-
induced OA model. We examined the expression of the most abundant TGF-β isoform, TGF-β3
(4) and the expression of its downstream signaling molecule Smad2 in its phosphorylated state,
indicating active TGF-β signaling.
Materials and Methods
Animals
Male Balb/C mice aged 10 weeks (n=12) and male STR/ort mice aged 8 weeks (n=6), 6 months
(n=5) and 1 year old (n=6) were used. Mice were kept in filter top cages with woodchip bedding
under standard pathogen free conditions. They were fed standard diet and tap water ad libitum.
This study has been approved by the Local Animal Experimentation Committee, Nijmegen, The
Netherlands.
Abstract
Objective
The primary feature of OA is cartilage loss. In addition, osteophytes can frequently be observed.
Transforming Growth Factor-β (TGF-β) has been suggested to be involved both in protection
against cartilage damage and new cartilage formation as seen in osteophytes. We studied TGF-β
and TGF-β signaling in experimental OA to gain insight in the role of TGF-β in cartilage
degradation and osteophyte formation during OA progression.
Methods
Histological sections of murine knee joints were stained immunohistochemically for TGF-β3 and
phosphorylated Smad2 (Smad-2P). Expression patterns were studied in two murine OA models,
representing spontaneous (STR/ort model) and instability-associated OA (collagenase-induced
instability model).
Results
TGF-β3 and Smad-2P staining was increasingly reduced in cartilage during OA progression in
both models. Severely damaged cartilage was negative for TGF-β3. In contrast, Bone Morpho-
genetic Protein-2 (BMP-2) expression was increased. In chondrocyte clusters, preceding osteophyte
formation, TGF-β3 and Smad-2P were highly expressed. In early osteophytes, TGF-β3 was found
in the outer fibrous layer, the peripheral chondroblasts and in the core. Late osteophytes only
expressed TGF-β3 in the fibrous layer. Smad-2P was found throughout the entire osteophyte in
all stages. In the late stage osteophytes, BMP-2 was highly expressed.
Conclusion
Our data show that lack of TGF-β3 is associated with cartilage damage suggesting loss of the pro-
tective effect of TGF-β3 during OA progression. Additionally, our results indicate that TGF-β3 is
involved in early osteophyte development, whereas BMP might be involved in late osteophyte
development.
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were visualized using DAB reagent, counterstained with haematoxylin, dehydrated and mounted
with Permount.
Scores
A blinded observer scored sections stained for either TGF-β3 or Smad-2P. The number of TGF-β3
and Smad-2P immunopositive cells and staining intensity in immunohistochemically stained
sections were examined in tibial cartilage, femoral cartilage and osteophytes developing on the
femur above the collateral ligament. For the spontaneous model both left and right knee joints
were included in the study. The number of cells staining positive for either TGF-β3 or Smad-2P
was determined visually and stratified into 5 categories: Negative (-), meaning no cells staining
positive; weakly positive (+/-), meaning a low number of cells staining positive; positive (+),
meaning less than 50% of the cells staining positive; highly positive, meaning between more
than 50% and close to all cells staining positive (++), or all cells stained positive with high staining
intensity (+++). We scored 4 different cartilage surfaces: medial femoral cartilage, lateral femoral
cartilage, medial tibial cartilage and the lateral tibial cartilage. Per joint at least 4 sections were
examined and averaged. The mean of all the averages determined the outcome of the score.
Osteophytes were scored in a similar manner, estimating the amount of cells expressing TGF β3
or Smad-2P, on the femur just below the collateral ligament on the medial side of the joint.
To validate our visual scores, we also determined the number of cells staining positive for Smad-2P
on the medial tibial cartilage with a computerized imaging system (Qwin, Leica Imaging Systems
Ltd.). A blinded observer selected the cartilage surface in at least 3 sections per knee joint. The
computerized imaging system subsequently determined the amount of positive cells in
the selected area. The obtained values were averaged per knee joint.
Statistical analysis
Statistical significance was calculated with a Mann-Whitney test. Values were considered
significant if the P-value was less than 0.05.
Results
Cartilage: instability model
Healthy cartilage was smooth and stained evenly red with Safranin O. Almost every chondrocyte
appeared to be TGF-β3 positive. When OA is induced by injection of collagenase, the joint
becomes unstable eventually resulting in cartilage damage. The cartilage of the OA joint showed
focal depletion of proteoglycans, indicated by reduced red staining in the non-calcified cartilage.
Experimental induction of osteoarthritis in BalbC mice
Six μl solution of bacterial collagenase (5 u/mg, 5 units/knee) was injected intra-articularly into
the right knee joint as previously described (14). Mice were sacrificed 1, 3, 7 and 14 days after col-
lagenase injection. Knee joints were dissected for histology. Non-injected mice served as controls.
The injection of bacterial collagenase leads to joint laxity and osteoarthritic lesions resembling
those occurring naturally in old mice: cartilage destruction, synovial fibrosis and osteophytes
(14). This model might be seen as an equivalent to human secondary OA resulting from joint
instability.
STR/ort mice
The STR/ort mice of ages 8 weeks, 6 months and 1 year old were sacrificed to compare pathology.
STR/ort mice are genetically predisposed to spontaneously develop OA-like lesions. Eighty per-
cent of the male STR/ort mice show degenerative cartilage lesions by 6 months of age, starting
with lesions at the interface of the cruciate ligament and the medial tibial plateau. The lesions
range from mild erosion of the cartilage surface to loss of cartilage exposing the subchondral
bone. In addition, the mice develop osteophytes at the joint margins. The histological lesions
seen in this model resemble those seen in humans (15-17). Therefore, the STR/ort mice might be
seen as a model for human primary OA.
Histology
Knee joints of mice were dissected and fixed in phosphate buffered formalin for 7 days. There-
after, they were decalcified in 10% formic acid for 1 week. Knee joints were dehydrated with an
automated tissue processing apparatus (VIP) and embedded in paraffin. Frontal whole sections
of 7 μm were made. Sections were stained with Safranin O and Fast Green.
Immunohistochemistry
Sections were deparaffinized and washed with PBS. Sections were incubated in citrate buffer
(0.1 M sodium citrate + 0.1 M citric acid) for two hours for antigen unmasking. Endogenous
peroxidase was blocked with 1% hydrogen peroxide in methanol for 30 minutes. Sections were
blocked with 5% normal serum of the species in which the secondary antibody was produced.
Specific primary antibodies against TGF-β3 (2 μg/ml) (Santa Cruz Biotechnology Inc.), Smad-2P
(1:100) (Cell Signaling Technology) or BMP-2 (2 μg/ml) (Santa Cruz Biotechnology Inc.) were incu-
bated overnight at 4oC. After extensive washing with PBS, the appropriate biotin labeled secondary
antibody was used (DAKO) for 30 minutes at room temperature followed by a biotin-streptavidin
detection system according to manufacturers protocol (Vector Laboratories). Bound complexes
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In naive joints, 80% of cartilage cells were immunopositive for Smad-2P on the lateral side of the
joint. On the medial side this was only 50%. The slightly proteoglycan depleted cartilage of day
3 already showed a reduced amount of Smad-2P expressing cells. On day 7, changes in Smad-2P
were minimal. By day 14, the depleted cartilage was almost completely negative for
Smad-2P on the medial side. The few cells that remained positive were predominantly located
in the lateral cartilage and stained very intense (Table 1, Figure 1A).
Figure 1B
Cartilage: spontaneous model. Original magnification: 200x. Sections were stained with Safranin O and Fast Green (A, B,
C), sections were stained immunohistochemically for TGF-β3 (D, E, F), SMAD-2P (G, H, I) and BMP-2 (J, K, L). In these sections
the cartilage is clearly degrading in time. After 1 year (C, F, I, L) there is hardly any cartilage left. At 8 weeks there is still
TGF-β3 and SMAD-2P staining (D, G), but at 6 months and 1 year the remaining cartilage is negative for both TGF-β3 and
SMAD-2P (E, F, H, I) BMP-2 expression is highly expressed in severely damaged cartilage. (L) For Safranin O and Fast Green
stained sections black arrows indicate loss of red staining in A and B. In immunohistochemically stained sections the black
arrows indicate positive staining. Asterisks indicate the location where cartilage is lost.
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This was first observed on day 3 on the medial side of the joint, accompanied with an overall
decrease in TGF-β3 expression. The amount of proteoglycans in cartilage diminished in time,
with pronounced reduction on day 14, mainly on the medial side of the joint (Figure 1A). Only
10% of the cells in the medial cartilage expressed TGF-β3, located near the surface of the carti-
lage. Proteoglycan loss and reduction in TGF-β3 expression on the lateral side of the joint were
only observed on day 14 and were less pronounced (Table 1).
Figure 1A
Cartilage: instability model. Original magnification: 200x. Sections were stained with Safranin O and Fast Green (A, B, C, D),
sections were stained immunohistochemically for TGF-β3 (E, F, G, H), SMAD-2P (I, J, K, L) and BMP-2 (M, N, O, P) In Safranin
O stained sections arrows indicate lighter stained cartilage representing proteoglycan depletion. TGF-β3 and SMAD-2P stained
sections show a clear reduction in immunopositive cells in time. BMP-2 staining increases in time. For Safranin O and Fast
Green stained sections arrows indicate loss of red staining in B, C and D. In immunohistochemically stained sections the
black arrows indicate positive staining and the open arrows indicate loss of staining.
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To validate our arbitrary scoring system we additionally scored Smad-2P positive cells with a
computerized imaging system. This showed that after induction of instability there were signi-
ficantly less cells staining positive for Smad-2P. Additionally, it showed that the amount of 
positive cells in the STR/ort mice was significantly less than in normal mice with almost no expression
at ages 6 months and 1 year (Figure 2).
Smad-2P staining in the medial tibial cartilage
Figure 2
Score of SMAD-2P in medial tibial cartilage. Sections were stained immunohistochemically for SMAD-2P. The number of
cells staining positive for SMAD-2P were measured with a computerized imaging system as a control for the visual score.
The number of cells after induction of instability was significantly lower than controls. STR/ort mice showed a decreased 
expression with age.
Cartilage: spontaneous model
Cartilage of 8-week-old STR/ort mice already displayed proteoglycan loss, which was more 
pronounced on the medial side of the joint. Both TGF-β3 and Smad-2P expression varied at this
age. The cartilage of the lateral side contained almost 90% TGF-β3 immunopositive cells whereas
the cartilage of the medial side displayed only 10-20% cells immunopositive for TGF-β3. Smad-2P
expression varied from 50-75% of the cells in the lateral cartilage and was non-existent to 20%
positive cells on the medial side.
After 6 months the Safranin O staining had diminished further and cartilage contained clefts or
was eroded. Occasionally, the calcified cartilage layer was devoid of proteoglycans. The cartilage
was negative for both TGF-β3 and Smad-2P except for some positive cells remaining in the lateral
tibial cartilage (<5% positive cells for both TGF-β3 and Smad-2P). After 1 year large portions of
the cartilage were gone. The remaining cartilage was completely negative for both TGF-β3 and
Smad-2P (Table 1, Figure 1B).
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Instability OA Spontaneous OA
Femur medial Femur lateral Tibia medial Tibia lateral Osteophyte
T-β3 S-2P T-β3 S-2P T-β3 S-2P T-β3 S-2P T-β3 S-2P
Instability OA
Naive ++ + ++ ++ ++ + ++ ++
Day 1 + + ++ ++ ++ + ++ ++
Day 3 + +/- + + + +/- + ++ ++ +
Day 7 +/- +/- +/- +/- +/- +/- +/- + +++ ++
Day 14 - - +/- +/- - - +/- +/- +++ +++
Spontaneous OA
8 weeks +/- - + - + - ++ ++ +++ +++
6 months - - - - - - + - +/- +
1 year - - - - - - +/- + +/- +
Table 1
Score of TGF-β3 (T-β3) and SMAD-2P (S-2P) expression in several cartilage surfaces, cruciate ligaments and osteophytes in
both a spontaneous and an instability OA model. - negative; +/- weakly positive; + positive; ++ more than 50% of the cells
immunopositive; +++ almost every cell immunopositive and high staining intensity.
42 43
B
M
P-
2
Sm
ad
-2
P
TG
F-
β
Sa
fr
an
in
 O
A B C
D E F
G H I
J K L
B
M
P-
2
Sm
ad
-2
P
TG
F-
β
Sa
fr
an
in
 O
A B C
D E F
G H I
J K L
*
*
*
*
* *
*
* *
*
* *






Figure 3B
Osteophyte development: spontaneous
model. Osteophyte is located on the
femur below the attachment of the 
collateral ligament. Original magnifica-
tion: 200x. Sections were stained with
Safranin O, (A, B, C) and immunohisto-
chemically for TGF-β3 (D, E, F) SMAD-2P
(G, H, I) and BMP-2 (J, K, L). Osteophytes
at the age of 8 weeks (A, D, G, J), 6
months (B, E, H, K) and 1 year (C, F, I, L).
In early development all of the cells of
the newly formed tissue stain positive
for both TGF-β3 and SMAD-2P (D, G)
and there is low expression of BMP-2 (J).
When osteophyte formation progresses
into more ossified structures TGF-β3 and
SMAD-2P expression diminishes (E, H).
When the osteophyte has turned into 
a bone structure some TGF-β3 and
SMAD-2P expression is found, but it is
unclear whether this is from the original
osteophyte or newly synthesized tissue
(arrowheads in F, I). BMP-2 expression is
low at first, but in mice aged 1 year the
expression of BMP-2 is clearly elevated
(L). Dotted lines approximate the 
original bone margin. Asterisks indicate 
ectopic bone formation.
Figure 3A
Osteophyte development: instability model. Osteophyte is
located on the femur below the attachment of the 
collateral ligament. Original magnification: 200x. Sections
were stained with Safranin O, (A, B, C) and immunohisto-
chemically for TGF-β3 (D, E, F) SMAD-2P (G, H, I) and BMP-2
(J, K, L). Osteophytes had developed 7 days (A, D, G, J) and
14 days (B, C, E, F, H, I, K, L) after collagenase injection. 
In early development all of the cells of the newly formed
tissue stain positive for both TGF-β3 and SMAD-2P (D, G).
When osteophyte formation progresses TGF-β3 resides in
the fibrous layer overlaying the cartilage while SMAD-2P is
seen in the entire structure (E, H). During ossification of
the osteophyte TGF-β3 is observed again in the fibrous
layer, but also in the core of the osteophyte. The cartilage-
like layer is still negative for TGF-β3 (F). SMAD-2P staining
can be observed in all layers of the osteophyte (I). BMP 
expression is present in all layers, but less prominent than
TGF-β (J, K, L).
BMP-2 in OA cartilage
TGF-β3 and Smad-2P were found declined in early OA-cartilage and even absent in severe 
OA-cartilage. To make sure that this was not caused by overall reduced cell viability resulting in
reduced protein synthesis, we examined the expression of another growth factor of the TGF-β
family: BMP-2. In contrast to TGF-β3, BMP-2 expression was elevated with increasing OA pathology.
BMP-2 was found in only a small number of chondrocytes in the deeper layer of normal cartilage.
In instability-induced OA we observed a small increase in number of positive cells on day 3. BMP-2
was also found in more superficial, non-calcified layers of cartilage. On day 7 and 14 the number
of positive cells had increased further, mainly in the deeper layers. The number of positive cells
in the non-calcified layers had increased as well, but still remained under 20% of the total 
number of cells (Figure 1A). 
In the spontaneous OA model we observed very intense staining for BMP-2 in degenerating 
cartilage. At 8 weeks of age staining was mainly seen in cells of the deeper cartilage layers. In 6
months old animals also cells in the superficial, non-calcified layers stained very intense. In one-
year-old mice almost every cell neighboring severely damaged cartilage stained very intense for
BMP-2 (Figure 1B).
Osteophytes: instability model
Osteophytes are newly formed bone outgrowths that develop at the edges of the joint. The first
observations in osteophyte formation are cell clusters in the periosteum resembling chondrocytes.
These cells are surrounded by ECM that stains red with Safranin O similar to cartilage and was
observed as early as 3 days after induction of OA. The chondrogenic structure had enlarged by
day 7. Some of the cells disappeared and round, empty lacunae remained. On day 14, lacunae in
the core of the osteophyte had joined together forming new bone marrow spaces, filled with
new cells. Deposition of bone had begun in the core of the osteophyte around the larger rough-
edged lacunae. The developing osteophyte was covered with a layer of fibroblast-like cells 
surrounded by a small amount of ECM with a different organization then cartilage. This layer
was thicker on day 14 than on day 7. 
The initial cell clusters on day 3, all expressed TGF-β3. When the chondrogenic structure enlarged
TGF-β3 was still expressed in every cell. The round lacunae on day 7 and 14 were negative for 
TGF-β3. The new bone marrow spaces contained small cells that expressed TGF-β3. The outer
layer of the osteophyte was covered with TGF-β3 immunopositive, fibroblast-like cells. When
the core of the osteophyte started to turn into bone (day 14) TGF-β3 resided at the margins 
(Figure 3A).
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The cell clusters of day 3 and 7 were all positive for Smad-2P. On day 14, when there was ossifi-
cation of the core of the osteophyte, the Smad-2P staining was very intense and, in contrast to
TGF-β3, observed throughout the entire structure (Figure 3A). Not all cells had similar staining in-
tensity. In general, cells near the edge usually stained more intense than those in the core (Figure
3A). 
Osteophytes: spontaneous model
One of the most apparent locations of osteophyte formation in STR/ort mice is above the root
of the collateral ligament at the medial side of the joint, but osteophytes also develop at other
locations. At 8 weeks of age, STR/ort mice displayed primary stages of osteophyte development.
The chondrogenic core of the osteophytes was located along the original bone margin. In con-
trast to osteophytes in the instability model, no red staining was observed in the outer layer
indicating a lack of proteoglycans. The chondrogenic core stained far less red compared to 
osteophytes in the instability-induced OA model. The direct surrounding of the chondrocytes
stained red but the spaces in between were pink or even green. After 6 months the osteophytes
had turned into bone. After 1 year the osteophytes that started development around 8 weeks
of age were hard to distinguish from the original bone as margins had become unclear. In some
of the 6 month old mice but most of the 1-year-old STR/ort mice, new osteophytes were develop-
ing in ligaments, extending from the menisci or grew on top of old osteophytes. Some of these
new osteophytes were already ossified while others were still in developmental stages displaying
chondrogenesis. 
The chondrogenic part of the osteophytes in 8-week-old mice was, in contrast to the osteophytes
in the instability model, negative for TGF-β3. Only the fibroblasts in the outer layer expressed
TGF-β3. Of the chondrogenic part 50% of the cells were immunopositive for Smad-2P and all of
the cells in the outer layer stained positive for Smad-2P. The ossified osteophytes of 6-month-old
mice displayed approximately 10% cells that were immunopositive for TGF-β3 and approximately
50% of the cells were positive for Smad-2P. This remained the same after 1 year (Table 1, Figure 3B)
Early osteophytes expressed only low levels of BMP-2, whereas the bone-like structures that had
developed after 1 year displayed intense BMP-2 staining indicating a role for BMP in late osteo-
phyte development (Figure 3B).
Discussion
We investigated the role of TGF-β in two OA models reflecting aspects of human OA. TGF-β3 and
TGF-β signaling, assessed by Smad-2P staining, were studied. TGF-β induces Smad-2 phosphory-
lation in a time- and dose dependent manner, giving insight in active TGF-β signaling (4,18,19). 
One of the main features of OA is destruction of cartilage, which is preceded by loss of proteo-
glycans. In both OA models proteoglycan loss is accompanied by reduced TGF-β3 and Smad-2P
staining. OA lesions in the spontaneous model were predominantly observed on the medial side
of the joint corresponding with previous findings of Dunham et al, describing progressive 
disorganization of proteoglycans in the medial cartilage plateau of STR/ort mice younger than
30 weeks of age (3,20,21). We observed that TGF-β3 and Smad-2P staining also diminished fastest
on the medial side in both OA models. The STR/ort mice are studied over a longer time period,
enabling us to study more progressive cartilage damage. The severely damaged articular cartilage
is totally negative for TGF-β3 and Smad-2P, whereas intact cartilage, even in older STR/ort mice,
contains TGF-β3 and Smad-2P immunopositive cells. Supportive of our findings, Verdier et al
show decreased TGF-β expression in degraded human OA cartilage and diminished TGF-βRII 
expression in fibrillated cartilage (22). Furthermore, Wang et al found a correlation 
between expression of TGF-βRII/TGF-β1 and intracellular levels of TIMP in human 
cartilage chondrocytes. TIMPs inhibit MMPs, thereby facilitating accumulation of ECM products
indicating a role for the TGF-β pathway in ECM homeostasis of the cartilage (23). Kizawa et al
show an asporin polymorphism in which asporin D14 has a greater inhibitory effect on TGF-β-
mediated expression of cartilage matrix gene than the common form D13. The D14 variant was
over-represented in individuals with arthritis indicating the lack of TGF-β responsiveness and its
association with OA progression (24). Taken together these data strongly suggests that loss 
TGF-β signaling is associated with cartilage damage.
In the papain model, TGF-β was found increased in damaged cartilage (25). However, papain
breaks down the ECM of the cartilage, thereby directly affecting cartilage integrity. It can be 
anticipated that chondrocytes respond differently to this insult when compared to instability-
induced cartilage damage, probably involving different roles for TGF-β (26-29). 
To confirm that our findings were not the effect of an overall drop in cell viability in OA cartilage,
but TGF-β specific, we studied the expression of another TGF-β family member: BMP-2. In contrast
to TGF-β3, BMP-2 is elevated with OA progression, indicating that the reduced TGF-β3 expression
is not simply the result of decreased cell viability.
Another prominent feature of OA is osteophyte formation. The chondrocyte-like cell clusters
that are observed in early osteophyte development are all positive for TGF-β3 and Smad-2P.
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More developed, but not fully ossified, osteophytes have a core of bone-like tissue covered with
a layer of cartilage-like tissue and an outer layer with fibroblast-like cells. In this stage, TGF-β3
is observed in the bone marrow of the osteophyte. The cartilage-like tissue is negative, whereas
the fibroblast-like cells are all positive for TGF-β3. In contrast, Smad-2P is found in every layer of
the osteophyte. TGF-β3 expression is low to absent in this phase of development or obscured by
matrix development. The first seems more plausible, in which case the TGF-β might diffuse from
the fibrous layer to the cartilage inducing TGF-β signaling. Either way, there is Smad-2P staining
indicating active TGF-β signaling.
Overexpression of TGF-β in murine knee joints has been shown to induce osteophytes while
blocking endogenous TGF-β in an OA model reduces osteophyte formation (3,5,6,11,25). These
findings suggest an important role for TGF-β in osteophyte formation. However, in older STR/ort
mice the osteophytes no longer express TGF-β3 or Smad-2P. The osteophytes in the instability
model have been monitored over a shorter time period showing only the early phases of 
development. Particularly in these phases TGF-β seems to be very important. In later phases 
of osteophyte development, as seen in older STR/ort mice, TGF-β function is supposedly substi-
tuted by factors such as BMP. BMP is known to be involved in osteophyte maturation (30,31) and
was found highly expressed in late osteophytes in our experiment. Uchino et al describes TGF-β
expression in human osteophytes (13). They were not able to discriminate between different 
stages of osteophyte formation, which might explain why they found various amounts of TGF-β
in osteophytes. However, the location of TGF-β expression mainly in the fibrous, superficial layer
of the human osteophytes corresponds to our findings in mice. This confirms that the process of
osteophyte formation observed in our murine OA models closely resembles that in human OA.
In the spontaneous OA model we observe ectopic bone formation in the collateral ligament.
Collins et al and Walton also found these chondro-osseous structures in synovia and ligaments
in STR/ort mice (32,33). This ectopic bone formation is observed initially by red staining in the 
ligament in Safranin O stained sections, indicating proteoglycan deposition. This particular area
contains cells positive for TGF-β3 and Smad-2P while the rest of the ligament, which looks 
normal, is negative for both. Further changes in ligaments resemble those observed in developing
osteophytes with respect to TGF-β3 and Smad-2P expression. In the early process of chondroge-
nesis TGF-β3 and Smad-2P are abundantly expressed whereas fully developed pseudo joints are
negative for TGF-β3 and Smad-2P. Again suggesting a role for TGF-β in the early developmental
stages of ectopic bone.
Although TGF-β expression is reduced in damaged cartilage, its expression is highly elevated in
other compartments of the joint (osteophytes, but also synovial tissue). Therefore, it can be 
expected that TGF-β will still be released into the joint cavity and could ultimately reach other
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tissue. We show that TGF-β signaling in cartilage is down regulated or even absent in OA carti-
lage. TGF-β that is produced outside the cartilage does not reach the chondrocytes, either due
to scavenging by the extracellular matrix or the cells have lost the ability to respond. The latter
is in concordance with the loss in TGF-β receptor II expression as has been shown in rabbits with
osteoarthritis (34). Loss of the ability to respond to TGF-β might be related to high levels of
proinflammatory cytokines like IL-1 and TNF present in OA cartilage. The absence of TGF-β3 
expression could also be attributed to effects of pro-inflammatory cytokines. Struder et al has
shown that pro-inflammatory cytokines can indirectly, via nitric oxide production, modulate
TGF-β production (35). In contrast, IL-1 and TNF have been shown to stimulate BMP-2 expression,
which could explain our findings of BMP-2 up regulation during OA progression (36).
From our observations we can conclude that TGF-β and Smad-2P expression is reduced in damaged
cartilage and completely absent in cartilage that has started to erode, suggesting a protective
role for TGF-β in cartilage. TGF-β and Smad-2P are up regulated during chondrogenesis, osteo-
phyte- and ectopic bone formation, but mainly in early stages of osteophyte development. In
progressive OA TGF-β expression in newly formed osteophytes is, although still present, reduced
when compared to newly formed osteophytes in early OA. At later stages of osteophyte 
development TGF-β and Smad-2P are no longer expressed and other factors are likely to be 
involved in further progression of osteophyte formation. 
48
Reference List
1. Stoop R, van der Kraan PM, Buma P, Hollander AP, Poole AR, van den Berg WB. Denaturation of type II collagen in 
articular cartilage in experimental murine arthritis. Evidence for collagen degradation in both reversible and irreversible
cartilage damage. J Pathol 1999;188:329-37.
2. Allen JB, Manthey CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM. Rapid onset synovial inflammation and hyperplasia 
induced by transforming growth factor beta. J Exp Med 1990 Jan 1;171(1):231-47.
3. Bakker AC, van de Loo FAJ, van Beuningen HM, Sime P, van Lent PLEM, van der Kraan PM, et al. Overexpression of 
active TGF-β-1 in the murine knee joint: evidence for synovial-layer-dependent chondro-osteophyte formation. 
Osteoarthritis Cartilage 2002;9:128-36.
4. Scharstuhl A, Glansbeek HL, van Beuningen HM, Vitters EL, van der Kraan PM, van den Berg WB. Inhibition of 
endogenous TGF-β during experimental osteoarthritis prevents osteophyte formation and impairs cartilage repair. 
J Immunol 2002 Jul 1;169(1):507-14.
5. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Transforming growth factor-β 1 stimulates 
articular chondrocyte proteoglycan synthesis and induces osteophyte formation in the murine knee joint. Lab Invest 
1994 Aug;71(2):279-90.
6. van den Berg WB, van Osch GJ, van der Kraan PM, van Beuningen HM. Cartilage destruction and osteophytes in 
instability-induced murine osteoarthritis: role of TGF beta in osteophyte formation? Agents Actions 1993 Nov;40 
(3-4):215-9.
7. Morales TI, Joyce ME, Sobel ME, Danielpour D, Roberts AB. Transforming growth factor-β in calf articular cartilage 
organ cultures: synthesis and distribution. Arch Biochem Biophys 1991 Aug 1;288(2):397-405.
8. Morales TI. Transforming growth factor-β 1 stimulates synthesis of proteoglycan aggregates in calf articular cartilage 
organ cultures. Arch Biochem Biophys 1991;286:99-106.
9. Redini F, Galera P, Mauviel A, Loyau G, Pujol JP. Transforming growth factor beta stimulates collagen and glycosa
minoglycan biosynthesis in cultured rabbit articular chondrocytes. FEBS Lett 1988;234:172-6.
10. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Does TGF-β protect articular cartilage in vivo? 
Agents Actions Suppl 1993;39:127-31.
11. van Beuningen HM, Glansbeek HL, van der Kraan PM, van den Berg WB. Osteoarthritis-like changes in the murine 
knee joint resulting from intra-articular transforming growth factor-β injections. Osteoarthritis Cartilage 2000 
Jan;8(1):25-33.
12. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A, Destefano J, et al. The role of subchondral bone remodeling 
in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the 
rat anterior cruciate ligament transection model. Arthritis Rheum 2004 May;50(4):1193-206.
13. Uchino M, Izumi T, Tominaga T, Wakita R, Minehara H, Sekiguchi M, et al. Growth factor expression in the osteophytes 
of the human femoral head in osteoarthritis. Clin Orthop 2000 Aug;(377):119-25.
14. van der Kraan PM, Vitters EL, van Beuningen HM, van de Putte LB, van den Berg WB. Degenerative knee joint lesions 
in mice after a single intra-articular collagenase injection. A new model of osteoarthritis. J Exp Pathol (Oxford) 1990 
Feb;71(1):19-31.
15. Das Gupta EP, Lyons TJ, Hoyland JA, Lawton DM, Freemont AJ. New histological observations in spontaneously 
developing osteoarthritis in the STR/ORT mouse questioning its acceptability as a model of human osteoarthritis. Int
J Exp Pathol 1993;74(6):627-34.
16. Mason RM, Chambers MG, Flannelly J, Gaffen JD, Dudhia J, Bayliss MT. The STR/ort mouse and its use as a model of 
osteoarthritis. Osteoarthritis Cartilage 2001 Feb;9(2):85-91.
17. Flannelly J, Chambers MG, Dudhia J, Hembry RM, Murphy G, Mason RM, et al. Metalloproteinase and tissue inhibitor 
of metalloproteinase expression in the murine STR/ort model of osteoarthritis. Osteoarthritis Cartilage 2002 
Sep;10(9):722-33.
18. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-β on renal tubular epithelial 
cells by blocking Smad2 activation. J Am Soc Nephrol 2002 Jun;13(6):1464-72.
19. Nakao A, Imamura T, Souchelnitskiy S, Kawabata M, Ishisaki A, Oeda E, et al. TGF beta receptor mediated signalling 
through Smad2, Smad3 and Smad4. EMBO J 1997;16(17):5353-62.
20. Dunham J, Chambers MG, Jasani MK, Bitensky L, Chayen J. Changes in oxidative activities of chondrocytes during the 
early development of natural murine osteoarthritis. Br J Exp Pathol 1988 Dec;69(6):845-53.
21. Dunham J, Chambers MG, Jasani MK, Bitensky L, Chayen J. Changes in the orientation of proteoglycans during the 
early development of natural murine osteoarthritis. J Orthop Res 1990 Jan;8(1):101-4.
22. Verdier MP, Seite S, Guntzer K, Pujol JP, Boumediene K. Immunohistochemical analysis of transforming growth factor 
beta isoforms and their receptors in human cartilage from normal and osteoarthritic femoral heads. Rheumatol Int
2005 Mar;25(2):118-24.
23. Wang L, Almqvist KF, Veys EM, Verbruggen G. Control of extracellular matrix homeostasis of normal cartilage by a 
TGFbeta autocrine pathway. Validation of flow cytometry as a tool to study chondrocyte metabolism in vitro. 
Osteoarthritis Cartilage 2002 Mar;10(3):188-98.
24. Kizawa H, Kou I, Iida A, Sudo A, Miyamoto Y, Fukuda A, et al. An aspartic acid repeat polymorphism in asporin inhibits 
chondrogenesis and increases susceptibility to osteoarthritis. Nat Genet 2005 Feb;37(2):138-44.
25. Scharstuhl A, Vitters EL, van der Kraan PM, van den Berg WB. Reduction of osteophyte formation and synovial 
thickening by adenoviral overexpression of transforming growth factor beta/bone morphogenetic protein inhibitors 
during experimental osteoarthritis. Arthritis Rheum 2003 Dec;48(12):3442-51.
26. van Osch GJ, van der Kraan PM, van den Berg WB. Site-specific cartilage changes in murine degenerative knee joint 
disease induced by iodoacetate and collagenase. J Orthop Res 1994 Mar;12(2):168-75.
27. Yang F, Shi Z. [A study on papain-induced osteoarthritis in rabbit temporomandibular joint]. Hua Xi Kou Qiang Yi Xue 
Za Zhi 2002 Oct;20(5):330-2.
5150
28. Moriizumi T, Yamashita N, Okada Y. Papain-induced changes in the guinea pig knee joint with special reference to 
cartilage healing. Virchows Arch B Cell Pathol Incl Mol Pathol 1986;51(6):461-74.
29. van der Kraan PM, Vitters EL, van de Putte LB, van den Berg WB. Development of osteoarthritic lesions in mice by 
"metabolic" and "mechanical" alterations in the knee joints. Am J Pathol 1989 Dec;135(6):1001-14.
30. Zoricic S, Maric I, Bobinac D, Vukicevic S. Expression of bone morphogenetic proteins and cartilage-derived 
morphogenetic proteins during osteophyte formation in humans. J Anat 2003 Mar;202(Pt 3):269-77.
31. Nakase T, Miyaji T, Tomita T, Kaneko M, Kuriyama K, Myoui A, et al. Localization of bone morphogenetic protein-2 
in human osteoarthritic cartilage and osteophyte. Osteoarthritis Cartilage 2003 Apr;11(4):278-84.
32. Collins C, Evans RG, Ponsford F, Miller P, Elson CJ. Chondro-osseous metaplasia, bone density and patellar cartilage 
proteoglycan content in the osteoarthritis of STR/ORT mice. Osteoarthritis Cartilage 1994 Jun;2(2):111-8.
33. Walton M. Degenerative joint disease in the mouse knee; radiological and morphological observations. J Pathol 1977 
Oct;123(2):97-107.
34. Boumediene K, Conrozier T, Mathieu P, Richard M, Marcelli C, Vignon E, et al. Decrease of cartilage transforming 
growth factor-β receptor II expression in the rabbit experimental steoarthritis - potential role in cartilage breakdown. 
Osteoarthritis Cartilage 1998;6(2):146-9.
35. Studer RK, Georgescu HI, Miller LA, Evans CH. Inhibition of transforming growth factor beta production by nitric 
oxide-treated chondrocytes: implications for matrix synthesis. Arthritis Rheum 1999 Feb;42(2):248-57.
36. Fukui N, Zhu Y, Maloney WJ, Clohisy J, Sandell LJ. Stimulation of BMP-2 expression by pro-inflammatory cytokines 
IL-1 and TNF-α in normal and osteoarthritic chondrocytes. J Bone Joint Surg Am 2003;85-A Suppl 3:59-66.
52
Chapter 3
Reduced transforming growth factor-β
signaling in cartilage of old mice: 
role in impaired repair capacity
Arthritis Research & Therapy. 2005;7(6):R1338-47. 
E.N. Blaney Davidson
A. Scharstuhl
E.L. Vitters
P.M. van der Kraan
W.B. van den Berg
Introduction
Osteoarthritis (OA) is characterized by cartilage damage, osteophyte formation and thickening
of the joint capsule. The etiology of OA is unknown, but OA is strongly correlated with age. OA
may be a result of an age-related alteration in responsiveness of cells to anabolic and catabolic
stimuli.
IL-1 is a cytokine that plays an important catabolic role in OA. IL-1 is highly expressed by 
chondrocytes of joints that are affected by OA, both in mice and humans (1,2). Patients with OA
have high levels of IL-1 in their synovial fluids as well (3). IL-1 itself can induce cartilage damage
(4) by reducing proteoglycan (PG) synthesis, increasing matrix metalloproteinase expression (5),
and stimulating nitric oxide production (6).
Transforming growth factor (TGF)-β is an important anabolic factor in OA. It is very beneficial
for cartilage as it stimulates PG and collagen type II synthesis and can down regulate cartilage-
degrading enzymes (7-13). In addition, TGF-β is able to counteract IL-1 induced suppression of PG
synthesis (9,14-16). Through this action TGF-β is able to protect cartilage from damage by IL-1
(9,17,18). In humans, expression of an asporin variant with a high TGF-β inhibitory effect is 
significantly correlated with an increased incidence of OA (19).
Old animals show more prolonged suppression of PG synthesis after IL-1 exposure than young
mice (4) and display a reduced response to counteraction of IL-1 by TGF-β (20). This indicates a
shift in response to catabolic and anabolic stimuli, eventually leading to loss of cartilage 
homeostasis and OA.
TGF-β signals predominantly through two receptors, TGF-β-RI (ALK5) and TGF-β-RII. TGF-β binds
to the type II receptor, recruits and phosphorylates the type I receptor and subsequently activates
its receptor Smad, Smad2 or Smad3, by phosphorylation (21). Thereafter, the phosphorylated
Smad2 or Smad3 forms a complex with the common-Smad, Smad4. The complex is subsequently
translocated to the nucleus where TGF-β responsive genes are transcribed (22). Inside the cell
there are also inhibitory Smads (Smad6 and Smad7) that can prevent TGF-β signaling (23,24). 
We postulate that the lack of responsiveness to TGF-β counteraction of IL-1 in old mice is due to
an overall lack of responsiveness to TGF-β caused by a down regulation of receptors and/or Smad
expression or and increase in inhibitory Smads. Therefore, we investigated the expression of the
various TGF-βs (1, 2 and 3) as well as their signaling molecules (TGF-β-RI and TGF-β-RII, Smad2,
Smad-2P, Smad3, Smad4, Smad6 and Smad7) immunohistochemically in the cartilage of knee
joints of young and old mice. In addition, we assessed whether these expression levels were 
altered differently in young and old mice by intra-articular injection of IL-1α.
We show that old mice have a profoundly lower expression of TGF-β receptors (I and II) than
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Abstract
Osteoarthritis (OA) is a common joint disease, mainly effecting the elderly population. The cause
of OA seems to be an imbalance in catabolic and anabolic factors that develops with age. IL-1 is
a catabolic factor known to induce cartilage damage, and transforming growth factor (TGF)-β
is an anabolic factor that can counteract many IL-1-induced effects. In old mice, we observed 
reduced responsiveness to TGF-β-induced IL-1 counteraction. We investigated whether  expression
of TGF-β and its signaling molecules altered with age. To mimic the TGF-β deprived conditions
in aged mice, we assessed the functional consequence of TGF-β blocking. We isolated knee joints
of mice aged 5 months or 2 years, half of which were exposed to IL-1 by intra-articular injection
24 h prior to knee joint isolation. Immunohistochemistry was performed, staining for TGF-β1, -2
or -3, TGF-βRI or -RII, Smad2, -3, -4, -6 and -7 and Smad-2P. The percentage of cells staining po-
sitive was determined in tibial cartilage. To mimic the lack of TGF-β signaling in old mice, young
mice were injected with IL-1 and after 2 days Ad-LAP (TGF-β inhibitor) or a control virus were 
injected. Proteoglycan (PG) synthesis (35S-sulfate incorporation) and PG content of the cartilage
were determined. Our experiments revealed that TGF-β2 and -3 expression decreased with age,
as did the TGF-β receptors. Although the number of cells positive for the Smad proteins was not
altered, the number of cells expressing Smad-2P strongly dropped in old mice. IL-1 did not alter
the expression patterns. We mimicked the lack of TGF-β signaling in old mice by TGF-β inhibition
with LAP. This resulted in a reduced level of PG synthesis and aggravation of PG depletion. The
limited response of old mice to TGF-β induced-IL-1 counteraction is not due to a diminished level
of intracellular signaling molecules or an up-regulation of intracellular inhibitors, but is likely due
to an intrinsic absence of sufficient TGF-β receptor expression. Blocking TGF-β distorted the 
natural repair response after IL-1 injection. In conclusion, TGF-β appears to play an important role
in repair of cartilage and a lack of TGF-β responsiveness in old mice might be at the root of OA
development.
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Immunohistochemistry for TGF-β1, TGF-β2, TGF-β3, TGF-βRI, TGF-βRII and Smad-2P, as well as 
Safranin O/Fast Green staining, were performed on paraffin sections from total knee joints. Knee
joints were fixed in phosphate buffered formalin for 7 days. They were the dehydrated using an
automated tissue-processing apparatus (Tissue Tek VIP, Sakura, Ramsey, MN, USA) and embed-
ded in paraffin. Tissue sections of 7 μM were prepared. 
Immunohistochemistry
Sections were deparaffinized and washed with PBS. For antigen unmasking, sections were 
incubated in citrate buffer (0.1 M sodiumcitrate, 0.1 M citric acid) for 2 hours. Endogenous 
peroxidase was blocked with 1% hydrogen peroxide in methanol for 30 minutes. Thereafter,
sections were blocked with 5% normal serum of the species in which the secondary antibody was
produced. Specific primary antibodies against TGF-β1, TGF-β2, and TGF-β3 (1.0 μg/ml), TGF-βRI
and TGF-βRII, Smad2, Smad3 and Smad4 (0.5 μg/ml), Smad6 (1.0 μg/ml), Smad7 (3.3 μg/ml) and
Smad-2P (1:100) were incubated overnight at 4°C. (Smad6 antibody was purchased from Invitro-
gen (Breda, The Netherlands), Smad-2P from Cell Signaling Technology (Beverly, MA, USA), and
all other primary antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA)) As a negative control, the primary antibody was replaced with goat or rabbit IgGs. After
extensive washing in PBS, the appropriate biotin labeled secondary antibody was used at a 
concentration of 2 μg/ml in 1% bovine serum albumin/PBS for 2 hours (Vector Laboratories Inc., 
Burlingame, CA, USA), followed by a biotin-streptavidine detection system according to the 
manufacturers protocol (Vector Laboratories Inc.). Bound complexes were visualized via reaction
with 3′,3′diaminobenzidine (Sigma Chemicals Co., Zwijndrecht, The Netherlands) and H2O2
resulting in a brown precipitate. Sections were briefly counterstained with heamatoxylin and
mounted with Permount.
Image analysis: quantification of positively stained articular chondrocytes
For the different antigens, the number of positive articular chondrocytes in the tibia was deter-
mined by a blinded observer. The microscopic image was displayed on a computer monitor using
the Qwin image analysis system (Leica Imaging Systems, Rijswijk, The Netherlands) and a Leica
DC 300F digital camera. The area representing the non-calcified articular cartilage was selected
by hand. For each antigen, a threshold was set in such a manner that only chondrocytes that
were found to be positive (brown stained cell) as judged by the observer were selected. The
computer program determined the number of positive cells in the cartilage for the different 
antigens. For each knee joint, the expression of the different antigens was measured in at least
three tissue sections. The intensity of the staining was not taken into account as no obvious 
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young mice, which correlates with less Smad2 phosphorylation. IL-1 itself had little effect on the
expression of TGF-β signaling molecules in cartilage.
To investigate whether reduced TGF-β response could cause the reduced repair capacity in old
mice, we mimicked the lack of TGF-β by blocking TGF-β activity with latency associated peptide
(LAP) after IL-1 insult. This demonstrated that endogenous TGF-β was required for a normal 
repair response and that lack thereof aggravates cartilage damage.
Materials and Methods
Animals
Male C57Bl/6 mice aged 5 months or 2 years were used. Animals were kept in filtertop cages
with woodchip bedding under standard pathogen free conditions. They were fed a standard
diet with tap water ad libitum. The local animal committee approved this study. 
Experimental design
TGF-β counteraction of IL-1 effects is most likely mediated by TGF-βRI, TGF-βRII and the intra-
cellular Smad proteins. We investigated if young (n = 14) and old (n = 14) mice differ in expression
of these TGF-β signaling mediators. Therefore, knee joints were isolated and prepared for 
immunohistochemistry. Half of the joints were prepared for paraffin sections, half were pre-
pared for frozen sections. The number of cells staining positive for the various proteins were
measured with a computerized imaging system. In addition to the comparison between young
and old mice, we checked whether IL-1α injection 24 h prior to knee joint isolation (10 ng) (R&D
Systems, Wiesbaden, Germany) influenced the expression patterns. Thus, the right knee joint of
every mouse was injected with IL-1α and the left knee served as the non-injected group. 
To assess whether lack of TGF-β could indeed cause reduced repair capacity in old mice, young
mice (n = 14) were injected intra-articularly with IL-1. Two days later we injected an adenovirus
overexpressing the TGF-β inhibitor LAP (25). This inhibitor scavenges endogenous TGF-β in the
synovial fluid, preventing it from binding to its receptor. After 4 days, patellae were isolated for
measurement of PG synthesis or whole knee joints were isolated for histology to measure PG
content in the cartilage.
Histology
For the different classes of Smads, knee joints were decalcified for 14 days in EDTA/PVP and 
subsequently cryosections of total knee joints (7 μM) were prepared and stored at -20°C. Before
use, sections were air-dried for 30 minutes and freshly prepared paraformaldehyde (4%, 
5 minutes) was used to fix the sections.
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Results
Chondrocyte cell number is reduced with age
The percentage of cells expressing the different TGF-β signaling proteins in murine cartilage
was calculated by correction for the total number of cells present in the articular cartilage of the
tibia. Therefore, the total number of cells in both medial and lateral tibial cartilage was quan-
tified for all experimental groups by computerized quantification of cell number in hematoxylin
and eosin (H&E) stained sections. Old mice had a significantly lower number of chondrocytes in
the tibial cartilage: the reduction was more pronounced in the medial tibial cartilage, with a 
reduction in cell number of 34%; the number of cells in lateral tibial cartilage had reduced 17%.
(Figure 1). Treatment with IL-1 had no effect on the total number of cells (data not shown). 
Reduction of various TGF-β signaling molecules with age
To assess whether the reduced TGF-β responsiveness in old mice was due to a lower amount of
TGF-β expression we compared the number of TGF-β positive cells in the tibial cartilage of young
(5 months old) and old mice (2 years old) in immunohistochemically stained sections. The number
of positive cells was quantified with a computerized imaging system and corrected for the total
amount of chondrocytes. In both medial and lateral tibial cartilage, age had no effect on the
number of TGF-β1 expressing cells. However, the number of cells expressing TGF-β2 in old mice 
had reduced from 30% to almost no positive cells left (average of 0.2%) on the medial side of 
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differences were observed in staining intensities in the different experimental groups: young/old
or -IL-1/+IL-1. The obtained values were averaged and the average per treatment group was 
determined. To correct for differences in cell number between young and old mice, the average
number of chondrocytes in the non-calcified cartilage was determined in sections stained with
haematoxylin only for both paraffin and frozen sections. This was based on a similar selection
procedure to that described above with the exception that selection of chondrocytes was based
on the blue staining from heamatoxylin instead of brown staining. The average number of chon-
drocytes per sections was calculated for every joint. 
Image analysis: proteoglycan content
PG content of articular cartilage was measured in sections stained with Safranin O and Fast
Green using a computerized imaging system as previously described (25). Briefly, Safranin O
stains PGs in the cartilage red. A blinded observer captured an image on screen and selected
the cartilage. The computer then measured the amount of blue light passing through the selected
area. The higher the amount of light passing through, the lower the amount of PGs in cartilage.
the average of three sections per knee joint was calculated.
Proteoglycan synthesis
PG synthesis was assessed by measurement of 35S-sulfate incorporation. Isolated patellae were
immediately placed in Dulbecco’s modified Eagle’s medium with gentamicin (50 mg/ml) and 
pyruvate. After half an hour, this medium was replaced by medium containing 35S-sulfate 20
μCi/ml in which patellae were incubated for 3 hours at 37°C and 5% CO2. Thereafter, patellae
were further prepared for determining the amount of 35S-sulfate incorporation in the articular 
cartilage as previously described (22).
Statistical analysis
Results were analyzed with the Student’s t-test and considered significant if the p-value was
smaller than 0.05.
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Number of cells in medial and lateral tibial cartilage of 5
month and 2 year old C57Bl/6 mice. Paraffin sections of knee
joints of young (5 months old) and old (2 years old) mice were
stained with haematoxylin and eosin after which a blinded
observer used a computerized imaging system to count the
number of chondrocytes in the tibial cartilage. Old mice have
a lower number of cells in their cartilage than young mice. The
reduction in cell number is more pronounced on the medial
side of the joint. Error bars display the standard error. For 
statistical analysis, a Student’s t-test was used. (* = p < 0.05; **
= p < 0.005; *** = p < 0.0005).
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the joint and from 32% to 2% on the lateral tibial cartilage (Figure 2F,H). TGF-β3 showed a similar
pattern in medial tibial cartilage, where the number of positive cells was 31% in young mice
compared to 1% in old mice. On the lateral side of the joint, ageing also resulted in a lower
number of TGF-β3 positive cells, but this was not significant (Figure 3).
We also examined the effect of aging on the number of cells staining positive for the TGF-βRs.
TGF-βRI was expressed by a significantly lower number of cells in the medial tibial cartilage in
old mice compared to young mice, 2% compared to 21%, respectively. On the lateral side, the
number of TGF-βRI positive cells was also lower in old mice, but this was not significant. The
amount of cells expressing TGF-βRII was significantly lower in old mice, both on the medial and
on the lateral side of the joint. On the medial side, the number of immunopositive cells was 
reduced with age from 27% in young mice to 4% in old mice; in the lateral tibial cartilage the
reduction was from 26% to 6% (Figs 4 and 2E,G). 
In contrast to the receptors, the number of cells positive for the several Smad molecules had
hardly changed with age. The percentage of cells positive for receptor-Smad Smad2 was equal
in young and old mice (Figure 2A,C). The expression of receptor-Smad Smad3 had increased in old 
Figure 4
Percentage of cells expressing TGF-βRs. Paraffin sections of knee joints of young (5 months old) and old mice (2 years old)
were stained immunohistochemically with antibodies against TGF-βRI or TGF-βRII. Subsequently, the number of cells staining
positive in the cartilage were scored with a computerized imaging system and corrected for the total number of cells. The
expression of both receptors was reduced with age in both (a) medial and (b) lateral tibial cartilage, but the reduced TGF-
βRII was significant only in lateral tibial cartilage. Error bars display the standard error. For statistical analysis, a Student’s
t-test was used. (* = p < 0.05; ** = p < 0.005; *** = p < 0.0005).
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Figure 2
Staining of various TGF-β signaling molecules in cartilage. Paraffin sections of knee joints of young and old mice were
stained with antibodies against (A,C) Smad2, (B,D) Smad-2P, (E,G) TGF-β receptor II (TGF-βRII) and (F,H) TGF-β2. The medial
tibia of the young mice clearly show a high number of cells staining positive for (B) Smad-2P, (E) TGF-βRII and (F) TGF-β2,
whereas the (D,G,H) old mice had only a very low number of cells staining positive for these factors. (A,C) Smad2 staining
remained unchanged with age. F, femur; T, tibia.
Figure 3
Percentage of cells expressing TGF-β in medial and lateral tibial cartilage. Paraffin sections of knee joints of young (5 months
old) and old (2 years old) mice were stained immunohistochemically with antibodies against TGF-β1, TGF-β2 or TGF-β3. 
Subsequently, the number of cells staining positive in the cartilage were scored with a computerized imaging system and
corrected for the total number of cells. (a) In medial cartilage, TGF-β2 and TGF-β3 expression were significantly reduced with
age. (b) In lateral cartilage, TGF-β2 was significantly reduced. Error bars display the standard error. For statistical analysis,
a Student’s t-test was used. (* = p < 0.05).
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amount of immunopositive cells from 85% to 30% (Figs 6 and 2B,D). This indicates a decrease
in active TGF-β signaling in old mice, possibly related to the decreased number of TGF-βRs in
old mice.
To assess whether IL-1 itself altered TGF-β signaling in old mice, thereby reducing the counter-
active abilities of TGF-β to IL-1, we examined the effect of IL-1 injection on the expression of
TGF-β signaling components in the articular cartilage. Injection of IL-1 24 hours prior to knee
joint isolation resulted in an increased expression of TGF-β1 and TGF-β2 in lateral tibial cartilage
in old mice and a higher number of Smad2 positive cells in the medial tibial cartilage. IL-1 treat-
ment did not influence TGF-β receptor, Smad or Smad2P expression in old mice (Figure 7). IL-1
did not alter the expression of the TGF-β signaling components in young mice.
Effect of blocking TGF-β on proteoglycan synthesis and proteoglycan content
To assess the functional consequence of depressed TGF-β signaling, we blocked TGF-β by 
adenoviral overexpression of the TGF-β inhibitor LAP two days after IL-1 insult. Four days after
primary insult, knee joints were isolated for assessment of PG synthesis and PG content. PG 
synthesis was measured by 35S-sulfate incorporation into cartilage ex vivo. A normal response
to IL-1 insult is an initial drop in PG synthesis the first 2 days after IL-1 injection, followed by a
rapid increase in synthesis within the next 2 days (4). The increased synthesis levels are above 
normal turnover levels. LAP overexpression after IL-1 injection was able to completely block this
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Figure 5
Percentage of cells expressing Smad in medial and lateral tibial cartilage. Frozen sections of knee joints of young (5 months
old) and old (2 years old) mice were stained immunohistochemically with antibodies against Smad2, Smad3, Smad4, Smad6
or Smad7. Subsequently, the number of cells staining positive were scored with a computerized imaging system and 
corrected for the total number of cells. (a) In medial tibial cartilage, expression of Smad3, Smad4 and Smad7 increased with
age. (b) In lateral tibial cartilage Smad3 and Smad6 expression increased with age. Error bars display the standard error. For
statistical analysis, a Student’s t-test was used. (* = p < 0.05; *** = p < 0.0005). 
mice as well as the percentage of cells positive for the common-Smad, Smad4, but only in the
medial tibial cartilage. The inhibitory Smad, Smad6, was not altered with age in the medial tibial
cartilage, but was higher in old mice on the lateral side. Smad 7 was significantly higher in old
mice, but this was limited to the medial tibial cartilage (Figure 5).
Despite the lack of difference in Smad2 expression between young and old mice, the phospho-
rylated variant of this Smad, Smad-2P, was significantly reduced in old mice in both medial and
tibial cartilage. In the medial tibial cartilage, the percentage of cells staining positive for Smad-2P
was 53% in young mice compared to 5% in old mice. On the lateral side, aging had lowered the
62
100
80
60
40
20
0p
er
ce
n
ta
g
e 
o
f 
ce
lls
 p
o
si
ti
ve
A: Smad expression in medial tibial cartilage
Smad4Smad3 Smad6 Smad7Smad2
100
80
60
40
20
0p
er
ce
n
ta
g
e 
o
f 
ce
lls
 p
o
si
ti
ve
B: Smad expression in lateral tibial cartilage
Smad4Smad3 Smad6 Smad7Smad2
p
er
ce
n
ta
g
e 
o
f 
ce
lls
 p
o
si
ti
ve
medial lateral
Smad-2P expression in tibial cartilage
Figure 6
Percentage of cells expressing Smad-2P in medial and lateral 
tibial cartilage. Paraffin sections of knee joints of young (5
months old) and old (2 years old) mice were stained immuno-
histochemically with antibodies against Smad-2P. Subsequently,
the number of cells staining positive were scored with a  
computerized imaging system and corrected for the total
number of cells. The Smad-2P expression was reduced with age
in both medial and lateral tibial cartilage. Error bars display
the standard error. For statistical analysis, a Student’s t-test
was used. (*** = p < 0.0005).
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intrinsic increase in PG synthesis as shown by the
35S-sulfate incorporation, which was lower than
after IL-1 insult alone (Figure 8A).
In addition, PG content was measured by quan-
tification of Safranin O staining intensity of the
cartilage. The block of endogenous TGF-β resulted
in an aggravation of cartilage damage as the PG
content of the cartilage was significantly reduced
beyond IL-1 induced PG depletion (Figure 8B).
These data show that deprivation of TGF-β 
resulted in a reduced repair capacity of the 
cartilage.
Figure 8
Effect of TGF-β deprivation on intrinsic cartilage repair capacity.
Murine knee joints of young mice were injected with IL-1.
After two days an adenovirus expressing the TGF-β inhibitor
latency associated peptide (LAP) was injected intra-articularly.
Four days after the initial injections with IL-1, patellae were
isolated for 35S-sulfate incorporation and whole knee joints
were isolated for histology. (a) 35S-sulfate incorporation into
isolated patellar cartilage after treatment with IL-1 and 
Ad-LAP. IL-1 treatment induces an initial decrease in 35S-
sulfate incorporation, but by day 4 the 35S-sulfate incorporation
increased above normal levels, indicating an overshoot in 
proteoglycan synthesis. By blocking endogenous TGF-β with
LAP, this overshoot is completely abolished. 
(b) Proteoglycan content of patellar cartilage after treatment
with IL-1 and Ad-LAP. IL-1 injection results in depletion of 
proteoglycans in cartilage. Blocking endogenous TGF-β with
LAP results in an aggravation of this depletion beyond IL-1 
induced damage alone.
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Figure 7
Effect of IL-1 expression of TGF-β signaling proteins in cartilage. Knee joints of (a) young (5 months old) and (b) old 
(2 years old) mice were injected with IL-1 24 hours prior to isolation of the knee joints. Paraffin sections of knee joints were 
stained immunohistochemically for TGF-β1, TGF-β2, TGF-β3, TGF-βRI, TGF-βRII, Smad2, Smad3, Smad4, Smad6, Smad7 and
Smad-2P. Subsequently, the number of cells staining positive were scored with a computerized imaging system and corrected
for the total number of cells. After IL-1 injection, Smad2 expression increased only in the medial tibial cartilage and TGF-β1
and TGF-β2 expression increased only in the lateral tibial cartilage. Error bars display the standard error. For statistical 
analysis, a Student’s t-test was used. (* = p < 0.05).
64
140
120
100
80
60
40
20
0
p
er
ce
n
ta
g
e 
o
f 
ce
lls
 p
o
si
ti
ve
A: IL-1 effect in old mice in medial tibial cartilage
TG
F-
β
1
TG
F-
β
2
TG
F-
β
3
TG
F-
β
R
I
TG
F-
β
R
II
Sm
ad
2
Sm
ad
3
Sm
ad
4
Sm
ad
6
Sm
ad
7
Sm
ad
-2
P
140
120
100
80
60
40
20
0
p
er
ce
n
ta
g
e 
o
f 
ce
lls
 p
o
si
ti
ve
B: IL-1 effect in old mice in lateral tibial cartilage
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Iqbal et al found a decrease in the expression of mRNA for TGF-β1, TGF-β2 and TGF-β3 with age
in equine cartilage, supporting our findings (29). It is not clear why the TGF-β isoforms show a
different pattern but it is known that all three isoforms are differentially regulated and have a
different promotor region. Also, during embryogenis all three isoforms show a different, 
developmental stage related expression pattern (30). Gómez-Camarillo et al also showed a 
progressive decrease of TGF-βRI with age (31). Matsunaga et al found similar expression patterns
in cervical intervertebral discs in mice (32). They showed a decrease in expression of TGF-β1, 
TGF-β2 and TGF-β3 as well as TGF-βRI and TGF-βRII with age. In myogenic progenitor cells in
mice, Beggs et al described similar observations (33). They found that TGF-βRI and TGF-βRII were
down regulated and Smad2, Smad3, Smad4 and Smad7 remained unchanged (33). These data 
indicate that our findings are similar to those found in other species and cell types and that the
phenomenon of reduced TGF-βRs and reduced TGF-β expression it is not limited to cartilage of
murine knee joints. 
IL-1 treatment increased the expression of TGF-β1 and TGF-β2 in tibial cartilage. Andriamanaljiaona
et al have also shown the ability of IL-1 to increase TGF-β1 of articular chondrocytes (34). 
Kaiser et al showed that IL-1 treatment resulted in elevated expression of Smad7 mRNA in vitro
after 3 days (35). In our in vivo experiment, however, no significant alterations in inhibitory Smad
expression were found. In contrast to Kaiser et al (35), we measured the percentage of cells 
expressing Smad7 1 day after IL-1 injection in vivo. The discrepancies in time, measurement and
system probably explain why different results were found. 
We previously examined TGF-β expression in OA. In severe OA in STR/ort mice, we did not find
any TGF-β expression or Smad-2P at all, whereas younger STR/ort mice with only mild damage
still expressed both factors (data not shown). In addition, others have also found discrepancies
between OA cartilage and healthy cartilage with respect to TGF-β expression. Gomez-Camarillo
and Kouri showed that TGF-β1 receptors were very scarce in experimental OA (31). The drop in
expression levels of TGF-β and their signaling molecules that we found in old mice might precede
OA.
The expression patterns in the cartilage suggest that a lack of TGF-β signaling plays a potential
role in the reduced repair capacity in old mice and possibly in OA. To further investigate whether
the disturbed TGF-β signaling could cause a reduction in repair, we inhibited endogenous TGF-β
after IL-1 insult. This resulted in a total block of the increased PG synthesis, thereby reducing the
intrinsic repair capacity of the cartilage. The reduced PG synthesis resulted in an aggravation of
the IL-1-induced PG loss in cartilage. These results show that not only do old mice have a reduced
TGF-β signaling capacity, but also that disrupted TGF-β signaling can indeed induce a distorted
repair capacity of cartilage.
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Discussion
OA is characterized by cartilage damage with an increasing incidence with age. The etiology of
OA is unknown, but an imbalance between catabolic and anabolic factors appears to be involved.
Whereas chondrocytes of young mice respond well to TGF-β counteraction of IL-1, those of old
mice show less efficient counteracting of IL-1 by TGF-β (20). In addition, they display prolonged
suppression of PG synthesis. This might be due to a decreased response to TGF-β in cartilage of
old mice. We compared, therefore, the expression of TGF-β and the TGF-β signaling components
in cartilage of young and old mice. The cartilage of old mice contained a lower number of cells
than young mice. We thus corrected our findings for the total number of cells in the examined
cartilage. In this study, only the tibial cartilage is discussed, but similar changes occurred in the
femoral cartilage. The reduced cell number we found in old mice corresponds to the decreased
number of cells that was found in cartilage of human donors older than 40 (26). A decrease in
chondrocyte cell number could be due to an age-related decline in (TGF-β-induced) chondrocyte
proliferation rate (27,28).
Our results show that old mice have significantly lower numbers of cells expressing TGF-β2 and
TGF-β3 than young mice. In addition, old animals had a significantly lower number of chondro-
cytes expressing TGF-βRs. The lack of responsiveness to TGF-β counteraction in old mice is not 
likely a result of alterations in Smad expression, as they are unaffected or even elevated by
aging. Smad3 was elevated in tibial cartilage, and in the medial tibial cartilage we found an 
elevation of Smad4 with age. The basal material for signaling inside the cell is present, only the
action is lacking. This lack of action might be due to the reduced receptor expression combined
with a drop in TGF-β2 and TGF-β3 in old mice. This could also explain the lower Smad2 phospho-
rylation in old mice. Smad2 itself is not a problem as it is present in equal numbers in both young
and old mice, but if there are less receptors and less ligands, Smads are unlikely to be phospho-
rylated in high amounts. 
In lateral tibial cartilage we found an elevation of Smad6 expression with age, while in medial
tibial cartilage Smad7 was elevated with age; these changes were restricted to one cartilage 
surface only instead of both. Although it might contribute, it is unlikely that this elevation is the
cause of the overall unresponsiveness to TGF-β. 
We wanted to make sure that IL-1 itself did not alter TGF-β signaling and cause the reduced
counteraction. Therefore, mice were exposed to IL-1 prior to knee joint isolation. IL-1 treatment
had only little effect on TGF-β signaling. In old mice, we found an up-regulation of TGF-β1 and
TGF-β2 in lateral tibial cartilage. In the medial tibial cartilage, we observed an IL-1-induced 
increase in Smad2. Although there was elevation of these factors, it had no effect on Smad-2P,
indicating that IL-1 treatment did not alter the outcome of TGF-β signaling. 
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It has been hypothesized that TGF-β treatment can be used as a factor for cartilage repair. 
However, old mice respond poorly to TGF-β, so the use of TGF-β for repair might be more diffi-
cult than expected. It has already been shown that human articular chondrocytes stimulated
with TGF-β1, fibroblast growth factor-2 and platelet derived growth factor-BB, contained more
glycosaminoglycans than non-stimulated controls, but only if donors were younger than 40 (26).
In addition, stimulation of equine articular cartilage with TGF-β resulted in lower [35S]Na2SO4
incorporation in horses of 20 years old compared to 9 month old horses (26,29). Although the
response to TGF-β is reduced with age, it does not mean that the cartilage does not respond at
all. There was still an increase in incorporation of [35S]Na2SO4 after TGF-β stimulation found by
Livne et al in mice (36), but it has to be considered that this response in old animals cannot be
compared to the massive stimulation in young animals. However, finding ways to stimulate 
cartilage repair bypassing the TGF-β receptor pathway appears to be an attractive option to
boost repair of aged cartilage. 
Conclusions
Our data show that there are less chondrocytes expressing TGF-βRs in cartilage in old mice. Smad
expression is unchanged, but Smad2 phosphorylation is reduced with age. These data suggest
that the reduced TGF-β counteraction of IL-1 induced cartilage damage of old mice is due to an
overall lack in TGF-β signaling capacity. Blocking endogenous TGF-β in young mice induced a dis-
torted repair capacity in cartilage. The reduced ability of chondrocytes to respond to anabolic
factors during aging might play a role in the development of the age-related disease OA.
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Chapter 4
TGF β-induced cartilage repair is 
maintained but fibrosis is blocked 
in the presence of Smad7
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Introduction
Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage breakdown, synovial
fibrosis, and bone spurs. An imbalance between catabolic and anabolic factors favoring the 
catabolic side is very likely involved in the pathological features of OA.
Currently, many attempts are being made to repair the cartilage that has been damaged in OA.
One approach focuses on shifting the metabolic imbalance back by stimulating the anabolic
side. Transforming growth factor-β (TGF-β) is one of the anabolic factors involved in cartilage
maintenance and appears to be a good candidate for cartilage repair. TGF-β is a stimulator of
extracellular matrix production, like collagen type II and proteoglycan (PG), in chondrocytes and
it down regulates matrix-degrading enzymes (1). High amounts of TGF-β are stored in healthy 
cartilage (2-6), whereas in OA cartilage the expression of TGF-β is reduced (7). Injection of TGF-β
into naive murine knee joints results in an increase in PG content of the articular cartilage (8).
Moreover, in murine experimental rheumatoid arthritis, injection of TGF-β protected cartilage
from PG loss (9). In addition, TGF-β counteracts the anabolic factor interleukin-1 (IL-1), which is
a very potent inducer of cartilage degradation (10;11) both in vivo and in vitro (1;12-16). These data
indicate that TGF-β has great potential as a tool for stimulating cartilage repair.
To obtain sufficient amounts of TGF-β in the joint for a prolonged period of time, an adenovirus
can be used as a vehicle. In vitro, chondrocytes that are transfected with an adenovirus encoding
TGF-β responded by elevation of PG and collagen production (17). We wanted to assess whether
adenoviral overexpression of TGF-β in the synovial lining could stimulate repair of damaged 
cartilage in vivo.
Unfortunately, introducing high amounts of TGF-β into a knee joint has adverse effects. Admi-
nistration of 20 ng TGF-β is already sufficient to result in an increased cellularity of the synovial
lining, expansion of fibroblast population in the synovial connective tissue, and continued 
collagen deposition (18). Injection of high amounts of TGF-β, either as a bolus injection or via
adenoviral transfection, results in marked hyperplasia of the synovium and chondro-osteophyte
formation (8;18-21). This illustrates that the use of TGF-β for cartilage repair can result in side 
effects that are deleterious for future therapeutic applications. 
The aim of this study was to use TGF-β as a cartilage repair factor but at the same time to prevent
the TGF-β-induced fibrotic side effect. Therefore, we examined the effect of adenoviral over-
expression of active TGF-β on cartilage repair and additionally studied whether simultaneous
Smad7 overexpression could block TGF-β-induced fibrosis. Smad7 is an intracellular molecule
that inhibits the TGF-β signaling pathway. TGF-β binds to its type II receptor, which then forms
a complex with the type I TGF-β receptor. 
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Abstract
Cartilage damage in osteoarthritis (OA) is considered an imbalance between catabolic and 
anabolic factors, favoring the catabolic side. We assessed whether adenoviral overexpression of
transforming growth factor-β (TGF-β) enhanced cartilage repair and whether TGF-β-induced 
fibrosis was blocked by local expression of the intracellular TGF-β inhibitor Smad7. We inflicted
cartilage damage by injection of interleukin-1 (IL-1) into murine knee joints. After 2 days, we 
injected an adenovirus encoding TGF-β. On day 4, we measured proteoglycan (PG) synthesis and
content. To examine whether we could block TGF-β-induced fibrosis and stimulate cartilage 
repair simultaneously, we injected Ad-TGF-β and Ad-Smad7. This was performed both after IL-1-
induced damage and in a model of primary OA. In addition to PG in cartilage, synovial fibrosis
was measured by determining the synovial width and the number of procollagen I-expressing
cells. Adenoviral overexpression of TGF-β restored the IL-1-induced reduction in PG content and
increased PG synthesis. TGF-β induced an elevation in PG content in cartilage of the OA model.
TGF-β-induced synovial fibrosis was strongly diminished by simultaneous synovial overexpression
of Smad7 in the synovial lining. Of great interest, overexpression of Smad7 did not reduce the
repair-stimulating effect of TGF-β on cartilage. Adenoviral overexpression of TGF-β stimulated
repair of IL-1- and OA-damaged cartilage. TGF-β-induced synovial fibrosis was blocked by locally
inhibiting TGF-β signaling in the synovial lining by simultaneously transfecting it with an ade-
novirus overexpressing Smad7. 
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Simultaneously stimulating cartilage repair and blocking of fibrosis
To make sure that Smad7 did not interfere with TGF-β-stimulated PG synthesis, we assessed whether
stimulation of cartilage repair was not blocked by co-transfection with Ad-Smad7, and cartilage
damage was again introduced in 48 C57Bl/6 mice by intra-articular injection with 10 ng IL-1. After
2 days, mice were injected with adenoviruses in the combinations of Ad-TGF-β223/225 + 
Ad-luc, Ad-TGF-β223/225 + Ad-Smad7, or Ad-luc alone. Four days after IL-1 injection, 24 mice were
used for isolation of patellae for 35SO4
2- incorporation measurements. After 2 weeks, the other
mice were used for isolation of knee joints for histological assessment of fibrosis.
Cartilage repair while blocking fibrosis in spontaneous OA
To test whether we could stimulate cartilage repair in a spontaneous experimental OA model
while preventing fibrosis, we extended our experiment to STR/ort mice. STR/ort mice develop OA
spontaneously and show pathological changes by 8 weeks of age. We injected adenoviruses
intra-articularly into the knee joint of 24 4-week-old STR/ort mice and repeated this injection
after 2 weeks. The adenoviruses were injected in the combinations of Ad-TGF-β223/225 + Ad-luc,
Ad-Smad7 + Ad-luc, and Ad-TGF-β223/225 + Ad-Smad7 at a pfu of 0.5 × 107 per adenovirus or 
Ad-luc at a pfu of 107 alone as a control. Four weeks after the first injection, knee joints were 
isolated for histological analysis of synovial fibrosis and PG content of the cartilage.
Histology
Knee joints of mice were dissected and fixed in phosphate-buffered formalin for 7 days. There-
after, they were decalcified in 10% formic acid for 1 week. Knee joints were dehydrated with an
automated tissue-processing apparatus (VIP) (Tissue Tek VIP, Sakura, Ramsey, MN, USA) and 
embedded in paraffin. Coronal whole knee joint sections of 7 μm were made. Sections were 
stained with Safranin O and Fast Green.
Immunohistochemistry
Sections were deparaffinized and washed with phosphate-buffered saline (PBS). For antigen 
unmasking, sections were incubated in citrate buffer (0.1 M sodium citrate + 0.1 M citric acid) for
2 hours. Endogenous peroxidase was blocked with 1% hydrogen peroxide in methanol for 30 
minutes. Thereafter, sections were blocked with 5% normal serum of the species in which the
secondary antibody was produced. Specific primary antibodies against procollagen type I 
(2 μg/ml) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) were incubated overnight at 4°C.
After extensive washing with PBS, the appropriate biotin-labeled secondary antibody was used
(DakoCytomation, Glostrup, Denmark) for 30 minutes at room temperature followed by a 
biotin-streptavidine detection system according to manufacturer’s protocol (Vector Laboratories,
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Subsequently, the intracellular signaling molecule Smad2 or Smad3 gets phosphorylated, forms
a complex with common Smad, Smad4, and shuttles to the nucleus for transcription (22). Smad7
inhibits Smad2 and Smad3 phosphorylation, thereby preventing further signaling (23;24).
To both stimulate cartilage and block side effects, we took advantage of the fact that adeno-
viruses, once injected into the murine knee joint, transfect the synovial lining but do not penetrate
the cartilage (25). We co-transfected the synovial lining with an adenovirus overexpressing TGF-β
and an adenovirus overexpressing Smad7. The transfected synovial lining cells will produce 
TGF-β but due to an intracellular signaling block caused by Smad7, will no longer respond to this
factor.
We show that adenoviral overexpression of TGF-β results in increased PG content of the cartilage
both after IL-1-induced damage and in a spontaneous model of experimental OA. In both cases,
the TGF-β-induced fibrosis can be prevented by simultaneous Smad7 overexpression.
Materials and Methods
Animals
C57Bl/6 mice (10 weeks old) and STR/ort mice (4 weeks old) were used. Mice were kept in filter-top
cages with woodchip bedding under standard pathogen-free conditions. They were fed a 
standard diet and tap water ad libitum. The local animal committee had approved this study.
Stimulation of cartilage repair by TGF-β after IL-1 insult
To asses whether adenoviral overexpression of TGF-β could stimulate cartilage repair, we inflicted
cartilage damage in 73 C57Bl/6 mice by intra-articular injection of 10 ng IL-1 (R&D Systems, Inc.,
Minneapolis, MN, USA). Two days after IL-1 injection, PG synthesis will have reached a low point
(11). At this time point, an adenovirus overexpressing active TGF-β (Ad-TGF-β223/225) (Gift by Dr.
C.D. Richards) was injected intra-articularly (plaque-forming units (pfu) 107/ 6 μl) and compared
with a control virus (Ad-del 70-3). Four days after the primary insult, 53 mice were used for
patellae isolation for PG synthesis measurement by 35SO4
2- incorporation. The other 20 mice
were used for isolation of whole knee joints for histology. 
Blocking TGF-β-induced fibrosis
To block TGF-β-induced fibrosis, 24 C57Bl/6 mice were injected intra-articularly with adenoviruses
in the combinations of Ad-TGF-β223/225 + Ad-luciferase (Ad-luc), Ad-Smad7 + Ad-luc, and Ad-
TGF-β223/ 225 + Ad-Smad7 (at a pfu of 0.5 × 107 per adenovirus in 6 μl) or Ad-luc alone (at a total
pfu of 107) as a control. After 14 days, when synovial fibrosis can be observed histologically, knee
joints were isolated for histology.
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Results
Overexpression of TGF-β stimulates cartilage repair
Knee joints that are injected with IL-1 initially show a reduced incorporation of 35SO4
2- into their
patellar cartilage. After 2-3 days, this has reached a low point, and thereafter the incorporation
rapidly increases above normal incorporation levels. By day 4, the incorporation of 35SO4
2- had
significantly increased to 165% of the normal value (p < 0.005). On day 2, an adenovirus encoding
active TGF-β was injected into the knee joint. The TGF-β overexpression boosted the incorpora-
tion of 35SO4
2- beyond the already elevated incorporation to 200% of the normal value (Figure
1A). As a result, the overexpression of TGF-β after IL-1 injection almost completely restored the
significantly reduced PG content of cartilage (96% of normal control,p < 0.0005) (Figure 1B).
These data show that adenoviral overexpression of TGF-β can stimulate cartilage repair.
Figure 1
Effect of adenoviral TGF-β expression on PG synthesis and content in cartilage. (a) PG synthesis was measured by 35SO4
2-
incorporation into patellar cartilage 4 days after IL-1 injection. (CPM = counts per minute) PG synthesis increased after IL-1
injection (p < 0.005), and this increase was boosted by TGF-β (p < 0.0005 compared with IL-1). (b) PG content of cartilage
was measured by Safranin O staining intensity of the cartilage in Safranin O/Fast Green stained sections. The mean PG con-
tent of non-treated knee joints was set at 100%. After IL-1 exposure, a clear reduction in PG content was observed 
(p < 0.05). By adenoviral expression of TGF-β after IL-1-induced damage, the PG content of the cartilage was almost normal.
Error bars display standard error.
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Burlingame, CA, USA). Bound complexes were visualized using DAB (3,3'-diaminobenzidine) 
reagent, counterstained with haematoxylin, dehydrated, and mounted with Permount.
PG synthesis
For measurement of PG synthesis, 35SO4
2- was incorporated into isolated patellae. Immediately
after isolation, the patellae were placed in Dulbecco’s modified Eagle’s medium with gentamicin
(50 mg/ml) and pyruvate. After half an hour, medium was replaced by medium containing
35SO4
2- (20 μCi/ml) and incubated for 3 hours at 37°C in 5% CO2. Patellae were then further 
prepared for measurement of 35SO4
2- incorporation in the articular cartilage as previously 
described (26).
PG content
PG content was measured in sections stained with Safranin O and Fast Green, using a computerized
imaging system as previously described (27). Briefly, Safranin O stains PGs in the cartilage red. The
amount of PGs is determined by a computerized calculation of the amount of blue light passing
through the red-stained cartilage. An increase in PGs leads to more intense red staining and 
reduced blue light passing through. The PG content of the tibia was calculated by the average
of three sections per joint.
Measurement of fibrosis
Sections were stained immunohistochemically for procollagen type I as a measure of fibrosis.
Subsequently, the number of cells that stain positive in the synovial tissue was determined. 
A blinded observer selected the synovial tissue in three sections per knee joint. A computerized
imaging system subsequently determined the number of positive cells in the selected area. 
The obtained values were averaged per knee joint.
In addition, synovial hyperplasia was assessed by measurement of synovial thickness. This was 
determined in sections stained with Safranin O and Fast Green. The thickness of the synovial 
tissue was measured with a computerized imaging system again in three sections per knee joint
and averaged per joint as previously described (27) (Qwin; Leica Imaging Systems Ltd., 
Cambridge, UK). In short, the width of the joint from bone edge to joint capsule, minus the
width of the joint space itself, was determined. 
Statistical analysis
Results were analyzed with a Student’s t test and stated significant if the p value was lower 
than 0.05.
78
2500
2000
1500
1000
500
0
C
PM
n
o
rm
al
 k
n
ee
 jo
in
t
IL
-1
 +
 c
o
n
tr
o
l v
ir
u
s
IL
-1
 +
 A
d
-T
G
F-
β
A: 35SO4
2- incorporation
105
100
95
90
85
80
75p
er
ce
n
ta
g
e 
o
f 
co
n
tr
o
l
n
o
rm
al
 k
n
ee
 jo
in
t
IL
-1
 +
 c
o
n
tr
o
l v
ir
u
s
IL
-1
 +
 A
d
-T
G
F-
β
B: Proteoglycan content
81
TGF-β induces synovial fibrosis that can be blocked with Smad7
Intra-articular injection of Ad-TGF-β resulted in a significant increase of synovial thickness (2.5-
fold the width of controls) 2 weeks after injection. The percentage of cells expressing procollagen
I increased accordingly (2.45-fold the amount of positive cells in controls) (Figure 2). By simulta-
neous overexpression of Ad-TGF-β and Ad-Smad7, the TGF-β-induced synovial thickness had
been significantly reduced (p < 0.05). Sixty-five percent of the increased thickness and 65% of
the elevated number of procollagen I-positive cells had been blocked by co-expression of Smad7 
(Figure 2). Smad7 itself had no effect on synovial thickness or procollagen I expression. This 
illustrates that the TGF-β-induced fibrosis can be significantly blocked by co-transfection with
Ad-Smad7.
Figure 2
Synovial fibrosis was assessed in knee joints 2 weeks after intra-articular injection of Ad-TGF-β combined with Ad-luc or
Ad-Smad7. As a measure of fibrosis, the synovial width opposite the growth plates in the femur was measured (a). In 
addition, the amount of cells staining positive in immunohistochemically stained sections for procollagen type I was 
calculated with a computerized imaging system (b). The data are represented as an increase of the viral control. Histological
representations of the measurements give an indication of actual thickness (c) and procollagen positive cells (d). There were
no differences between viral and non-injected controls. TGF-β overexpression resulted in an increase in synovial thickness
and number of procollagen type I-positive cells (p < 0.05). By co-expression with Smad7, most of the TGF-β-induced fibrosis
was prevented (p < 0.05). Error bars display standard error. 
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These data show that after IL-1-induced cartilage damage, the TGF-β-induced fibrosis could still
be blocked by Smad7 overexpression without interfering with the effect TGF-β elicits on cartilage.
Figure 4
Cartilage damage was introduced by IL-1 injection, and 2 days later TGF-β was injected intra-articularly combined with 
Ad-luc or Ad-Smad7. Two weeks after adenoviral transfection, knee joints were isolated for assessment of fibrosis. (a) 
Synovial thickness had increased significantly (p < 0.005) after exposure to TGF-β. The TGF-β-induced increase was 
reduced by simultaneous overexpression of Smad7 (p < 0.05). (b) The number of procollagen type I-expressing cells had 
increased after TGF-β exposures accordingly (p < 0.0005). This was also partially blocked by Smad7 (p < 0.005). Error bars
display standard error.
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TGF-β overexpression repairs cartilage while fibrosis is blocked with Smad7
To use the combination of TGF-β and Smad7 as a potential therapeutic intervention, we had to
make sure that Smad7 overexpression did not interfere with the beneficial effect of TGF-β on 
cartilage repair. Therefore, TGF-β and Smad7 adenoviruses were injected 2 days after IL-1 injection.
This combination turned out to be beneficial for PG synthesis and could still induce a significant
increase in PG synthesis (80% increase of PG synthesis compared with IL-1 alone, p < 0.005). 
Simultaneously overexpressing Smad7 and TGF-β did not result in blocking of the repair-stimu-
lating effects of TGF-β on cartilage (Figure 3).
Adenoviral overexpression of TGF-β resulted in a significant increase of 3.5 times as many cells
expressing procollagen type I as the IL-1 control alone (p < 0.005). By co-expression of Smad7,
38% of the increase was blocked (p < 0.005). The synovial tissue had expanded significantly to
almost four times in width after TGF-β overexpression compared with IL-1 + control virus 
(p < 0.0005). Almost half of the increase was significantly blocked by simultaneous exposure of
the synovial cells to TGF-β and Smad7 (p < 0.005) (Figure 4).
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PG-synthesis Figure 3
Proteoglycan (PG) synthesis in patellar cartilage after exposure
to both TGF-β and Smad7. PG synthesis was measured by
35SO4
2- incorporation into patellar cartilage 4 days after IL-1
injection. (CPM = counts per minute) Simultaneous injection
of Ad-TGF-β and Ad-Smad7 significantly increased PG synthesis
compared with IL-1 + control virus (p < 0.005) and therefore
did not block 35SO4
2- incorporation. Error bars display stan-
dard error.
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In experimental OA, simultaneous overexpression of TGF-β and Smad7 increased PG content of
cartilage and prevented synovial fibrosis
The experiments conducted so far had been done in a relatively simple model introducing
cartilage damage by injection of IL-1. However, in OA we are dealing with a more complex 
situation. We introduced combined overexpression of TGF-β and Smad7 in STR/ort mice. These
mice develop OA spontaneously; therefore, they can be used as a model of primary OA. 
In STR/ort mice, OA progresses relatively slowly. Therefore, we examined the final result of TGF-β
and Smad7 overexpression 2 weeks after the second of (in total) two viral injections. STR/ort
mice that had been injected with the adenovirus for TGF-β (combined with a control virus) alone
displayed a significantly higher PG content in cartilage than did controls without TGF-β over-
expression (p < 0.05) (Figure 5). However, these mice had massive synovial hyperplasia. The 
synovial thickness had increased significantly to 4.4 times the width of non-injected controls,
and almost every cell expressed procollagen type I (p < 0.005) (Figure 6).
Combining overexpression of TGF-β and Smad7 managed to maintain a significantly higher PG
content in cartilage than controls (p < 0.005) (Figure 5). More than half of the increased synovial
thickening that had been caused by TGF-β was inhibited significantly by overexpression of Smad7
(p < 0.005). The amount of procollagen type I-positive cells had been reduced accordingly (Figure 6). 
These data clearly indicate that PG synthesis can be stimulated while inhibiting an increase of 
synovial fibrosis in an experimental model of OA.
90
85
80
75
70
65
60
55
50p
er
ce
n
ta
g
e 
o
f 
n
o
n
-S
TR
/o
rt
 n
ai
ve
 c
o
n
tr
o
l
co
n
tr
o
l v
ir
u
s
A
d
-T
G
F-
β
 +
 c
o
n
tr
o
l v
ir
u
s
A
d
-T
G
F-
β
 +
 S
m
ad
 7
A
d
-S
m
ad
7
PG-content Figure 5
Proteoglycan content of osteoarthritis cartilage in
STR/ort mice. STR/ort mice (4 weeks old) were 
injected intra-articularly with Ad-TGF-β combined
with Ad-Smad7 or Ad-luciferase and injected again
2 weeks later. Four weeks after the first injection,
knee joints were isolated and the effect of TGF-β
overexpression on PG content was assessed. TGF-β
exposure resulted in a significantly higher PG 
content of cartilage than Ad-luc-injected controls
(p < 0.05). Co-expression with Smad7 had no effect
on the PG content. Error bars display standard error. 
Figure 6
Blocking of TGF-β-induced synovial 
fibrosis in osteoarthritits. STR/ort mice 
(4 weeks old) were injected intra-articu-
larly with Ad-TGF-β combined with 
Ad-Smad7 or Ad-luciferase (Ad-luc) and
injected again 2 weeks later. Two weeks
after the last injection, knee joints were
isolated for histology and synovial fibro-
sis was assessed. Synovial thickness was
determined by measuring the width of
the synovium opposite the growth 
plates in the femur. (a) Synovial  thick-
ness had increased significantly after
adenoviral TGF-β overexpression 
(p < 0.005). More than 50% of this 
increase in width was prevented by 
simultaneous expression of Smad7 
(p < 0.005). The number of procollagen
type I-expressing cells (b) had increased
as well after exposure to TGF-β (p <
0.0005). This was also inhibited by more
than 50% by co-expression of Smad7.
Histological representations of the 
measurements give an indication of 
actual thickness (c) and procollagen 
positive cells (d). Error bars display 
standard error.
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Discussion
The cartilage damage in OA is thought to be a consequence of a misbalance between anabolic
and catabolic factors, favoring the catabolic side. In this study, we used TGF-β as the anabolic 
factor for cartilage repair. TGF-β has been reported to enhance periosteal chondrogenesis in 
explants in a dose-dependent manner (28). Morales et al demonstrated that TGF-β increased PG
synthesis and suppressed its degradation in articular cartilage organ cultures (4;5). In addition,
van Beuningen et al showed that in vivo TGF-β injections result in prolonged elevation of PG syn-
thesis and PG content of cartilage in mice (8). These studies indicate that TGF-β has good potential
for repairing cartilage. We showed that adenoviral overexpression of TGF-β was indeed able to
boost cartilage repair in vivo. In vitro, it had already been shown that chondrocytes exposed si-
multaneously to IL-1 and TGF-β could reverse the IL-1-induced suppression of PG incorporation
in their extracellular matrix (15). Supportive of our findings, van Beuningen et al demonstrated
that, in vivo, TGF-β also counteracted deleterious effects of IL-1 on cartilage PG synthesis and PG
content (13). In the current study, we first damaged cartilage by IL-1 injection and subsequently
overexpressed TGF-β. In this way, we could assess whether TGF-β was able to restore, instead of
prevent cartilage damage. We introduced TGF-β via adenoviral overexpression, thereby gaining
prolonged high expression of TGF-β, instead of via a bolus injection that results in short TGF-β
exposure. This way, we were able to demonstrate increased PG synthesis and higher PG content
in cartilage not only in a clean setting introducing cartilage damage with IL-1 but also in a spon-
taneous OA model.
The drawback of using TGF-β is that it can have adverse effects in joints. TGF-β is a known inducer
of fibrosis in various tissues, and synovial tissue is no exception (8;21). We took advantage of the
fact that adenoviruses transfect only the synovial lining. In addition, we profited from the fact
that Smad7 is an intracellular inhibitor of TGF-β. Smad7 stays inside the cell that is transfected
with the adenovirus encoding Smad7. Because the synovial lining is where TGF-β induces synovial
fibrosis, by co-transfection with Smad7, the lining appeared to be less sensitive to TGF-β-induced
fibrosis. The reduction of TGF-β-induced fibrosis was not optimal and resulted in only a partial
block of the fibrosis. This is likely due to the fact that not all cells in the synovial lining will be
targeted. By optimizing this, we might be able to target every single one of the synovial lining
cells and thereby fully block the TGF-β-induced fibrosis.
We have previously demonstrated that blocking TGF-β with Ad-Smad7 in OA resulted in reduc-
tion of the synovial fibrosis that was induced by the OA process itself (27). Now we combined the
Smad7 adenovirus with Ad-TGF-β to block the TGF-β-induced fibrosis. We showed that the 
Ad-TGF-β transfection was still functional in combination with Smad7. Moreover, we demon-
naive Ad-Smad7 Ad-TGF-β Ad-TGF-β
STR/ort + control virus + control virus + Ad-Smad7
C:
naive Ad-Smad7 Ad-TGF-β Ad-TGF-β
STR/ort + control virus + control virus + Ad-Smad7
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Introduction
Osteoarthritis (OA) is a joint disease affecting most of the elderly population. The disease is 
characterized by cartilage damage, fibrosis and osteophyte formation. However, the etiology of
OA is still unknown. Currently, many efforts are made to find cures for OA (1-3). To find targets
for OA therapy it is important to know the factors that are involved in the etiology of this 
disease. CTGF (=CCN2) is the most abundantly expressed growth factor in chondrocytes in severe
human OA (4). In addition, CTGF mRNA was found to be up regulated next to damaged areas
of cartilage surfaces and present in chondro-osteophytes (5). Therefore, CTGF is a likely candidate
to contribute to the pathogenesis of OA and is likely to play a role in synovial fibrosis and 
osteophyte formation. However, it is unclear whether CTGF protects against cartilage damage.
From many reports focussed on distinct disorders that involve fibrosis it can be concluded that
CTGF has a major role in fibrotic diseases, including disorders like Crohn’s disease, liver fibrosis,
scleroderma, systemic sclerosis lung fibrosis and heart fibrosis (6-11). This gave rise to the hypo-
thesis that CTGF is likely involved in synovial fibrosis as seen in OA. 
Furthermore, CTGF is expressed in hypertrophic chondrocytes, proliferating chondrocytes and
proliferating periostal cells. It induces chondrocyte maturation and differentiation (12;13). 
Additionally, CTGF has angiogenic activities and promotes proliferation and differentiation of
osteoblasts. Therefore, CTGF is considered a major factor for promoting enchondral ossification
(14-17). These are all processes that are involved in initiation or progression of osteophyte 
formation similar to that observed in OA, suggesting a potential role for CTGF in OA osteophyte
formation. 
Nishida et al introduced CTGF in hydrogel into the joint cavity of rats in an OA model and
showed repair of damaged cartilage (18). They also demonstrated that CTGF is capable of stimu-
lating proliferation and differentiation in cultured articular chondrocytes. The cells that were
transfected with CTGF also produced higher levels of proteoglycans in a dose dependent manner
(19). These data indicate that CTGF can have protective effects on cartilage.
Until now it is unknown whether CTGF is even capable of inducing fibrosis in diarthrodal joints.
The presence of CTGF in OA joints and the potential of CTGF to induce fibrosis in many tissues
make a role for CTGF in OA synovial fibrosis probable. From literature it seems that CTGF has 
beneficial effects on cartilage and it is likely to play a role in osteophyte development. Therefore,
we investigated the overall effect overexpression of CTGF in the synovial lining of normal knee
joints. We assessed effects of adenoviral CTGF overexpression in murine knee joints histologically,
and subsequently focussed on the most prominently changed tissues: synovial tissue and carti-
lage. In addition, we examined alterations in gene expression patterns in synovia and cartilage
Abstract
Objective 
The characteristics of osteoarthritis (OA) are cartilage damage, fibrosis and osteophyte formation.
To find cures for OA, we have to elucidate the factors causing OA pathology. Connective Tissue
Growth Factor (CTGF, also known as CCN2 (for CYR61, CTGF, NOV), is found in high levels in OA
chondrocytes and is frequently involved in fibrosis, bone formation and cartilage repair. There-
fore, we investigated the potential role of CTGF in OA pathophysiology.
Methods 
We transfected the synovial lining of murine knee joints with a recombinant adenovirus 
expressing human CTGF and measured synovial fibrosis and proteoglycan content in cartilage 
on days 1, 3, 7, 14 and 28. We measured mRNA expression in synovium and cartilage at days 3, 7
and 21.
Results 
CTGF induced synovial fibrosis, as indicated by accumulation of extracellular matrix and increase
in procollagen-I positive cells. The fibrosis reached a maximum at day 7 and had reversed by day
28. Matrix Metalloproteinases (MMPs) 3 and 13, A Disintegrin and Metalloproteinase with 
Thrombospondin motifs (ADAMTS) 4 and 5, Tissue Inhibitor of Metalloproteases 1 (TIMP1) and
Transforming Growth Factor-β (TGF-β) mRNA were elevated in the fibrotic tissue. TIMP-1 
expression was elevated on day 3 while expression of other genes did not increase before day
7. CTGF induced proteoglycan depletion in cartilage already on day 1. Maximal depletion was 
observed at days 3-7. Cartilage damage was reduced by day 28. In cartilage, a high MMP3 mRNA
expression was found. CTGF overexpression did not induce osteophytes.
Conclusion 
CTGF induces transient fibrosis that is reversible within 28 days. Overexpression of CTGF in knee
joints results in reversible cartilage damage, either induced by the high CTGF levels or via factors
produced by the CTGF-induced fibrotic tissue.
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the appropriate biotin labelled secondary antibody was used (DAKO) for 30 minutes at room
temperature followed by a biotin-streptavidine detection according to the manufacturers 
protocol (Vector Laboratories). Bound complexes were visualised using DAB reagent, counter-
stained with haematoxylin, dehydrated and mounted with Permount.
Quantification of synovial fibrosis
Sections were stained immunohistochemically for procollagen type I as a measure of fibrosis.
Subsequently, the amount of cells that stain positive in the synovial tissue was determined. 
A blinded observer selected the synovial tissue in 3 sections per knee joint. A computerized imaging
system (Qwin, Leica Imaging Systems Ltd.) subsequently determined the amount of positive cells
in the selected area. The obtained values were averaged per knee joint.
In addition, the amount of extracellular matrix present in synovial tissue was measured in a 
similar manner. This was determined in Safranin O and Fast Green stained sections: Fast Green
stains the collagen green. The area of the green stained extracellular matrix in the synovial tissue
was measured with a computerized imaging system, again in 3 sections per knee joint and 
averaged per joint.
Quantification of proteoglycan content of cartilage
The proteoglycan (PG) content of the articular cartilage was measured on the tibia. The cartilage
was selected in 3 sections per knee. The amount of blue light passing through the red, Safranin
O-stained, cartilage was measured with a computerized imaging system as described previously
(20). Control joints were measured and considered to represent 100% PG content.
Quantitative PCR
Tibial cartilage was stripped off the joint and biopsy punches were taken from synovium as 
previously described (time points 3, 7, and 21 after injection of the adenovirus, n=5 per group per
time point). RNA was isolated from the tissue with an RNeasy Mini Kit (Qiagen) after which an
RT-PCR was performed. Individual samples of each group were pooled and a Q-PCR was run in
duplicate. A Q-PCR was prepared as follows: a primer mix of 1.5 μl forward primer (5 μM), 1.5 μl
reverse primer (5 μM) and 4.5 μl dH2O2, was added to 12.5 μl Sybr Green. Then 5 μl cDNA was
added and the Q-PCR was performed by a “ABI/PRISM 7000 sequence detection system” (Applied
Biosystems) according to manufacturers protocol. PCR conditions were as follows: 2 minutes at
50°C and 10 min at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C, with
data collection in the last 30 seconds. In addition, for each PCR melting curves were run. The
genes that were measured and the corresponding primer sets are displayed in Table 1. Efficiencies
after adenoviral CTGF overexpression. We found that CTGF is capable of inducing transient 
synovial fibrosis. Moreover, we found unexpected deleterious effects on proteoglycan content
in cartilage. No osteophyte formation was found.
Materials and Methods
Transfection with Ad-CTGF
We injected murine knee joints intra-articularly with 1x107 pfu virus in the right knee joint, 
thereby transfecting the synovial lining with an adenovirus overexpressing human CTGF 
(Ad-CTGF) (provided by FibroGen, Inc., South San Fransisco, CA, USA) (n=65). As a viral control
Ad5.CMV-Null was used, which has the same backbone as the CTGF virus (Qbiogene, Irvine, CA,
USA) (n=40). To gain insight into the effect of CTGF we investigated a time course of 1, 3, 7, 14
and 28 days after viral injection. The mice were sacrificed on these days and knee joints were 
isolated for histology. For RNA isolation of synovial tissue or cartilage knee joints were isolated
3, 7 and 21 days after viral injection.
Animals
Male C57Bl/6 mice aged 12 weeks were used. Animals were kept in filtertop cages with woodchip
bedding. They were fed a standard diet with tap water ad libitum. The local animal committee
has approved this study. 
Histology
Knee joints of mice were dissected and fixed in phosphate buffered formalin for 7 days. There-
after they were decalcified in 10% formic acid for 1 week. The knee joints were then dehydrated
with an automated tissue processing apparatus (Miles Scientific Tissue-Tek VIP tissue processor)
and embedded in paraffin. Frontal whole sections of 7 μm were made. Sections were stained
with Safranin O and Fast Green.
Immunohistochemistry
Sections were deparaffinized and washed with PBS. For antigen unmasking, sections were 
incubated in citrate buffer (0.1 M sodium citrate + 0.1 M citric acid) for two hours. Endogenous
peroxidase was blocked with 1% hydrogen peroxide in methanol for 30 minutes. Subsequently,
sections were blocked with 5% normal serum of the species in which the secondary antibody was
produced. Specific primary antibodies against CTGF or procollagen type I (both 2 μg/ml) (Santa
Cruz Biotechnology Inc.) were incubated overnight at 4°C. After extensive washing with PBS,
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CTGF that is expressed by the adenovirus is of human origin. We designed primers specific for
either human or murine CTGF mRNA. This made it possible to discriminate between human CTGF
mRNA, which is encoded by the Ad-CTGF adenovirus, and the endogenous murine CTGF mRNA.
Nucleotide sequences of the human CTGF primers were:
5’- AGGCAGTTGGCTCTAATCATAGTTG - 3’
5’- GCCCTCGCGGCTTACC - 3’
Statistics 
Results were analyzed with the student T-test and considered significant if the p-value was 
smaller than 0.05.
Results
CTGF expression after synovial transfection
Injection of Ad-CTGF in murine knee joints resulted in transfection of the synovial lining with the
adenovirus. Immunohistochemical staining with an antibody against CTGF showed clear up 
regulation of CTGF expression compared to controls (Figure 1A). Three days after injection with
the adenovirus the synovial tissue showed high expression of human CTGF, which diminished in
time (Figure 1B). Human CTGF was not detected in control samples.
CTGF overexpression induces fibrosis
Three different parameters were used to assess synovial fibrosis: synovial thickening, procollagen
type I expression and ECM area.
The synovium of knee joints that had been transfected with Ad-CTGF had increasingly thickened
on day 1, 3, and 7. The synovial enlargement was most prominent 7 days after viral transfection.
On day 14 and 28, the synovial thickness had still increased compared to controls, but was less
thick than on day 7 (Figure 2 and 3A).
Knee joints that had been injected with Ad-CTGF also had significantly increased content of 
procollagen type I positive cells in the synovial tissue on day 7 and 14. This increase was most 
prominent on day 7 (138% compared to controls). On day 28, the amount of procollagen type I
positive cells was restored to normal values (Figure 3B).
The area of synovial ECM had increased on day 1, 3, 7 and 14 in knee joints injected with 
Ad-CTGF compared to controls. This increase was only significant on day 1, when the increase was
most prominent. On day 28 the amount of ECM present in the synovium was comparable to 
controls (Figure 3C).
Gene R2 E Forward primer (5’  3’) Reverse primer (5’  3’)
GAPDH 0.997 2.05 GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG
Collagen IA 0.997 2.10 TGACTGGAAGAGCGGAGAGTACT CCTTGATGGCGTCCAGGTT
Collagen II 0.992 2.15 TTCCACTTCAGCTATGGCGA GACGTTAGCGGTGTTGGGAG
Collagen III 0.997 2.05 CCCCGAGGGCTGTGCTA TGAACTTCAACTGGAACAGGGTATC
Aggrecan 0.992 2.15 TCTACCCCAACCAAACCGG AGGCATGGTGCTTTGACAGTG
MMP3 0.997 2.21 TGGAGCTGATGCATAAGCCC TGAAGCCACCAACATCAGGA
MMP9 0.998 2.15 GGAACTCACACGACATCTTCCA GAAACTCACACGCCAGAAGAATTT
MMP13 0.992 1.93 ACCTTGTGTTTGCAGAGCACTAACTT CTTCAGGATTCCCGCAAGAGT
ADAMTS4 0.996 2.10 CACTGACTTCCTGGACAATGGTTAT GGAAAAGTCGTCGGTAGATGGA
ADAMTS5 0.994 1.97 GATGATCACGAAGAGCACTACGA TCACATGAATGATGCCCACAT
TIMP1 0.972 1.93 CAACTCGGACCTGGTCATAAGG CATCTTGATCTTATAACGCTGGTATAAGG
TIMP2 0.986 1.93 GCAATGCAGACGTAGTGATCAGA GCTTGATCTCATACTGAATCCTCTTG
TIMP3 0.926 2.21 GGCACTCTGGTCTACACTATTAAGCA TTTCAGAGGCTTCCGTGTGA
TIMP4 0.975 2.00 GCAGTGCCATGTACCATCTCA TACCCATAGAGCTTCCGTTCCA
TGF-β1 0.996 2.00 GCAGTGGCTGAACCAAGGA AAGAGCAGTGAGCGCTGAATC
TGF-β2 0.974 2.05 AGAGCTCGAGGCGAGATTTG TTCTGATCACCACTGGCATATGT
TGF-β3 0.999 2.00 CAATCCGTTCTTTCTGCAACTG CTAATTACATGATCTGTGATGACTCATGA
BMP-2 0.994 2.15 CGCAGCTTCCATCACGAA GCCGGGCCGTTTTCC
BMP4 0.978 2.15 CCGCTTCTGCAGGAACCA AGTGCGTCGCTCCGAATG
CTGF 0.998 2.15 CCGCCAACCGCAAGATC ACCGACCCACCGAAGACA
Table 1
Murine primers used for Q-PCR. Primers were designed using the ABI/PRISM Primer Express software (Applied Biosystems).
Efficiencies (E) of all primers were validated with a standard curve of 5 cDNA dilutions in water. E is expressed as fold
increase in fluorescence per PCR cycle. R2 is the correlation coefficient for the PCR dilution series.
(E) for all primer sets were determined (Table 1) using a standard curve of 5 serial cDNA dilutions
in water in duplicate. Primers were accepted if the deviation from slope of the standard curve
was less than 0.3 compared to the slope of GAPDH standard curve and if the melting curve
showed only one product. For each primer pair non-template controls were run in duplicate.
The cycle threshold value (Ct) of the genes of interest were corrected for the Ct of the reference
gene GAPDH. Relative mRNA expression was calculated by 2 to the power of delta Ct. Gene 
expression levels after transfection with CTGF were compared to the control virus group. The
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Figure 2
Increase in synovial fibrosis after transfection with Ad-CTGF. Paraffin sections of murine knee joints were stained with 
Safranin O and Fast Green. Left figure displays a normal joint indicating the area displayed in right figure. Synovial 
tissue stained with Safranin O and Fast Green. Synovial fibrosis had increased after CTGF overexpression compared to naïve
knee joints. Maximum fibrosis was reached on day 7 and thereafter returned to almost normal on day 28. (Original 
magnification 100x)
Besides histological assessment of fibrosis, biopsies of the synovium were taken for gene expression
analysis by determination of mRNA levels. CTGF overexpression in the synovial lining resulted in
an increase in mRNA of MMP3, MMP13, ADAMTS4, ADAMTS5, TIMP-1 and TGF-β1 in the 
synovium. These factors were up regulated on day 3 and even more on day 7. By day 21, expression
levels of genes that were elevated on day 3 and 7 were restored to normal levels, except for
ADAMTS4. No auto induction of murine CTGF and only minimal up-regulation of collagen type
I mRNA were found (Figure 4A).
Effects of CTGF overexpression on cartilage
CTGF overexpression in the synovial lining induced a reduction in PG content in articular carti-
lage. A maximum reduction in PG content was observed 7 days after injection. Reduction was still
present 28 days after transfection with CTGF (Figure 5). Although the PG content was reduced
there was no sign of cartilage erosion.
For mRNA analysis, the cartilage from the tibia was isolated. This revealed that the cartilage 
degrading enzymes MMP3, MMP13, and ADAMTS4 were clearly up regulated by adenoviral 
naive day 1 day 1 day 3 day 7 day 14 day28
control virus Ad-CTGF
synovial area displayed 
patella
femur
tibia
Figure 1
Expression of human CTGF in murine synovium. (A) Comparison of CTGF expression in a normal versus Ad-CTGF injected
joint, 3 days after injection. The synovial lining in the Ad-CTGF injected joint showed a clear positive staining indicating high
expression of CTGF protein. (Original magnification 100x) (B) Relative mRNA expression of human versus murine CTGF in the
synovial tissue of knee joints transfected with Ad-CTGF (n=5) or a control virus (n=5). Knee joints injected with a control virus
did not have any human CTGF RNA expression. 
Overall these data show that CTGF is able to induce transient synovial fibrosis. The maximum 
fibrosis was found on day 7, thereafter thickening slightly decreased on day 14, and normal levels
were reached by day 28.
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Figure 4
Relative expression levels of murine genes likely to be influenced by CTGF. Right knee joints were injected with Ad-CTGF
(n=5 per time point) or a control virus (n=5 per time point). After 3, 7 and 21 days synovial punches were taken and tibial
cartilage was obtained for RNA isolation. The samples were pooled and measured twice. RNA levels were first corrected for
GAPDH, and then corrected for the viral control. 1 equals no change. Messenger RNA expression in synovial tissue is depicted
in Figure A, cartilage in Figure B.
relative mRNA expression
day 3
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Figure 3
Effects of CTGF transfection on the synovial tissue. Right knee joints were injected with Ad-CTGF (n=10 per time point) or
a control virus (n=5 per time point). Paraffin sections of the knee joints were made and stained with Safranin O and Fast
Green after which various parameters were measured with a computerized imaging system coupled to a microscope. 
Synovial thickness increased after injection with Ad-CTGF (A). The amount of procollagen type I positive cells (B) and ECM
area (C) were higher than controls after overexpression of CTGF. (For statistical analysis a Student T-test was used. Error bars
depict SEM, (* = p<0.05; ** = p<0.005; *** = p<0.0005)
overexpression of CTGF. MMP-3 was influenced the most by CTGF overexpression in the synovial
lining: it was up regulated 11 fold compared to controls on day 7. MMP3 expression was normal 
on day 21. TIMP1 was already up regulated on day 3, displayed normal expression levels on day
7, and was also down regulated by day 21. In contrast to synovial tissue, the cartilage did show
an up regulation of murine CTGF mRNA. The response of cartilage to adenoviral CTGF over-
expression in the synovium was mainly up regulation of degrading enzymes (Figure 4B).
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Discussion
This study shows the ability of CTGF to induce synovial fibrosis and cartilage damage, both of
which are also OA characteristics. No osteophyte formation was seen after CTGF overexpression.
The fibrosis that was induced by CTGF overexpression had reversed by day 28. Although CTGF
expression in the synovial lining was high at day 3, the synovial thickness and procollagen I 
expression were highest at day 7. All factors that were examined by Q-PCR showed maximum 
effect on day 7 as well. The synovial thickness had reached a maximum at day 7, was slightly 
reduced at day 14 and had resolved by day 28. Bonniaud et al have found similar fibrotic patterns
after adenoviral CTGF overexpression in the lung. They show a moderate fibrosis with a maximum
around day 14, which had reversed by day 28 (10). 
Strikingly, we found high numbers of cells that stained intensely positive for procollagen type I
after CTGF expression, but hardly any up regulation of collagen type I mRNA. This implies that
a post-translational alteration is more likely than an up regulation of mRNA. CTGF is known to
interact directly with other growth factors, thereby stimulating or inhibiting their actions (21;22).
There is a possibility that CTGF elicits effects through these interactions rather than direct up 
regulation of genes.
We did find an up regulation of TIMP-1, which was up regulated earlier than other genes (day
3). McLennan et al studied the expression of TIMP-1, -2 and –3 in mesangial cells after treatment
with rhCTGF and also found an up regulation of TIMP-1 (23).They also observed an up regulation
of TIMP-3 and no effect on TIMP-2 expression. The increase in TIMP-3 gene expression, however,
was reflected in the media at the protein level, nor did they find TIMP-2, whereas TIMP-1 was 
clearly detectable. It has been suggested that CTGF requires TIMP-1 to cause fibrosis (10). Bonniaud
et al show a correlation between TIMP-1 expression and the sensitivity for fibrosis development.
Strains of mice that were prone to develop fibrosis showed higher levels of TIMP-1 than fibrosis-
resistant strains (24). Moreover, resistant strains could develop pulmonary fibrosis when transfected
with Ad-CTGF combined with a bleomycin. Also in the joint TIMP-1 up regulation and fibrosis 
appears to be related. 
Of all the factors examined mainly the MMPs were up regulated in the synovial tissue. Although
these are ECM-degrading enzymes, there is still an increase in ECM in the synovial tissue at first.
After day 7 the synovial fibrosis resolves, but the MMP expression decreases to normal levels as
well. MMPs are excreted in an inactive pro-form and have to be activated outside the cell, so the
high levels of MMP mRNA are not necessarily correlated with high levels of active proteases.
During accumulation of the fibrotic tissue MMP activity might be low, while there are high levels
of the MMP inhibitor TIMP-1. Beyond day 7 the TIMP-1 expression drops and newly synthesized
Figure 5
Proteoglycan content in cartilage. Right knee joints were injected with Ad-CTGF (n=10 per time point) or a control virus (n=5
per time point). Paraffin sections of the knee joints were made and stained with Safranin O and Fast Green after which 
various parameters were measured with a computerized imaging system coupled to a microscope. CTGF overexpression 
resulted in reduced PG content of tibial cartilage on both the lateral (A) and the medial (B) side of the joint. The PG content
was most significantly reduced on day 3 and 7, but was still present on day 28. (Statistical analysis was performed with a 
Student T-test. Error bars depict SEM, * = p<0.05; ** = p<0.005; *** = p<0.0005)
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regulation of degrading enzymes. The cartilage proteoglycans could have been degraded by
factors that were excreted by the fibrotic synovial tissue into the synovial fluid and reach the 
articular cartilage. The high MMP3 expression found in the cartilage, as well as the lack of 
aggrecan and collagen type II up regulation, could also be a result of factors secreted by the 
synovial tissue instead of a direct effect of high CTGF levels. The latter might explain the discre-
pancy between our findings and those of Nishida et al. who showed that local administration
of recombinant CTGF in cartilage defects could regenerate the articular cartilage (18),
Although we found clear reduction in proteoglycan content in cartilage, this does not mean
that the cartilage is irreversibly damaged. As long as the collagen network is still intact, damage
can be reversed. Since there is no consensus on whether CTGF is a factor inducing either degra-
dation of cartilage or an anabolic stimulus, one might consider CTGF to be both a degrading and
stimulating factor, thereby playing a role in cartilage remodelling.
Much research has shown a role for CTGF in chondrogenesis and endochondral bone formation
(14;16;35-38), but we found no osteophyte formation after CTGF overexpression. If CTGF plays a
role in osteophyte formation in OA at all, it is clear that CTGF needs another factor to start the
process and cannot do it alone.
In conclusion, our data show that CTGF overexpression in murine knee joints induces fibrosis
and cartilage damage, both reversible within 28 days, but does not induce osteophytes. CTGF is
likely to play a role in fibrosis in OA, but is not the only factor involved. It could be that TGF-β
starts the process and that CTGF causes persistence of the fibrosis. The cartilage damage that was
found could be either a direct effect of CTGF overexpression, or a result of factors excreted by
the CTGF-induced fibrotic synovial tissue. 
MMPs might become activated. It can be speculated that increased MMP activity in combination
with decreased TIMP-1 expression could be a cause for the resolving of fibrosis by day 28.
The synovial fibrosis that was found in our CTGF experiments was milder than the TGF-β induced
synovial fibrosis in earlier experiments we performed (25;26). However, TGF-β is the main inducer
of CTGF (9;27-29), therefore overexpression of TGF-β induces a strong CTGF up regulation 
presumably enhancing the TGF-β induced fibrosis. We cannot exclude the possibility that CTGF
has a key role in the more persistent TGF-β induced fibrosis. In OA-fibrosis, TGF-β is also found
(30). TGF-β and CTGF might work together or in turn to maintain the fibrosis. Moussad et al
have proposed that for persistent fibrosis TGF-β is needed as an induction factor followed by
CTGF as a maintenance factor (31). Chujo et al have also demonstrated that serial injections of
CTGF after TGF-β induced more persistent skin fibrosis than TGF-β alone (32). In line with their
conclusions, our data show that a single injection of Ad-CTGF alone is not enough to induce
persistent fibrosis. Adenoviral overexpression of CTGF is only transient. Our data only show that
a short exposure to CTGF is not sufficient to maintain prolonged synovial fibrosis. More sustained
presence of CTGF might cause more persistent effects.
We found depletion of proteoglycans in cartilage after CTGF overexpression in the synovial 
tissue. Supportive of our finding, Omoto et al had previously suggested a relation between CTGF
expression and degeneration of cartilage in OA. They showed strong immunopositivity for 
CTGF next to damaged cartilage surfaces (5). In addition, Minato et al demonstrated that 3 
different antibodies against CTGF stimulated PG synthesis in chondrocyte cell lines (33) indicating
that CTGF is involved in inhibition of PG synthesis.
In contrast, Nishida et al found increased proteoglycan synthesis in a rabbit articular cartilage cell
line, as well as an increase in type II collagen and aggrecan, 48 hours after transfection with an
adenovirus expressing CTGF in vitro (19). We found only a mild increase in type II collagen 
expression on day 7 alone and no changes in aggrecan expression. Nishida et al suggested that
CTGF might be useful for cartilage repair, but in our experiment we saw a reduction in proteo-
glycan content suggesting the opposite. Nakanishi et al illustrated that proteoglycan synthesis
stimulation could be neutralized by adding anti-CTGF antibodies suggesting that CTGF stimulates
PG synthesis (34). Although the general consensus in literature is that CTGF induces chondrocyte
production of PG, our data show that adenoviral overexpression of CTGF results in a reduction
of PG-content in the articular cartilage.
In our experiment we examined complete knee joints, thereby taking into account the entire 
cartilage and not ruling out indirect effects of CTGF via other tissue. Our findings of reduced 
proteoglycan content in cartilage might be explained by the high up regulation of MMP3 after
CTGF overexpression in the cartilage itself. However, fibrotic tissue also shows mRNA up 
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Introduction
Fibrosis is characterized by excess connective tissue formation, which can occur in many organs
and can lead to organ failure. One of the main players in fibrotic diseases is TGF-β. It has been
shown to play a role in fibrosis in organs like kidney, liver, lung, skin, heart etcetera (1-6). TGF-β
promotes extracellular matrix deposition, decreases expression of matrix metalloproteinases and
increases expression of tissue inhibitors of metalloproteinases (7-9). 
In murine models of osteoarthritis (OA) we have found that fibrosis is an unwanted characteristic
of OA. We have shown that the growth factor TGF-β plays an important role in synovial fibrosis
during experimental OA as blocking TGF-β could prevent synovial fibrosis (10). However, blocking
TGF-β during OA is not an option as it is crucial for cartilage maintenance and repair (11;12). As
overall blocking of TGF-β is not an option, we wanted to find another way to block the fibrosis
and searched for a secondary pathway that induced fibrosis, which we could block specifically.
In search for a potential mediator of synovial fibrosis, we found that besides TGF-β, CTGF has
been proposed as a major player in fibrotic diseases. 
CTGF belongs to the CCN family (for CYR61, CTGF and nov) and is also known as CCN2 and 
fisp-12. It has been discovered in 1991 by Bradham et al as a molecule with PDGF-like biological
activity (13). During development it is important for skeletal development (14). Under non-patho-
logical conditions it is expressed during adulthood in endothelia and neurons in the cerebral
cortex where it promotes angiogenesis and tissue integrity and in the female reproductive tract
(13;15;16). When it is expressed in other tissues during adulthood, it is mostly due to pathology
such as wound healing, vascular diseases and fibrosis (17). During repair of skin wounds and after
partial hepatectomy an up regulation of TGF-β mRNA preceded elevation of CTGF, suggesting
that CTGF was induced by TGF-β (18;19). CTGF can indeed be induced by TGF-β through a TGF-β
response element, but can also work independent of TGF-β (20-22). CTGF can also be induced by
other factors like PDGF, EGF and FGF, but this induction is very weak compared to TGF-β-
dependent up regulation (18).
To investigate whether there was a role for CTGF in inducing synovial fibrosis, we previously 
injected an adenovirus overexpressing CTGF and found that it did induce fibrosis (23). However,
in contrast to TGF-β induced fibrosis, which is persistent, CTGF overexpression resulted in fibrosis
that had been resorbed by day 28. Others have also found that adenoviral expression of TGF-β
induced marked fibrosis, while adenoviral expression of CTGF induced only transient fibrosis
(4;24). This raised the question what was different between TGF-β and CTGF-induced fibrosis.
Therefore, we assessed the effect of either TGF-β or CTGF overexpression on mRNA expression
levels of various ECM components, ECM degraders, growth factors and differences in cross-linking. 
Abstract
Major players in fibrotic disorders are TGF-β and CTGF. We found that synovial fibrosis that is
induced by TGF-β is persistent for at least 3 months, whereas CTGF-induced fibrosis is resorbed
by day 28. We wanted to investigate what might cause the differences in persistence between
TGF-β and CTGF-induced fibrosis. Therefore, we evaluated mRNA expression levels of various
ECM components, ECM degraders, growth factors and lysyl hydroxylases in synovial fibrosis that
was induced either by TGF-β or by CTGF.
We injected C57Bl/6 mice intra-articularly with either Ad-TGF-β or Ad-CTGF. After 3, 7 and 21
days we isolated synovial tissue for RNA isolation. Using Q-PCR we measured relative mRNA 
levels of several extracellular matrix components, proteases, tissue inhibitors of matrix metallo-
proteinases, growth factors and mediators of collagen cross-linking.
We found that TGF-β induced more pronounced changes on mRNA level when compared to
CTGF. TGF-β induced elevated expression of collagen type I and a drastic increase in aggrecan
expression, whereas CTGF induced a reduction in aggrecan expression. MMP3, 9, 13, ADAMTS4
and-5 were all elevated on day 7 by TGF-β and could therefore not explain the persistent nature
of TGF-β induced fibrosis. However, we found that TIMP1 was highly up regulated by TGF-β on
all days measured and was only slightly up regulated by CTGF on day 7. TGF-β also induced 
elevated mRNA levels of TGF-β1 and CTGF. Only TGF-β induced high levels of lysyl hydroxylase
expression, especially LH2b, which has been implicated in hard-to-degrade collagen linkage and
has been found up regulated in fibrotic lesions.
Our data show that the persistent nature of TGF-β induced fibrosis might be due to the elevation
of mRNA levels of TIMP1 and LH2b and that lack thereof might cause the transient nature of
CTGF-induced fibrosis.
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Gene R2 E Forward primer (5’  3’) Reverse primer (5’  3’)
GAPDH 0.997 2.05 GGCAAATTCAACGGCACA GTTAGTGGGGTCTCGCTCCTG
Collagen IA 0.997 2.10 TGACTGGAAGAGCGGAGAGTACT CCTTGATGGCGTCCAGGTT
Collagen II 0.992 2.15 TTCCACTTCAGCTATGGCGA GACGTTAGCGGTGTTGGGAG
Collagen III 0.997 2.05 CCCCGAGGGCTGTGCTA TGAACTTCAACTGGAACAGGGTATC
Aggrecan 0.992 2.15 TCTACCCCAACCAAACCGG AGGCATGGTGCTTTGACAGTG
MMP3 0.997 2.21 TGGAGCTGATGCATAAGCCC TGAAGCCACCAACATCAGGA
MMP9 0.998 2.15 GGAACTCACACGACATCTTCCA GAAACTCACACGCCAGAAGAATTT
MMP13 0.992 1.93 ACCTTGTGTTTGCAGAGCACTAACTT CTTCAGGATTCCCGCAAGAGT
ADAMTS4 0.996 2.10 CACTGACTTCCTGGACAATGGTTAT GGAAAAGTCGTCGGTAGATGGA
ADAMTS5 0.994 1.97 GATGATCACGAAGAGCACTACGA TCACATGAATGATGCCCACAT
TIMP1 0.972 1.93 CAACTCGGACCTGGTCATAAGG CATCTTGATCTTATAACGCTGGTATAAGG
TIMP2 0.986 1.93 GCAATGCAGACGTAGTGATCAGA GCTTGATCTCATACTGAATCCTCTTG
TIMP3 0.926 2.21 GGCACTCTGGTCTACACTATTAAGCA TTTCAGAGGCTTCCGTGTGA
TIMP4 0.975 2.00 GCAGTGCCATGTACCATCTCA TACCCATAGAGCTTCCGTTCCA
TGF-β1 0.996 2.00 GCAGTGGCTGAACCAAGGA AAGAGCAGTGAGCGCTGAATC
TGF-β2 0.974 2.05 AGAGCTCGAGGCGAGATTTG TTCTGATCACCACTGGCATATGT
TGF-β3 0.999 2.00 CAATCCGTTCTTTCTGCAACTG CTAATTACATGATCTGTGATGACTCATGA
BMP-2 0.994 2.15 CGCAGCTTCCATCACGAA GCCGGGCCGTTTTCC
BMP4 0.978 2.15 CCGCTTCTGCAGGAACCA AGTGCGTCGCTCCGAATG
CTGF 0.998 2.15 CCGCCAACCGCAAGATC ACCGACCCACCGAAGACA
LH1 0.997 1.90 GGAGCCGAACAGCCTAAGG TGAGTGGCGCAATGACATTC
LH2 0.997 2.08 GAGCAGCCTTGTCCAGATGTC CCAACTCATCACAGGCTCGTT
LH2b 0.999 1.93 CCGCAATGCTAGAGATATGACCTT CATTTGGAATGTTTCCGGAGTAG
LH3 0.993 2.02 AAGACACGGGCAGTGATGAACT AAGCGAGGGCTGCTCATCT
Human CTGF 0.999 2.03 GCCCTCGCGGCTTACC AGGCAGTTGGCTCTAATCATAGTTG
Porcine TGF-β1 0.997 1.99 TGACCTGGCCACCATTCAT TCCGTGGAGCTGAAGCAATA
Table 1
Primers that were used for Q-PCR.
We found that TGF-β induced more pronounced changes in expression of the analysed factors
when compared to CTGF. TGF-β up regulated collagen type I, aggrecan, MMP3, -9, -13, ADAMTS4
and –5, TIMP1 and -2, TGF-β1 and CTGF. In addition, we found that TGF-β induced lysyl hydroxy-
lase expression, especially LH2b, which eventually induce cross-links that are hard to degrade.
These data suggest that the induction of LH2b and TIMP1 by TGF-β might contribute to the 
persistent nature of TGF-β induced fibrosis.
Materials and Methods
Animals
Male C57Bl/6 mice aged 12 weeks were used. Animals were kept in filtertop cages with woodchip
bedding. They were fed a standard diet with tap water ad libitum. The local animal committee
has approved this study.
Experimental setting
We injected murine knee joints intra-articularly with 1x107 pfu virus in the right knee joint, 
thereby transfecting the synovial lining with an adenovirus overexpressing active TGF-β 
(Ad-TGF-β223/225) (gift from Dr. C.D. Richards) (n=30) human CTGF (Ad-CTGF) (provided by
FibroGen, Inc., South San Fransisco, CA, USA) (n=30). As a viral control Ad-del70-4 was used
(n=30). The mice were sacrificed on day 3, 7 and 21 and synovial biopsies were taken for RNA
isolation of synovial tissue.
Quantitative PCR
Biopsy punches were taken from synovium as previously described (time points 3, 7, and 21 after
injection of the adenovirus). RNA was isolated from the tissue with an RNeasy Mini Kit (Qiagen)
after which an RT-PCR was performed. Individual samples of each group were pooled and a 
Q-PCR was run in duplicate. A Q-PCR was prepared as follows: a primer mix of 1.5 μl forward 
primer (5 μM), 1.5 μl reverse primer (5 μM) and 4.5 μl dH2O2, was added to 12.5 μl Sybr Green.
Then 5 μl cDNA was added and the Q-PCR was performed by a “7000 sequence detection system”
(ABI Prism) according to manufacturers protocol. The genes that were measured and the corres-
ponding primer sets are displayed in Table 1. Efficiencies (E) for all primer sets were determined
(Table 1) using a standard curve of 5 serial cDNA dilutions in water in duplicate. Primers were 
accepted if the deviation from slope of the standard curve was less than 0.3 compared to the
slope of GAPDH standard curve and if the melting curve showed only one product. For each 
primer pair non-template controls were run in duplicate. The cycle threshold value (Ct) of the
genes of interest were corrected for the Ct of the reference gene GAPDH. Relative mRNA expres-
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Results
We have previously found that TGF-β-induced fibrosis was more pronounced and more persistent
than CTGF-induced fibrosis. CTGF-induced fibrosis was reversed by day 28 after viral injection
(23). In contrast, TGF-β induced fibrosis is still pronounced 3 months after the last of triple injec-
tions with 200 ng TGF-β and also 28 days after intra-articular injection of Ad-TGF-β (data not
shown). To gain insight in the differences between the two types of fibrosis we analyzed the 
synovial tissue of mice injected with either Ad-CTGF or Ad-TGF-β on mRNA level. To address the
question which factors are expressed differently in the synovial tissue upon exposure to high 
levels of TGF-β or CTGF, we evaluated the expression of several extracellular matrix components,
matrix proteases, as well as growth factor expression and modulators of collagen cross linking.
First we checked whether the adenoviruses induced expression of human CTGF and porcine 
TGF-β. This showed that the expression of both factors was still elevated at day 21. (Table 2)
Sample Human CTGF Porcine TGF-β
Control virus day 3 nd nd
Control virus day 7 nd nd
Control virus day 21 nd nd
Ad-TGF-β day 3 nd 9.59
Ad-TGF-β day 7 nd 11.16
Ad-TGF-β day 21 nd 13.61
Ad-CTGF day 3 7 nd
Ad-CTGF day 7 10.17 nd
Ad-CTGF day 21 12.97 nd
Table 2 
Ct values of human CTGF and procine TGF-β. Mice were injected intra-articularly with an adenovirus encoding either TGF-β
or CTGF or a control virus. Three, 7 and 21 days after injection of the adenovirus synovial biopsy punches were taken of which
RNA was isolated. Primers detecting only viral CTGF (human, not murine) and only viral TGF-β (porcine, not murine) were
used to evaluate whether expression was sustained over a period of time. Ct values were corrected for GAPDH. Higher Ct
values thus represent a lower expression. Nd = not detectable. Clearly, viral CTGF was only found in synovial biopsy punches
of mice injected with Ad-CTGF and viral TGF-β was only detected in synovial biopsy punches of mice injected with Ad-TGF-β.
The expression levels declined in time, but were still clearly detectable by day 21.
sion was calculated by 2 to the power of delta Ct. Gene expression, after transfection with TGF-β
or CTGF adenovirus, was corrected for GAPDH and compared to the control virus group. The
TGF-β and CTGF that is expressed by the adenovirus is of porcine and human origin respectively.
By designing primers specific for mouse RNA it was possible to discriminate between viral 
TGF-β or CTGF and mouse TGF-β or CTGF. 
CTGF ELISA
To assess the effect of TGF-β overexpression on CTGF levels, we injected 15 C57Bl/6 mice with 
Ad-TGF-β. After 3, 7 and 14 days patella’s were isolated and incubated with DMEM for 24 hours.
The CTGF was measured in the medium by means of sandwich ELISA using 2 distinct monoclonal
antibodies specifically recognizing the N-terminal part of the CTGF protein (FibroGen Inc, San
Francisco, California). Microtiter plates were coated overnight at 4°C with capture monoclonal
antibody (10 µg/ml) in coating buffer (0.05 M sodium bicarbonate; pH, 9.6). The following day,
the plates were blocked with 100 µl of 1% bovine serum albumin in phosphate-buffered saline
for 2 hours at room temperature and washed with wash buffer (phosphate-buffered saline with
0.05% Tween 20). Samples were diluted 5 times in assay buffer (50 mM Tris buffer, pH, 7.7; 0.1%
bovine serum albumin; 4 mM magnesium chloride; 0.4 M zinc chloride; 0.05% sodium azide; 50
mg/l of sodium heparin; 0.1% Triton X-100), and 50 µl of diluted sample was added to each well
with 50 µl of biotinylated monoclonal antihuman CTGF detection antibody in assay buffer. 
Plates were incubated for 2 hours at 37°C, washed with wash buffer, and incubated with 100 µl
per well of streptavidin-conjugated alkaline phosphatase (Jackson Immunoresearch, Cambridge-
shire, England), 1 µg/ml in assay buffer, for 1 hour at room temperature. Plates were washed
again with wash buffer, and 100 µl of substrate solution that contained 1 mg/ml of p-nitrophenyl
phosphate (Sigma, St Louis, Mo) in diethanolamine buffer (1M diethanolamine, pH 9.8; 0.5 mM
magnesium chloride; 0.02% sodium azide) was added to each well. After 20-minute 
incubation in the dark, absorbancies were read at 405 nm on a microplate reader (BioRad 
Laboratories, Hercules, California). Purified recombinant human CTGF (FibroGen) was used as
the standard. All measurements were performed in duplicate.
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Figure 2 
Relative RNA expression levels of various enzymes in the synovial tissue. Mice were injected intra-articularly with an 
adenovirus encoding either TGF-β or CTGF. Three, 7 and 21 days after injection of the adenovirus synovial biopsy punches
were taken of which RNA was isolated. Relative mRNA levels were calculated by correction for GAPDH and for control samples.
CTGF overexpression resulted in elevated levels of MMP3, MMP13, ADAMTS4 and ADAMTS5 after 7 days. The levels of 
elevation do not compare to the highly elevated levels of RNA expression seen after TGF-β overexpression. TGF-β induced
the highest changes on day 7, with most marked changes in expression of MMP3, MMP13 and ADAMTS4. 
III expression. It decreased the expression of collagen type II on all days with a maximum of al-
most 9 fold on day 7. Aggrecan expression had decreased drastically on day 21 (55 fold) (Figure 1B).
Oddly enough, although CTGF is known as a major player in fibrosis, and did induce increased
extracellular matrix and procollagen I in synovial tissue, it did not induce major changes in 
relative RNA expression levels of the expected extracellular matrix components.
Degrading enzymes
Besides inducing expression of several ECM components, TGF-β also induced elevated levels of
several MMPs and ADAMTS. We measured the expression of MMP3, 9, 13 and ADAMTS 4, and 5.
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Extracellular Matrix: Collagen and aggrecan
To evaluate the effect of adenoviral overexpression of both growth factors on the extracellular
matrix, we measured the relative RNA levels of collagen type I, II and III as well as aggrecan. 
Adenoviral overexpression of TGF-β resulted in up regulation of collagen type I mRNA on all
days measured, with a maximum of 37.9 fold compared to controls at day 7. Collagen type II and
III showed only very mild changes, whereas aggrecan expression displayed a striking increase
after injection with the TGF-β adenovirus, which reached a maximum around 7 days after injec-
tion to almost 700 fold (Figure 1A). In contrast to TGF-β, and rather unexpected, CTGF did not
influence the expression of collagen type I mRNA, nor did it induce any changes in collagen type
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Figure 1
Relative RNA expression levels of various ECM
components in the synovial tissue. Mice were
injected intra-articularly with an adenovirus
encoding either TGF-β or CTGF. Three, 7 and
21 days after injection of the adenovirus 
synovial biopsy punches were taken of which
RNA was isolated. Relative mRNA levels were
calculated by correction for GAPDH and for
control samples. TGF-β elevated the expres-
sion of all of the measured ECM components.
The most marked changes were observed in
collagen type I expression and the drastic 
increase in aggrecan expression. In contrast,
CTGF decreased aggrecan expression on day 21.
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Figure 4
Relative RNA expression levels of various growth factors in the synovial tissue. Mice were injected intra-articularly with an
adenovirus encoding either TGF-β or CTGF. Three, 7 and 21 days after injection of the adenovirus synovial biopsy punches
were taken of which RNA was isolated. Relative mRNA levels were calculated by correction for GAPDH and for control
samples. Both TGF-β and CTGF induced elevated levels of TGF-β1 RNA, but the effect was higher after exposure to TGF-β.
In addition, TGF-β overexpression resulted in elevation of CTGF RNA expression.
Expression of TIMPs
As TGF-β induced elevated levels of matrix degrading enzymes, but at the same time induced a
more persistent fibrosis, we additionally evaluated the levels of RNA expression of various TIMPs.
TIMP1 expression was highly elevated by TGF-β overexpression with a maximum of 87.7 times
normal expression by day 7. TIMP2 showed a similar pattern, only in much lower values with a
maximum of 10.1 times normal on day 7 (Figure 3A). CTGF also elevated TIMP1 expression on day
7, but this was much lower (5.7 fold). In contrast to the other TIMPs, TIMP4 was decreased both
by TGF-β and CTGF (Figure 3B).
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Figure 3
Relative RNA expression levels of TIMPs in the synovial tissue. Mice were injected intra-articularly with an adenovirus enco-
ding either TGF-β or CTGF. Three, 7 and 21 days after injection of the adenovirus synovial biopsy punches were taken of
which RNA was isolated. Relative mRNA levels were calculated by correction for GAPDH and for control samples. Injection
of the CTGF adenovirus induced elevated levels of TIMP1 RNA 7 days after injection. The elevation of TIMP1 was much higher
in the group exposed to the TGF-β adenovirus and this was still present on day 21. In addition, TIMP2 was elevated 7 days
after injection of ad-TGF-β. TIMP4 was down regulated by both TGF-β and CTGF.
All of these enzymes had high levels of RNA expression on day 7. Expression of MMP13 elevated
to 94.4 times normal expression on day 7 and to 50 times normal expression by day 21. ADAMTS4
had increased expression on all days measured up to 73.3 times relative to controls on day 7 
(Figure 2A).
Compared to TGF-β, CTGF hardly changed expression levels of any of the enzymes measured. The
biggest change was observed in ADAMTS4 expression that had reached a 5.6 fold increase on
day 7, but this did not linger as it had dropped below normal expression levels by day 21 (Figure
2B). Thus, although TGF-β induced a more persistent kind of fibrosis, it also induces much higher
RNA levels of matrix-degrading enzymes.
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Lysyl hydroxylases
As we found a difference in persistence of the fibrosis between CTGF and TGF-β we also addressed
possibility of differences in cross-linking of the extracellular matrix between the two growth
factors. Hydroxylation of lysine residues is a key step in collagen maturation and determines the
nature of crosslinking. Lysyl Hydroxylase is responsible for converting lysine into hydroxylysine,
thereby inducing a route leading to crosslinks that are more difficult to degrade (25). The family
of lysyl hydroxylases consists of: LH1, LH2 and LH3. LH2 has 2 alternative splice-variants: LH2a and
LH2b. The latter was found associated with overhydroxylation. CTGF had only minimal effect on
LH expression levels, whereas TGF-β induced an elevation of all LH, with the highest levels by day
21. Strikingly, TGF-β overexpression resulted in very high levels of LH2, especially LH2b by day 21,
indicating a high degree of hard to degrade cross-links (Figure 5).
TGF-β induced elevation in CTGF levels
When comparing TGF-β induced fibrosis to CTGF-induced fibrosis, we found that TGF-β over-
expression also enhanced CTGF mRNA levels. Therefore, we measured whether this indeed 
translated into elevated levels of CTGF protein. Three, 7 and 14 days after Ad-TGF-β injection
we isolated the patella-synovial area of the knee joints of the C57Bl/6 mice and incubated them
for 24 hours with DMEM. The protein levels were measured in these wash-outs and showed that
indeed TGF-β overexpression led to elevated levels of CTGF protein which was still elevated at
day 14. (Figure 6) Therefore, during TGF-β induced synovial fibrosis we have to take into account
the potential additional effect of CTGF.
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Figure 6
CTGF protein levels upon Ad-
TGF-β injection. Mice were
injected intra-articularly with
Ad-TGF-β. Three, 7 and 21 days
after injection of the adenovirus
the patella-synovial area was 
isolated and incubated in DMEM
for 24 hours. Protein levels were
measured in the 24 hour wash
outs. Ad-TGF-β exposure clearly
induced elevation of CTGF pro-
tein levels compared to controls.
Figure 5
Relative RNA expression levels of various lysyl hydroxylases in the synovial tissue. Mice were injected intra-articularly with
an adenovirus encoding either TGF-β or CTGF. Three, 7 and 21 days after injection of the adenovirus synovial biopsy punches
were taken of which RNA was isolated. Relative mRNA levels were calculated by correction for GAPDH and for control-
samples. In contrast to CTGF, TGF-β induced elevated expression levels of all measured LH’s. The most marked and most 
interesting change was observed in LH2b expression, which continued to increase until day 21.
Growth factor expression
Adenoviral overexpression of TGF-β mainly induced high relative RNA levels of endogenous 
TGF-β1 and endogenous CTGF. TGF-β1 had been elevated already by day 3, but was highest on
day 7, where it had reached 18.5 fold compared to normal. In contrast, CTGF was induced highest
on day 3, where its expression was 15.8 fold compared to normal CTGF expression. By day 7 it had
decreased, but was still 5.5 fold compared to normal and it continued to decrease to 3.9 fold at
day 21 (Figure 4A). Adenoviral overexpression of CTGF hardly changed any expression levels of
the various growth factors that were assessed. Only a very mild increase of TGF-β1 was found on
day 7 (3.9 fold) (Figure 4B).
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The TIMP1 levels that we found were comparable to those of Bonniaud et al in rat lungs trans-
fected with Ad-CTGF and Ad-TGF-β (4;24). They also found that Ad-CTGF resulted in elevation
of TIMP1 mRNA only on day 7, whereas TGF-β induced elevation TIMP1 mRNA expression was 
persistent until day 21. Their group also found that TIMP1 expression was associated with strain
dependent fibrosis sensitivity in mice (32). In addition, TIMP1 expression has been found associated
with matrix accumulation in other fibrosis disorders (4;33-35). Thus the elevation of TIMP1 might
contribute to persistent fibrosis.
Van der Slot et al found an association between expression of the lysyl hydroxylase 2 isoform
LH2b and overhydroxylation of lysine residues within collagen telopeptides in fibrotic skin of
patients with Systemic Sclerosis (36). They suggested that LH2b plays an important role in the 
irreversible accumulation of collagen in fibrosis. They also showed that fibroblasts of several 
fibrotic disorders had increased levels of LH2b mRNA expression (25). TGF-β was found to be
able to induce LH2b in skin fibroblasts (37). Therefore we also evaluated whether there was a 
difference in lysyl hydroxylase expression in synovial fibrosis induced by TGF-β or CTGF. A 
prominent observation is that TGF-β induced high expression of LH2, especially 2b, whereas CTGF
does not induce any changes in LH mRNA levels. LH2b expression will result in cross-linking of
collagens that are hard to degrade. This might explain why the elevated MMP13 and ADAMTS4
RNA levels do not interfere with the persistence of TGF-β induced fibrosis. This also might explain
why CTGF-induced fibrosis is transient, whereas TGF-β-induced fibrosis lingers for months. It is
still under discussion whether CTGF alone is sufficient to induce fibrotic disorders, or whether it
acts as a downstream mediator of TGF-β in fibrosis induction. TGF-β overexpression results in the
induction of endogenous TGF-β, thereby providing an amplifying loop, which could contribute
to potentiation of the TGF-β induced effects. However, several groups have established that 
fibrosis induced by TGF-β alone was not persistent and that simultaneous application of CTGF
and TGF-β resulted in long-term fibrotic tissue formation in skin of mice (38-40).
One must keep in mind that once TGF-β is overexpressed, CTGF is up regulated resulting in a 
biased comparison. In the case of TGF-β induced fibrosis as we have shown in this paper, CTGF
is induced as well, already on day 3. This implicates that the fibrosis that is observed is no longer
induced by TGF-β alone, but also affected by CTGF. 
This should not be ignored as CTGF has been shown to potentiate TGF-β signaling. In mesangial
cells it has been shown that CTGF can block the negative feedback loop of TGF-β by down
regulating Smad7. Smad7 prevents phosphorylation of receptor Smads that is required for TGF-β 
signaling. CTGF up regulates TIEG which in turn represses Smad7 transcription, thereby allowing
continued TGF-β activation (41). In addition, CTGF has the ability to bind to growth factors like
TGF-β, BMP and VEGF, thereby modulating their function. For example, CTGF binding to BMP4
Discussion 
In this paper we evaluated the differences between TGF-β and CTGF-induced synovial fibrosis on
mRNA levels. We found major differences in expression of collagen type I, aggrecan, TIMP1 and
LH2b on mRNA levels, which were highly up regulated by TGF-β when compared to controls and
to CTGF. These changes might contribute to the more persistent nature of TGF-β induced fibrosis. 
Although we would have expected collagen type I up regulation by both TGF-β and CTGF, we
only found a 1.3 and 1.5 fold up regulation on day 3 and day 7 respectively and 0.73 fold on day
21 after Ad-CTGF exposure. This was unexpected as collagen type I is the major component of 
fibrosis and has frequently been found up regulated by CTGF (21;24;26;27). In addition, we had
previously found an increase in procollagen type I positive cells and an increase in extracellular
matrix in the synovium upon Ad-CTGF injection (23). However, Bonniaud et al found approximately
1.5 fold increase in procollagen type I mRNA expression on day 3 and 7 after Ad-CTGF exposure
and approximately 0.75 fold at day 21, which perfectly fits our results (24). In addition, they did
find a 3 fold up regulation of procollagen type I mRNA at day 14. Thus, we might have missed
the window in which this increased expression could have been found. In addition, the elevation
in collagen type III was also minimal after CTGF overexpression, whereas TGF-β elevated, collagen
type III, but also type II and aggrecan. The expression of aggrecan was elevated already on day
3, but drastically increased on day 7. In contrast, CTGF induced a down regulation of aggrecan
on day 21. Apparently TGF-β also induces a cartilage like-matrix, whereas CTGF does the opposite.
We had expected that the reversibility observed in CTGF-induced fibrosis might be due to a 
higher degree of ECM degradation, but in fact TGF-β exposure lead to elevated levels of MMP 
expression, whereas CTGF hardly influenced any of the MMP levels explored. It gave a slight 
elevation of MMP3 and ADAMTS4 at day 7, but not as high as the levels observed upon TGF-β
stimulation. Of course, the presence of elevated levels of MMP mRNA does not imply high acti-
vity per se as pro-MMPs have to be activated before they can cleave ECM components. But as
TGF-β induced fibrosis is persistent and MMP levels are higher rather than lower when compared
to CTGF induced fibrosis, lower MMP levels are not responsible for TGF-β induced persistence. 
TGF-β also induced elevation in TIMP levels, which are able to inhibit MMPs and might prevent
or reduce MMP-mediated degradation. TIMP1 expression was induced by both TGF-β and CTGF.
However, CTGF only induced TIMP1 expression on day 7, whereas TGF-β induced sustained levels
of TIMP1 mRNA on all days measured. In addition, the levels of TIMP1 expression by TGF-β were
more than 15 times higher compared to CTGF. TIMP1 and TIMP2 have growth-promoting effects
on a variety of cells including fibroblasts, independent of MMP-inhibition (28-30). However,
whereas TIMP1, -3 and -4 can be induced by a variety of stimuli whereas TIMP2 is constitutive (31).
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Introduction
Cartilage damage is a major problem in joint diseases like osteoarthritis (OA) and rheumatoid
arthritis (RA). As a response to cartilage injury, chondrocytes display a reparative response (1,2).
Unfortunately, this response is very limited, resulting in suboptimal repair (3). Until now, 
reparative responses that have been induced by drilling and microfractures are unable to 
overcome this problem (4). They yield a new tissue, often fibrocartilage that does not compare
to original cartilage in structural, biomechanical and biochemical aspects (5). Currently, in 
experimental settings, growth factors are utilized to promote chondrogenic differentiation 
in vitro. This has the potential to eventually produce cartilage that can overcome the current 
problems. 
Bone Morphogenetic Protein-2 (BMP-2) is one of the candidate growth factors with good potential
in cartilage tissue engineering as well as cartilage repair. BMP-2 belongs to the Transforming
Growth Factor-β (TGF-β) superfamily, consisting of TGF-βs, growth differentiation factors, BMPs,
activins, inhibins, and glial cell line-derived neurotrophic factor (6). BMPs have been identified
as very potent inducers of bone, but since then it has become evident that its function is not 
limited to skeletal development (7). BMP-2 expression is found in mesenchymal condensation in
embryonic development (8). BMP-2 is able to induce chondrogenesis in human mesenchymal
stem cells in culture (9). For cartilage reparative reasons BMP-2 can be used to induce chondro-
genesis by coating a scaffold with BMP-2 before implantation (10). Thereby the scaffold itself can
be replaced by the original tissue. This can be combined with culturing mesenchymal stem cells
or tissue specific cells on the coated scaffold to gain de novo tissue formation in the scaffold (11).
Although BMP-2 is able to induce cartilage formation, we found that the expression of BMP-2 in
normal cartilage was low, but that its expression was elevated in area’s surrounding cartilage 
lesions and in OA cartilage (12). In addition, mechanical injury was found to up regulate BMP-2
as well as BMP-2 signaling in human cartilage explants (13). This could indicate that BMP-2 is up
regulated as a reparative response, but could also indicate that BMP-2 is merely up regulated as
a pathological side effect, thereby further stimulating injury. Therefore, the effect of elevated
BMP-2 on healthy cartilage and in cartilage that has been damaged by exposure to IL-1 was
investigated. 
Abstract
BMP-2 has been proposed as a tool for cartilage repair and as a stimulant of chondrogenesis. In
normal cartilage, BMP-2 is hardly present, whereas it is highly expressed during OA. To assess its
function in cartilage, BMP-2 was over expressed in normal murine knee joints and the effects on
proteoglycan synthesis and degradation were evaluated. Moreover, the contribution of BMP to
repair of damage induced by IL-1 was investigated.
Ad-BMP-2 was injected intra-articularly into murine knee joints, which were isolated 3, 7 and 21
days after injection for histology, immunohistochemistry and autoradiography. In addition, 
patellar and tibial cartilage was isolated for RNA isolation or measurement of proteoglycan (PG)
synthesis by means of 35SO4
2- incorporation.
To investigate the role for BMP-2 in cartilage repair, cartilage damage was induced by i.a. injec-
tion of IL-1. After 2 days Ad-BMP-2, Ad-BMP-2 + Ad-gremlin, Ad-gremlin or a control virus were
injected. Whole knee joints were isolated for histology at day 4 or patellae were isolated to
measure 35SO4
2- incorporation.
BMP-2 stimulated PG-synthesis in patellar cartilage on all days and in tibial cartilage on day 21.
Aggrecan mRNA expression had increased on all days in patellar cartilage with the highest 
increase on day 7. Collagen type II expression showed a similar expression pattern. In tibial 
cartilage, collagen type II and aggrecan mRNA expression had increased on day 7 and 21. 
BMP-2 overexpression also induced increased aggrecan degradation in cartilage. VDIPEN 
staining (indicating MMP activity) was elevated on day 3 on tibial cartilage and on day 3 and 7
in patellar cartilage, but no longer by day 21. Increased NITEGE staining (indicating aggrecanase
activity) was found on day 7 and 21. 
In IL-1 damaged patellar cartilage BMP-2 boosted proteoglycan synthesis. Blocking of BMP 
activity resulted in a decreased proteoglycan synthesis compared to IL-1 alone. This decreased
proteoglycan synthesis was associated with proteoglycan depletion in the cartilage.
These data show that BMP-2 boosts matrix turnover in intact and in IL-damaged cartilage. 
Moreover, BMP contributes to the intrinsic repair capacity of damaged cartilage. Increased 
matrix turnover might be functional to replace matrix molecules in the repair of a damaged 
cartilage matrix.
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Functional test Ad-BMP-2 and Ad-gremlin: BRE-luciferase stably transfected cell-line
The BRE-luciferase construct was obtained from Dr. ten Dijke (14). It contains a BMP Responsive
Element (BRE) that drives a luciferase gene. The BRE-luciferase construct was isolated from its
pGL3-Basic vector by cutting with the enzymes MluI and BamHI (New England Biolabs, Ipswich,
MA, USA). The pcDNA3.1(-)/Myc-HisB vector (Invitrogen, Grand Island, N.Y., USA) was cut with the
same enzymes, thereby also removing the CMV-promoter. Subsequently, the BRE-luciferase 
construct was cloned into the pcDNA3.1 vector. After restriction analysis confirming the correct
product, 3T3 cells were transfected with polyfectamin (Invitrogen, Grand Island, N.Y., USA) and
cultured with neomycin (800 μg/ml). By limiting dilution cloning, a cell-line was created. Its 
responsiveness was effectively tested with serial dilutions of BMP-2 (R&D Systems Inc, Minnea-
polis, MN, USA) in culture medium as well as a combination of BMP-2 with several concentrations
of noggin (R&D Systems Inc, Minneapolis, USA).
To test the functionality of the BMP-2 adenovirus, 911 cells were transfected with Ad-BMP-2 (MOI
10). After 48 hours the supernatant of the cells was incubated with the BRE-luciferase cell line.
The luciferase production had reached a maximum, thus production could not be quantified.
Therefore, the supernatant of the transfected cells was diluted 25 or 125 times to measure the
quantity of BMP-2 that was produced. 
To test the functionality of the Ad-gremlin adenovirus 3T3 cells were transfected with Ad-gremlin
(MOI 25). After 28 hours the supernatant of the cells was incubated with the BRE-luciferase cell
line and a variety of known concentrations of BMP-2 protein.
Animals
Male C57Bl/6N mice (n=272) aged 8 weeks were used. Mice were kept in filter top cages with
woodchip bedding under standard pathogen free conditions. They were fed standard diet and
tap water ad libitum. This study has been approved by the Local Animal Experimentation 
Committee, Nijmegen, The Netherlands.
Experimental design
To assess the effect of BMP-2 on normal cartilage, mice were injected intra-articularly with either
Ad-BMP-2 (an adenovirus expressing human BMP-2) or Ad-luc as a control virus (an adenovirus
expressing the luciferase gene) at a pfu of 2x106. After 3, 7 and 21 days knee joints were isolated
for histology, autoradiography and immunohistochemistry (n = 30; 5 mice per group per time
point); for RNA-isolation of tibial and patellar cartilage (n = 54; 9 mice per group per time point)
or for measurement of proteoglycan synthesis by 35SO4
2- incorporation in tibial and patellar 
cartilage (n = 72; 12 mice per group per time point). 
Materials and Methods
Construction of the BMP-2 adenovirus
A PCR was performed on cDNA of synovial fibroblast cells isolated from a human knee joint 
biopsy samples. As primers (Biolegio, Nijmegen, the Netherlands) 5’-CCCAGCGTGAAAGAGA-
GAC-3’ (forward primer) and 5’-AAATCTAGACTAGCGA-3’ (reverse primer) were used, thereby 
introducing the XbaI restriction site. The PCR-product was ligated blunt into the Srf restriction
site of the PCR-Script vector (Statagene, La Jolla, CA , USA). The vector containing the product
was introduced into JM109 cells via heat shock and plated on ampicilin resistant agar plates. 
Several colonies were cultured and the vector was isolated by miniprep (QIAGEN, Venlo, the 
Netherlands) according to manufacturers protocol, followed by restriction analysis. The miniprep
product of one of the colonies that contained the BMP-2 PCR-product was cut with restriction
enzymes XbaI and SalI (New England Biolabs, Ipswich, MA, USA). The same restriction was 
performed on the pShuttle-CMV vector (Statagene, La Jolla, CA , USA). Thereafter, the PCR-
product that was isolated from the PCR-Script vector was ligated into the pShuttle-CMV vector
using T4 DNA Ligase. (Invitrogen, Grand Island, N.Y., USA) The adenovirus was then produced
with the AdEasy Adenoviral Vector System (Statagene, La Jolla, CA , USA) by co-transfection of
the vector with the plasmid in N52E6 cells according to manufacturers protocol.
Construction of the gremlin adenovirus
An adenovirus overexpressing the BMP-inhibitor gremlin was constructed. Therefore, a PCR was
performed on cDNA of 3T3 cells. The following primers were used: (Biolegio, Nijmegen, the 
Netherlands) 5’-ACCACCATGAATCGCACCGC -3’ (forward primer) and 5’- GTCAAAGCGGGCA-
CATTCA-3’ (reverse primer). The PCR-product was ligated blunt into the Srf restriction site of the
PCR-Script vector (Statagene, La Jolla, CA , USA). The vector containing the product was introduced
into JM109 cells via heat shock and plated on ampicilin resistant agar plates. Several colonies
were cultured and the vector was isolated by miniprep (QIAGEN, Venlo, the Netherlands) according
to manufacturers protocol, followed by restriction analysis. The miniprep product of one of the
colonies that contained the gremlin PCR-product was used for PCR again in order to introduce
the XhoI and XbaI restriction sites. This was performed with 5’-CCGCTCGAGACCACCATGAATC-
GCACCGC -3’ as a forward primer and 5’-GCTCTAGATGAATGTGCCCGCTTGAC-3’ as the reverse
primer. The PCR product was cut with XhoI and XbaI. The same enzymes were used to cut the
pShuttle-CMV vector (Statagene, La Jolla, CA , USA). The PCR-product was then ligated into 
the pShuttle-CMV vector using T4 DNA Ligase. (Invitrogen, Grand Island, N.Y., USA) The adenovirus
was produced with the AdEasy Adenoviral Vector System (Statagene, La Jolla, CA, USA) by co-
transfection of the vector with the plasmid in N52E6 cells according to manufacturers protocol.
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the slope of GAPDH standard curve and if the melting curve showed only one product. For each
primer pair non-template controls were run in duplicate. The cycle threshold value (Ct) of the
genes of interest were corrected for the Ct of the reference gene GAPDH. Relative mRNA expression
was calculated by 2 to the power of delta Ct. Gene expression levels after transfection with BMP-2
were compared to the control virus group. If the mRNA expression was higher after 
BMP-2 expression, the fold change is positive, decreases in expression are negative.
Quantitative measurement of proteoglycan synthesis
Proteoglycan synthesis was assessed by measurement of 35SO4
2- incorporation. Isolated patellae
and tibia were immediately placed in DMEM medium (Invitrogen, Grand Island, NY, USA) with
gentamicin (Centrafarm Services B.V, Etten-Leur, the Netherlands) (50 mg/ml) and pyruvate (In-
vitrogen, Grand Island, NY, USA). After half an hour medium was replaced by medium containing
35SO4
2-- (20 μCi/ml) and incubated for 3 hours at 37°C 5% CO2. Thereafter, patellae and tibia
were further prepared for determining amount of 35SO4
2- incorporation in the articular cartilage
as previously described using a liquid scintillation counter (17). Cartilage from the separate 
surfaces of one tibia were pooled.
Autoradiography
For assessment of proteoglycan synthesis the amount of 35SO4
2- incorporation in cartilage was
measured histologically. Mice were injected i.p. with 75 μCi radiolabelled 35SO4
2- 4 hours prior
to knee joint isolation. After histological processing, sections were dipped in nuclear research
emulsion (Ilford, Basildon, Essex, U.K.) and exposed for 4-8 weeks. Slides were developed in
Kodak D-19 developer (Kodak, Chalon-sur-Saone, France) and counterstained with H&E.
Immunohistochemistry: NITEGE 
Sections were deparaffinized and washed with PBS. Sections were incubated in citrate buffer
(0.1 M sodium citrate + 0.1 M citric acid) for two hours for antigen unmasking. Endogenous 
peroxidase was blocked with 1% hydrogen peroxide in methanol for 30 minutes. Sections were
blocked with 5% normal serum of the species in which the secondary antibody was produced.
Specific primary antibodies were incubated overnight at 4°C. To asses degradation of aggrecan
a polyclonal antibody to the aggrecan neoepitope NITEGE (1:1000) (Aggrecan Neo) (Acris, 
Hiddenhausen, Germany) was used. The antibody recognizes CGGNITEGE, which is an epitope 
revealed from aggrecan core proteins upon aggrecanase cleavage at the Glu373-Ala374 site.
After extensive washing with PBS, the appropriate biotin labeled secondary antibody was used
(DAKO, Glostrup, Denmark) for 30 minutes at room temperature followed by a biotin-strepta-
In addition, the role of BMP in the intrinsic cartilage repair upon damage was investigated. 
Therefore, mice were injected with 6 μl solution of IL-1β (10 ng/knee) (R&D Systems, Minneapolis,
USA) in 0.9% NaCl intra-articularly into the right knee joint (n = 116). Two days after IL-1 injection
Ad-BMP-2 (pfu of 2x106), an adenovirus expressing the specific BMP-inhibitor gremlin (Ad-gremlin;
pfu of 1x107) or a combination of both or a control virus (Ad-luc) that has been previously 
described (15) was injected intra-articularly into the right knee joint (pfu of 1x107). Four days
after IL-1 injection patellae were isolated for proteoglycan synthesis measurement by 35SO4
2 -
incorporation (n = 92) or whole knee joints were isolated for histological assessment of proteo-
glycan content of patellar and tibial cartilage (n = 24). Gremlin inhibits not only BMP-2 signaling,
but also that of other BMPs. Therefore, in cases where gremlin was used, BMP instead of 
BMP-2 was mentioned.
Histology
Knee joints of mice were isolated and fixed for 7 days in phosphate buffered formalin. They
were decalcified for a week in 10% formic acid. Knee joints were dehydrated with an automated
tissue processing apparatus (Miles Scientific Tissue-Tek VIP tissue processor, Elkhart, IN, USA) and
embedded in paraffin. Frontal whole sections of 7 μm were made. Sections were used for immu-
nohistochemistry, autoradiography, or stained with Safranin O and counterstained with Fast
Green (Brunschwig, Amsterdam, The Netherlands).
Quantitative PCR
Patellar and tibial cartilage was stripped off the joint as previously described (16) (time points 3,
7, and 21 after injection of the adenovirus, n = 9 per group per time point). RNA was isolated
from the tissue with an RNeasy Mini Kit (QIAGEN, Venlo, the Netherlands) after which an RT-PCR
was performed. Individual samples of each group were pooled and a Q-PCR was run in duplicate.
A Q-PCR was prepared as follows: a primer mix of 1.5 µl forward primer (5 µM), 1.5 µl reverse 
primer (5 µM) and 4.5 μl dH2O, was added to 12.5 µl Sybr Green PCR master mix (Applied Biosystems,
Foster City, CA, USA). Then 5 μl cDNA was added and the Q-PCR was performed by an “ABI/PRISM
7000 sequence detection system” (Applied Biosystems, Foster City, CA, USA) according to 
manufacturers protocol. PCR conditions were: 2 minutes at 50°C and 10 min at 95°C followed by
40 cycles of 15 seconds at 95°C and 1 minute at 60°C, with data collection in the last 30 seconds.
In addition, for each PCR melting curves were run. The genes that were measured and the 
corresponding primer sets are displayed in Table 1. Efficiencies (E) for all primer sets were deter-
mined (Table 1) using a standard curve of 5 serial cDNA dilutions in water in duplicate. Primers
were accepted if the deviation from slope of the standard curve was less than 0.3 compared to
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Results
Ad-BMP-2 and Ad-gremlin tested on stably transfected BRE-luciferase cell line
To examine the efficiency of Ad-BMP-2, 911 cells were transfected with Ad-BMP-2 at a MOI of 10.
The amount of BMP-2 produced in the diluted samples was 40.16 ng/ml in the sample diluted 25
times and 8.39 ng/ml in the sample diluted 125 times. Thus, transfection with MOI 10 Ad-BMP-2
results in a production of 1 μg/ml BMP-2 biologically active protein after 48 hours.
Figure 1
Histological appearance of knee joints injected with an adenovirus overexpressing BMP-2. Right knee joints were injected
i.a. with Ad-BMP-2 or a control virus. Mice were injected with 35SO4
2- prior to knee joint isolation for histology on day 3, 7
or 21. Paraffin sections were stained with Safranin O/Fast Green (A-D), prepared for autoradiography (E-H), stained immu-
nohistochemically for VDIPEN (I-L) or NITEGE (M-P). Controls displayed here are day 3 (A, E, I, M). Cartilage of mice injected
with Ad-BMP-2 appeared to have larger chondrocytes than controls (C, D). Proteoglycan synthesis had increased by 
stimulation with BMP-2 (F-H). BMP-2 stimulation also leads to increased VDIPEN staining (K) and NITEGE staining (Q,P). 
Arrows point to intense staining around chondrocytes. 
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vidin detection system according to manufacturers protocol (Vector Laboratories, Burlingame,
CA, USA). Bound complexes were visualized using diaminobenzidine reagent (Sigma Chemicals
Co, St. Louis, MO USA), counterstained with haematoxylin (Merck, Whitehouse Station, NJ, USA,
dehydrated and mounted with Permount (Fischer Chemicals, Hampton, NH USA).
Immunohistochemistry: VDIPEN staining
After deparaffinization of the sections, they were digested with chondroitinase ABC for 2 hours
at 37°C. Then the sections were treated with 1% H2O2 in methanol for 20 minutes and sub-
sequently washed with 0.1% Triton X-100 in PBS for 5 minutes followed by an incubation in 1.5%
normal goat serum for 20 minutes. The primary antibody was affinity-purified rabbit anti-VDIPEN
IgG, detecting the VDIPEN C-terminal neoepitope of aggrecan generated by MMPs (18-20). The
primary antibody was incubated overnight at room temperature. As a secondary antibody 
biotinylated goat anti-rabbit antibody was used and detected with biotin-streptavidin-
peroxidase staining (Elite kit; Vector Laboratories, Burlingame, CA, USA). Peroxidase staining
was developed using nickel enhancement and counterstained with orange G (2%).
Histological scores
A blinded observer scored sections stained with Safranin O, VDIPEN, NITEGE and autoradiography.
The uncalcified area of the cartilage surfaces was selected in at least 3 sections per knee joint.
The computerized imaging system subsequently determined the area that stained positive and
the total area that was selected. The percentage of the total area that stained positive was 
calculated. A computerized imaging system was used for all histological measurements (Qwin,
Leica Imaging Systems Ltd., Wetzlar, Germany). The obtained values were averaged per knee
joint.
Statistical analysis
Data were analyzed with a student t-test. P values smaller than 0.05 were considered significant.
Error bars in all graphs display the Standard Error of the Mean. Bonferroni correction was 
performed in cases of multiple comparisons.
 
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Co-incubation of several dilutions of BMP-2 protein with the supernatant of cells transfected
with Ad-gremlin showed that gremlin was able to effectively block luciferase expression whereas
supernatant of control virus transfected cells had no effect. Thus transfection with the 
Ad-gremlin adenovirus results in efficient blocking of BMP-2 (Figure 5A).
Histological appearance of cartilage
To assess the effect of BMP-2 overexpression on joint cartilage, C57Bl/6N mice were injected with
either Ad-BMP-2 or Ad-luc. BMP-2 over expression resulted in an altered appearance of chondro-
cytes in the cartilage. The chondrocytes that had been exposed to BMP-2 were larger than nor-
mal. In some joints this was already visible by day 3, but all joints displayed altered chondrocyte
appearance by day 7 (Figure 1A-D). This was more apparent in the patella than in the tibia. 
BMP-2 induces expression of aggrecan and collagen type II 
On mRNA levels Ad-BMP-2 transfection induced elevated expression of the extracellular matrix
molecules collagen type II and aggrecan, both on the tibia and the patella in a similar magnitude.
Aggrecan mRNA was highest on day 7 with 13 and 15-fold increase on patella and tibia respec-
tively. On the patella, collagen type II mRNA had reached a 17-fold increase compared to controls
(day 7). On the tibia collagen type II had increased 12-fold on day 7 and was even higher by day
21 (14-fold increase compared to controls) (Figure 2A and B).
In addition, mRNA levels of collagen type X were measured to investigate the possibility of chon-
drocyte hypertrophy because of the enlarged chondrocytes, but no differences were found 
between BMP-2 exposed cartilage and controls (Figure 2A and B).
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Figure 2
(A and B) Relative mRNA levels expression of extracellular matrix molecules. Cartilage of mice injected with either Ad-BMP-2
or Ad-luc was isolated after 3, 7 and 21 days. Cartilage was pooled per group per time point and RNA was isolated. Ct values
were first corrected for GAPDH, and then corrected for the viral control after which the fold increase/decrease was cal-
culated. Decreases in mRNA levels compared to controls are on the negative scale. (N.D. = not detectable) BMP-2 induced 
elevated levels of collagen type II and aggrecan. No changes were found in collagen type X expression.
(C and D) Effect of BMP-2 over expression on proteoglycan synthesis. Murine knee joints were injected with either Ad-BMP-
2 or a control virus. Cartilage was isolated 3, 7 or 21 days after viral injection and incubated with 35SO4
2- after which the
amount of incorporation was measured (A). In addition, other mice were injected with 35SO4
2- i.p. prior to knee joints were
isolation 3, 7 or 21 days after viral injection for autoradiography. (B) These data show that BMP-2 stimulation of 
cartilage results in increased synthesis proteoglycans. (Statistical analysis with a Student T-test. * = p<0.05 ; ** = p<0.005 ;
*** = p<0.0005)
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Figure 3
Proteoglycan content after ad-BMP-2 injection. Knee joints of mice injected with ad-BMP-2 or a control virus were isolated
at day 3, 7 or 21 and processed for histology. Sections were stained with Safranin O and Fast Green after which Safranin O
staining intensity was measured in the articular cartilage with a computerized imaging system as a measure for proteoglycan
content of the cartilage. At least 3 sections were measured per knee joint. Measurements were averaged per knee joint. 
(Statistical analysis with a Student T-test. * = p<0.05 ; ** = p<0.005 ; *** = p<0.0005)
MMP-mediated proteoglycan cleavage
To explore the possibility of elevated aggrecan degradation upon BMP-2 stimulation, paraffin
sections of the knee joints isolated on day 3, 7 and 21 after Ad-BMP-2 injection and stained 
immunohistochemically for VDIPEN (Figure 1I-L). BMP-2 initially induced an increase in VDIPEN
staining on day 7 in patellar cartilage. In tibial cartilage elevated levels of VDIPEN staining were
found on day 3. A significant decrease in VDIPEN staining was observed on the medial side of
the tibia on day 21 (Figure 4A). 
ADAMTS-mediated proteoglycan cleavage
In addition to VDIPEN staining, NITEGE was stained as well (Figure 1M-P). NITEGE staining was
lower than controls on day 3 in the cartilage on the medial side of the tibia and no differences
in the lateral tibial cartilage after BMP-2 stimulation. By day 7 NITEGE staining had increased in
BMP-2-treated samples with a significant 2.5 fold increase in the patella. By day 21 NITEGE 
staining was still significantly increased in the patella, but no differences were found in the tibia
(Figure 4B).
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BMP-2 induces elevated proteoglycan synthesis
Elevated aggrecan expression was found on mRNA-level. To investigate whether this translated
into an actual production of aggrecan, 35SO4
2- incorporation into patellar and tibial cartilage
was assessed. The cartilage of patella and the tibia were isolated 3, 7 and 21 days after viral 
injection and incubated with 35SO4
2- for 3 hours. The proteoglycan synthesis was found elevated
in all cartilage surfaces. In tibial cartilage, 35SO4
2- incorporation had increased significantly on
day 7 with 2.5 fold compared to Ad-luc controls. In patellar cartilage, the 35SO4
2- incorporation
had reached 2.6 fold by day 3, 2.5 fold on day 7 and 1.7 fold by day 21 (Figure 2C).
In addition, to evaluate whether the increase in 35SO4
2- incorporation was evenly distributed in
the cartilage or incorporated in a more focal fashion autoradiography was performed. 
Therefore, mice were injected with 35SO4
2- prior to knee joint isolation. Autoradiography 
displayed the 35SO4
2- incorporated into the cartilage, which was distributed evenly along the
chondrocytes in the non-calcified cartilage (Figure 1E-H). BMP-2 significantly increased proteo-
glycan synthesis in patellar cartilage on all days, up to almost 3 fold on day 7. The tibia also
showed clear elevated proteoglycan synthesis upon stimulation with BMP-2, which had reached
statistical significance by day 7. In patellar cartilage the elevated proteoglycan synthesis seemed
to have reached a plateau around day 7. In the cartilage of the tibia, 35SO4
2- incorporation 
increased with time (Figure 2D). The data obtained with autoradiography were not exactly 
similar with the data obtained with in vitro 35SO4
2- incorporation. However, the data were 
collected in different experiments and incubation periods and conditions were different (vivo
versus vitro) which could have led to a difference in pattern. In both methods a clear increase in
proteoglycan synthesis was found.
Proteoglycan content
Although elevated levels of proteoglycan synthesis were found, by mere visual investigation,
no differences in Safranin O staining intensity were observed between BMP-2 exposed cartilage
and controls. Therefore, the Safranin O staining intensity was scored in patellar and tibial 
cartilage with a computerized imaging system. There was a significant 30% increase in Safranin
O staining intensity in the patella on day 7. When the data of all time points were pooled a 
significant increase in Safranin O staining was observed. The tibial cartilage however, did not 
display any alterations in Safranin O staining intensity (Figure 3). This is a discrepancy with the
previously found elevated proteoglycan synthesis in the tibia indicating there might be additional
degradation as well. 
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adenovirus gave rise to an increase in proteoglycan synthesis to over 300% compared to normal
turnover proteoglycan synthesis. To investigate the role of endogenous BMP in cartilage repair,
BMP activity was inhibited by adenoviral overexpression of the BMP inhibitor gremlin. The 
adenovirus overexpressing gremlin was found to efficiently block BMP activity (Figure 5A). 
Gremlin expression was not only able to totally abolish the boost in proteoglycan synthesis that
was induced by BMP-2, but restrained the IL-1 related elevation in proteoglycan synthesis (Figure 5B). 
To investigate the influence of the various conditions on the total proteoglycan content, the
staining intensity of the Safranin O was measured in the cartilage. The damage that had been
inflicted by IL-1 had been overcome by the natural repair of chondrocytes by day 4 (Figure 5C).
Although BMP-2 induced an increase in proteoglycan synthesis, the outcome in proteoglycan
content was comparable to the natural reparative response. However, when BMP activity was
blocked by gremlin, the natural reparative response was abolished and resulted in proteoglycan
depletion of the cartilage. 
These data show that not only is BMP-2 able to boost proteoglycan synthesis in damaged 
cartilage, but BMP also plays a role in the natural reparative response of chondrocytes as a 
reaction to damage.
Figure 5A
Role for BMP during natural reparative response to cartilage damage. To test whether the newly synthesized gremlin 
adenovirus was efficient in blocking BMP. 3T3 cells were transfected with Ad-gremlin or a control virus and the 28-hour 
supernatant was incubated with a variety of known concentrations BMP-2 protein and the BRE-luciferase cell line. This cell
line contains a luciferase construct coupled to a BMP-responsive element. Luminescence was measured and showed that 
Ad-gremlin blocked BMP-2 efficiently. (A) 
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Figure 4
Effect of BMP-2 on cartilage matrix degradation. Immunohistochemistry for VDIPEN and NITEGE was performed on paraffin
sections of knee joints 3, 7, and 21 days after Ad-BMP-2 or Ad-luc injection. The area of the cartilage staining positive was
determined with a computerized imaging system. BMP-2 was compared to controls and shows an increase in VDIPEN staining
on day 3 and 7 in patellar cartilage, which was only significant and most prominent on day 7. The elevated VDIPEN staining
had reversed by day 21 to levels lower than controls. (A) NITEGE staining was low on day 3, but was clearly elevated by day
7 on the patella. This had reduced more than 50% by day 21. (B) (Statistical analysis with a Student T-test. * = p<0.05 ;
** = p<0.005 ; *** = p<0.0005)
Role for BMP during natural reparative response upon damage
To assess whether BMP signaling is required for cartilage repair, and whether BMP activity can
enhance cartilage repair, cartilage damage was induced with IL-1. Thereafter, either BMP activity
was blocked, or BMP-2 was added, to see whether this influenced the natural reparative 
response. In vivo exposure of cartilage to IL-1 initially resulted in a decrease in proteoglycan 
synthesis. Thereafter, the synthesis levels quickly elevate even beyond normal turnover levels
(overshoot). This can first be observed around day 4 after a single IL-1 injection (21). On day 4
after IL-1 injection proteoglycan synthesis was significantly increased with 53% beyond that in
cartilage of control knee joints (overshoot) (Figure 5B). Overexpression of BMP-2 with an 
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Discussion
In literature, BMP-2 is proposed as a stimulant for cartilage (re-)generation. BMP-2 is able to 
stimulate proteoglycan synthesis in murine cartilage and enhances collagen type II expression in
chondrocytes seeded in alginate (22,23). Also in species like rats and most important, humans,
BMP-2 is able to stimulate the chondrogenic phenotype on mRNA level and to stimulate cartilage
extracellular matrix proteoglycan production (24,25). In this study, BMP-2 induced an increase in
mRNA levels of collagen type II and aggrecan and stimulated proteoglycan synthesis up to 
3-fold in vivo, both in healthy and in damaged cartilage. All these data, including current data,
confirm a strong anabolic effect of BMP-2 on cartilage.
What most studies neglect to investigate is whether there is a catabolic effect of BMP on intact
cartilage. Indeed BMP-2 exposure led to degradation of aggrecan as shown by the increase in
MMP- and ADAMTS- mediated proteoglycan degradation. This is not necessarily negative for
cartilage integrity, especially if the use of BMP-2 is intended as a stimulant of cartilage repair.
In that case, it is not unlikely that old tissue has to be removed in order to provide space for the
high amounts of newly synthesized extracellular matrix. The catabolic effects that were observed
were temporary, as the evidence for MMP-mediated degradation was totally reversed by day 21
to levels lower than in control cartilage. ADAMTS-mediated degradation lingered, but had also
been reduced more than 50% compared to day 7. The degradational response might be initial
impulse of the chondrocytes to create space in the cartilage for the new tissue that will be 
generated. However, for BMP-2 to have a reparative effect it is crucial that the degradational
properties do not exceed the production of extracellular matrix. Overall, BMP-2 increased 
proteoglycan content in patellar cartilage, showing that although there was degradational 
activity, BMP-2 had an overall anabolic effect. 
The cartilage surfaces that were measured responded differently in the magnitude of their 
response. The conformation of the cartilage is likely to be different, as their weight-baring 
properties require different stiffness of the cartilage. This might also influence the properties of
the chondrocytes in the cartilage, hence their response to a stimulus. However, since the nature
of the response is the same, this indicates that the response that was found is predictive for 
different cartilage surfaces.
Although the overall effect was anabolic, an altered appearance of the chondrocytes was 
observed, which was expected to be an alteration towards a hypertrophic state. On PCR levels
no up regulation of collagen type X was found, nor an up regulation in MMP13 expression. This 
indicates that the altered appearance is not a hallmark of terminal differentiation. Therefore the
possibility of an altered proliferation rate causing the altered appearance was explored, poten-
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Figure 5B + 5C
Mice were injected i.a. with IL-1β to 
induce cartilage damage. After 2 days an
adenovirus expressing either BMP-2, 
BMP-2 + gremlin or a control virus were 
injected. After 4 days patellae were isola-
ted and incubated in medium with
35SO4
2- to assess proteoglycan synthesis
(B), or whole knee joints were isolated to
measure proteoglycan content of the car-
tilage (C). This showed that BMP-2 boosts
proteoglycan synthesis and that blocking
of BMP activity results in an abrogation of
the natural reparative response after 
cartilage damage. (B) Moreover, blocking
of BMP activity with gremlin resulted in
an overall outcome of proteoglycan 
depletion. (C) Ad-gremlin injection alone,
without IL-1, has no effect (data not
shown).
*
*
*** ***
*
*
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to injury in an attempt of the chondrocytes to compensate the catabolic effects of both cytokine
induced and mechanically induced injury. The BMP-2-induced elevated degradational activity is
most likely an attempt to clear away old matrix molecules to make room for the newly synthe-
sized molecules, indicating a role for BMP-2 in cartilage remodeling. Alternatively it can be that
the newly synthesized aggrecan molecules are more vulnerable for degradation leading to 
increased presence of VDIPEN and NITEGE epitopes in the BMP-2 exposed cartilage. 
Conclusions
These data show that BMP-2 exposure resulted in a strong stimulation of proteoglycan synthesis,
both in healthy and in damaged cartilage. Blocking endogenous BMP activity compromised 
cartilage repair. Moreover, BMP-2 clearly elevated degradation of aggrecan, mediated by MMP’s
and ADAMTS. Thus, BMP activity appears to be involved in cartilage repair and the replacement
of damaged matrix molecules. 
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tially causing the cartilage to appear more cellular. Immunohistochemical staining for proliferating
cell nuclear antigen (PCNA) showed no difference between BMP-2 and controls resulting in 
dismissal of this theory (data not shown). The chondrocytes displayed a highly increased proteo-
glycan production, but also a high degree of degradational activity. VDIPEN and NITEGE 
staining was particularly intense in the pericellular area surrounding the unusually large 
chondrocytes. It could be speculated that the degradational activity led to resorbtion of the 
pericellular matrix, combined with a potential activated state of the chondrocyte this could have
given to the impression of cell enlargement.
BMPs are growth factors that are necessary for cartilage formation during embryonic skeletal 
development (26). Lack of BMP signaling in mice will result in loss of cartilage as it wears away
in BMP-receptor1a deficient mice. These data show that BMP is necessary for cartilage mainte-
nance (27). Besides cartilage maintenance, BMP-2 is also beneficial for cartilage repair. This has
been demonstrated by the fact that BMP-2 stimulates cartilage repair in defects filled with 
collagen sponges (28). In addition, utilization of rh-BMP-2 in full thickness defects improves the
properties of the newly synthesized cartilage (29). Our group previously found that BMP-2 was
low in normal cartilage, but was expressed in areas surrounding cartilage damage or in osteo-
arthritic cartilage in mice (12). Nakase et al found a similar localization in humans (30). This 
indicates that BMP-2 is up regulated in injured areas. BMP up regulation was also found in other
kinds of injury like in mechanically injured cartilage explants but also in chondrocytes stimulated
with either IL-1 or TNF-α (13,31). In this study the importance of BMP for cartilage repair was 
confirmed blocking of BMP activity after IL-1 induced cartilage damage resulted in an abrogation
of the natural reparative response by chondrocytes. These data confirm those of Fukui et al,
who demonstrated a similar effect in chondrocytes exposed to TNF-α (32). When BMP activity was
blocked by noggin during TNF-α exposure, the proteoglycan synthesis was reduced. BMP-2 is ap-
parently necessary for cartilage integrity and improves its repair. 
Our group has previously shown that, like BMP, TGF-β increased proteoglycan synthesis and that
blocking of TGF-β abolished the proteoglycan overshoot after IL-1 induced cartilage damage, in
a similar fashion as BMPs ability to do so shown in this paper (33). Blocking either TGF-β or BMP
is apparently sufficient to block the natural reparative response. This indicates that intrinsic TGF β
and BMP act synergistically in IL-damaged articular cartilage. During experimental OA TGF-β 
signaling decreases, whereas BMP-2 expression is induced (12). Taking into account the present
data, one could speculate that the increase in BMP-2 is a means of compensation for the lack of
TGF-β and thus a functional response to injury. The eventual cartilage loss observed in OA shows
that BMP activity alone is not sufficient to adequately protect cartilage against destruction.
Overall these findings imply that the expression of BMP in OA cartilage is an anabolic response
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Introduction
Osteoarthritis (OA) is a major problem amongst the ageing population. The main characteristics
are cartilage degeneration, synovial fibrosis, and osteophytes. The formation of osteophytes is
thought to be a response to either the altered joint loading or to the changed metabolic 
environment in osteoarthritic joints. Osteophytes are considered an attempt of the joint to 
redistribute the altered weight bearing by widening the loading area. Unfortunately this 
attempt is often a waste as the osteophytes result in joint deformation, movement inhibition and
can compress neighboring tissue resulting in pain and loss of joint function. Osteophytes develop
either at the insertions site of tendons (enthesophytes) or arise from the periost covering the
bone. This process starts with chondrogenesis resulting in a cartilage-like structure termed a
chondrophyte. Thereafter, the core of the chondrophyte undergoes hypertrophy followed by 
ossification (chondro-osteophyte). Eventually the entire structure turns into bone (osteophyte).
It is unknown what initiates the osteophyte formation, but it involves both mechanical and 
humoral stimuli. Transforming Growth Factor- β1 (TGF-β1) and (Bone Morphogenetic Protein-2
(BMP-2) are factors that can induce de novo osteophyte formation in normal murine knee joints
(1-4). The chondrogenic phase of osteophyte formation is accompanied by high levels of pro-
teoglycan synthesis (3). Both TGF-β and BMP-2 are able to induce chondrogenesis in stem cells
in vitro (5-8). In addition, both factors are very potent stimulators of proteoglycan synthesis in
cartilage, but with different kinetics. TGF-β induces a lower, but longer lasting stimulation, while
BMP-2 induces a short, but very strong increase in proteoglycan synthesis (3).
Both growth factors are expressed in osteophytes in murine OA (9). Blocking TGF-β during 
murine osteoarthritis has been shown to reduce osteophyte formation indicating that not only
exogenous TGF-β but also endogenously produced TGF-β is able to induce osteophytes (10;11).
Our group has demonstrated that TGF-β is involved in osteophyte formation during experimental
OA, but the role for BMP-2 during this process remained to be elucidated.
We set out to compare location and nature of TGF-β1 and BMP-2 induced osteophytes to those
developing in experimental murine OA. We found that osteophyte formation that occurs during
experimental OA resembles osteophyte formation induced by TGF-β. In this paper we show that
blocking BMP activity during osteophyte development in experimental OA and induced by TGF-β
could not abrogate osteophyte development indicating a very limited involvement for BMP in
early osteophyte formation.
Abstract
Objective
Osteoarthritis (OA) is characterized by cartilage damage, synovial fibrosis and osteophyte form-
ation. TGF-β and BMP-2 can both induce the formation of osteophytes during OA but their 
specific role in this process is unclear. Therefore, we investigated the respective contribution of
TGF-β and BMP-2.
Methods
Murine knee joints were injected with Ad-TGF-β or Ad-BMP-2 and compared histologically to
knee joints of murine models of OA: collagenase injection and STR/ort mice. In addition, 
Ad-gremlin was injected into knee joints injected with Ad-TGF-β or collagenase to further 
investigate the role of BMP during osteophyte formation.
Results
BMP-2 induced early osteophytes bulging out of the growth plates on the femur and growing
on top of the patella, whereas TGF-β induced early osteophyte formation on the bone shaft 
beneath the collateral ligament on the femur, and also on top of the patella. Osteophyte 
formation during experimental OA closely resembled TGF-β induced osteophyte formation, but
differed from the pattern induced by BMP-2.
Ad-gremlin proved to be able to totally block BMP-2 induced osteophyte formation. However,
blocking BMP activity did neither inhibit TGF-β-induced nor experimental OA associated osteo-
phyte formation.
Conclusion
We demonstrate that the role for BMP during onset of TGF-β and experimental OA-induced 
osteophyte formation is limited. The latter does not rule out a role for BMP during osteophyte
maturation.
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was ligated into the pShuttle-CMV vector using T4 DNA Ligase (Invitrogen, Grand Island, N.Y.,
USA). The adenovirus was then produced with the AdEasy Adenoviral Vector System (Statagene,
La Jolla, CA, USA) by co-transfection of the vector with the plasmid in N52E6 cells according to
manufacturers protocol.
Animals
Male C57Bl/6N mice or male STR/ort mice were used. Mice were kept in filter top cages with
woodchip bedding under standard pathogen free conditions. They were fed standard diet and
tap water ad libitum. This study has been approved by the Local Animal Experimentation 
Committee, Nijmegen, The Netherlands.
Testing Ad-BMP-2 and Ad-gremlin in vivo
To test the ability of the BMP-2 adenovirus to induce osteophytes as expected from previous 
results with BMP-2 protein and the ability of the gremlin adenovirus to block the formation of
these osteophytes, we injected the adenoviruses intra-articularly into murine knee joints, thereby
transfecting synovial lining cells.
Therefore, C57Bl/6 mice (n = 48) were injected with either a control virus, Ad-BMP-2 + control
virus, Ad-BMP-2 + Ad-gremlin or Ad-gremlin + control virus at a pfu of 0.5 x107 per virus. Knee
joints were isolated 14 and 28 days after viral injection for histology.
Animal models
Ad-TGF-β in mice
C57Bl/6N mice (n = 24) were injected intra-articularly with Ad-TGF-β223/225 (an adenovirus 
expressing active TGF-β1) (gift by Dr. C.D. Richards) at a pfu of 1x107. Knee joints were isolated
3, 7, 14 and 21 days after injection for histology.
Ad-BMP-2 in mice
C57Bl/6N mice (n = 54) were injected intra-articularly with either Ad-BMP-2 (an adenovirus 
expressing human BMP-2) or Ad-luc as a control virus (an adenovirus expressing the luciferase
gene) at a pfu of 2x106. Knee joints were isolated on day 3, 7, 14, 21 or 28 for histology.
Instability-induced OA
To induce OA, C57Bl/6N mice (n = 30) were injected with collagenase (5 units) to induce joint 
instability. After 3, 7, 14 and 28 days knee joints were isolated for histology.
Materials and Methods
Construction of the BMP-2 adenovirus
A PCR was performed on cDNA of synovial fibroblast cells isolated from a human knee joint 
biopsy samples. As primers (Biolegio, Nijmegen, the Netherlands) we used 5’-CCCAGCGTGAA-
AGAGAGAC-3’ as a forward primer and 5’-AAATCTAGACTAGCGA-3’ as the reversed primer, 
thereby introducing the XbaI restriction site. The PCR-product was ligated blunt into the Srf 
restriction site of the PCR-Script vector (Statagene, La Jolla, CA, USA). The vector containing the
product was introduced into JM109 cells via heat shock and plated on ampicilin resistant agar
plates. Several colonies were cultured and the vector was isolated by miniprep (QIAGEN, Venlo,
the Netherlands) according to manufacturers protocol, followed by restriction analysis. The 
miniprep product of one of the colonies that contained the BMP-2 PCR-product was cut with
restriction enzymes XbaI and SalI (New England Biolabs, Ipswich, MA, USA). The same restriction
was performed on the pShuttle-CMV vector (Statagene, La Jolla, CA , USA). Thereafter, the 
PCR-product that was isolated from the PCR-Script vector was ligated into the pShuttle-CMV
vector using T4 DNA Ligase. (Invitrogen, Grand Island, N.Y., USA) The adenovirus was then 
produced with the AdEasy Adenoviral Vector System (Statagene, La Jolla, CA, USA) by co-
transfection of the vector with the plasmid in N52E6 cells according to manufacturers protocol.
Construction of the gremlin adenovirus
To investigate the involvement of BMP in osteophyte formation we needed a BMP-inhibitor.
Therefore, we constructed an adenovirus that overexpressed the BMP-inhibitor gremlin. A PCR
was performed on cDNA of 3T3 cells. As primers (Biolegio, Nijmegen, the Netherlands) we used
5’-ACCACCATGAATCGCACCGC -3’ as a forward primer and 5’- GTCAAAGCGGGCACATTCA-3’ as
the reversed primer. The PCR-product was ligated blunt into the Srf restriction site of the PCR-
Script vector (Statagene, La Jolla, CA , USA). The vector containing the product was introduced
into JM109 cells via heat shock and plated on ampicilin resistant agar plates. Several colonies
were cultured and the vector was isolated by miniprep (QIAGEN, Venlo, the Netherlands) 
according to manufacturers protocol, followed by restriction analysis. The miniprep product of
one of the colonies that contained the gremlin PCR-product was used for PCR again in order to 
introduce the XhoI and XbaI restriction sites. Therefore we used the primers 5’-CCGCTCGAGAC-
CACCATGAATCGCACCGC -3’ as a forward primer and 5’-GCTCTAGATGAATGTGCCCGCTTGAC-3’
as the reversed primer. The PCR product was cut with XhoI and XbaI. The same enzymes were
used to cut the pShuttle-CMV vector (Statagene, La Jolla, CA, USA). Thereafter, the PCR-product
161160
Scoring of osteophyte size
As no differences in osteophyte incidence were found upon exposure to gremlin, we set out to
investigate whether we overlooked more subtle changes in osteophyte formation. Therefore, we
decided to investigate whether the size of the osteophyte had been altered. Therefore, we chose
to select the osteophyte on the medial side of the joint on the femur just below the collateral
ligament (number 5). This osteophyte, to our experience, is almost always present in our OA
models. Per joint 3 sections were scored containing the (chondro-)osteophyte on the medial side
of the joint on the femur just below the collateral ligament. We captured a picture of this 
(chondro-)osteophyte with a computerized imaging system (Leica) and measured the area of
the (chondro-)osteophyte. This was averaged per joint.
Results 
Testing Ad-BMP-2 and Ad-gremlin in vivo
To verify the activity of BMP-2 we injected Ad-BMP2 intra-articularly into murine knee joints. To
test whether Ad-gremlin was able to block BMP-2-induced osteophyte formation we co-injected
Ad-BMP-2 and Ad-gremlin. This showed that Ad-BMP-2 injection induced osteophyte formation
and that co-injection with Ad-gremlin could totally block osteophyte development induced by
BMP-2 (Figure 1). Intra-articular injection of Ad-gremlin alone did not result in any effects observed
by histology. RNA isolation of the transfected synovial tissue for Q-PCR showed that co-injection
of the adenoviruses did not interfere with the expression of viral BMP-2 or gremlin mRNA (data
not shown).
Osteophytes induced by adenoviral TGF-β overexpression
To investigate the pattern of osteophyte formation induced by TGF-β, we injected murine knee
joints intra-articularly with Ad-TGF-β. TGF-β overexpression induced chondrophyte formation,
which could be evaluated clearly by day 14. Before that time point there were hardly any chon-
drophytes present. The most apparent locations of first chondrophyte development were on
the patella, on the bone shaft beneath the collateral ligament close to the femoral-tibial joint
space both on the tibia and on the femur, neighboring the insertion site of the collateral 
ligament and inside the collateral ligament. By day 21 some of the chondrophytes had developed
into chondro-osteophytes. Although the lateral side of the joint also displayed chondro-osteo-
phytes, the incidence of osteophyte formation was highest on the medial side of the joint. 
Spontaneous OA model
STR/ort mice spontaneously develop OA starting at the age of 8 weeks. We isolated knee joints
of mice aged 8 weeks (n = 18), 6 months (n = 9) and 1 year (n = 11) to investigate osteophyte 
development in this strain.
Role for BMP during TGF-β-induced osteophyte formation
To investigate the role of BMP in TGF-β induced osteophyte formation we evaluated if blocking
BMP could abrogate the osteophyte formation induced by TGF-β. Therefore, we co-injected 
Ad-TGF-β with the BMP-inhibitor Ad-gremlin i.a. into knee joints of C57Bl/6 mice and compared
that to Ad-TGF-β + control virus, Ad-gremlin + control virus or control virus alone at a pfu of 0.5
x107 per virus (n=48 total). Knee joints were isolated 7 and 14 days after viral injection for histology.
Role for BMP during OA-induced osteophyte formation
To investigate the role of BMP during osteophyte formation as seen during experimental OA
knee joints of C57Bl/6 mice (n = 16) were injected intra-articularly with 5 units collagenase. One
day after collagenase injection either Ad-gremlin or a control virus was injected i.a. Knee joints
were isolated after 14 days for histology.
Histology
Knee joints of mice were isolated and fixed for 7 days in phosphate buffered formalin. They
were decalcified for a week in 10% formic acid. Knee joints were dehydrated with an automated
tissue processing apparatus (Tissue Tek VIP, Sakura, Ramsey, MN, USA) and embedded in paraffin.
Frontal whole sections of 7 μm were made. 
Scoring of osteophyte incidence
To investigate patterns of osteophyte formation, we assessed at which locations chondrophytes,
chondro-osteophytes, osteophytes and enthesophytes developed in all knee joints. These were
all termed osteophytes in this scoring system. Every joint was scored for osteophyte formation
at all locations. Locations are numbered 1-9 both on the medial and on the lateral side of the
joint. Locations are: cruciate ligaments (1), on top of the bone of the tibia beneath the collateral
ligament (2), in the collateral ligament (3), on the rim of the meniscus (4), on top of the bone of
the femur beneath the collateral ligament (5), at or around the root of the collateral ligament
on the femur (6), protruding from growth plate on the femur located furthest from the patella,
sometimes extending towards the insert from the collateral ligament (7), protruding from the
growth plate on the femur located close to the patella (8), on top of the patella (9). The percentage
of mice having an osteophyte at each particular location was depicted per time point. (Figure 2)
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Osteophyte induction by adenoviral expression of BMP-2
Adenoviral overexpression of BMP-2 in murine knee joints typically induced chondrophytes 
bulging out of the growth plate on the femur by day 3 (Figure 2). By day 7 chondrophytes were
found on top of the patella and protruding from the growth plate on the tibia (Figure 2). After
14 days the chondrophytes had enlarged and some had developed into chondro-osteophytes.
Twenty-one days after Ad-BMP-2 injection other locations displayed chondro-osteophytes as
well, with a higher incidence on the medial side of the joint. This resulted in restriction of joint
movement as the chondro-osteophyte developing in the collateral ligament eventually fused to
the ones in the meniscus and tibia gradually fixing the joint. By day 28 most of the chondrophytes
had developed into chondro-osteophytes (Figure 1).
Osteophytes during experimental OA
To compare growth factor induced (chondro-)osteophytes to those developing during OA, we
evaluated osteophyte formation in two of our OA models: the instability-induced OA model
(collagenase) and the spontaneous OA model (STR/ort). After induction of instability the first
chondrophytes were found beneath the collateral ligament, clearly present on day 7. At this
time point we also found chondrophytes adjacent to the insertion sites of the collateral ligament.
In addition, we found initial chondrogenesis in the collateral and cruciate ligaments. At day 7 
apparition of osteophytes was restricted to the medial side of the joint. By day 14 chondrophytes
were observed protruding from the growth plates opposite of the patella and on the patella 
itself both on the medial and on the lateral side of the joint. In addition, chondrogenesis on the
outer border of the meniscus could be found, which evolved into a chondro-osteophyte by day
28. (Figure 2)
In the spontaneous OA model the earliest chondrophyte formation was found on the medial
femur beneath the collateral ligament close to the joint space. This could be observed already
in mice aged 8 weeks. In some cases chondrophyte formation adjacent to the insertion site of
the collateral ligament on the femur could be seen as well. By 6 months of age and older 
(chondro-)osteophytes were observed at all locations, but due to the great variability between
mice in this model not all mice displayed osteophyte formation and the locations varied. (Figure 2)
Some mice hardly showed any alterations by 1 year of age whereas others had completely 
deformed joints.
Figure 1
Histology of knee joints injected with a control virus (A, E, I, M, Q, U), Ad-BMP-2 + control virus (B, F, J, N, R, V), Ad-BMP-2
+ Ad-gremlin (C, G, K, O, S, W) or Ad-gremlin + control virus (D, H, L, P, T, X) (n=48 total, n=12 per group). Knee joints were
isolated 14 (A-D; I-L; Q-T) or 28 days (E-H; M-P; U-X) after viral injection. Sections were stained with Safranin O and Fast Green.
Panels represent the patella-femoral area (A-H), the tibial-femoral area on the medial side of the joint (I-P) and on the
lateral side of the joint (Q-X). These pictures clearly demonstrate that Ad-BMP-2 induces osteophyte formation (B, F, J, N,
R, V), which can totally be blocked by co-injection with Ad-gremlin (C, G, K, O, S, W).
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instability-induced OA (collagenase model) (n = 30 in total, n = 10 per group), Ad-TGF-β (n = 24 in total, n = 8 per group)
and Ad-BMP-2 (n = 54 in total, n = 18 per group) induced osteophytes. The numbers on the Y-axis correspond to the numbers 
assigned to the various locations of osteophyte formation. Bars on the left side of the Y-axis represent osteophytes on the
lateral side of the joint whereas bars on the right side represent those on the medial side of the joint. Location nr 1 is a central
location, therefore its depiction on the medial side is arbitrary. The incidence indicates the % of mice having an osteophyte
at a particular location, regardless of the size or developmental stage of the osteophyte. This graph shows that there are
differences in osteophyte formation at early developmental stages of osteophyte formation (black bars) between BMP-2 and
OA-induced osteophytes, whereas TGF-β shows a great deal of overlap with OA-induced osteophytes (black rectangle).
BMP-2 and TGF-β also show some overlap (dotted rectangle).
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Figure 2
Locations of osteophyte formation in the murine knee joint.
Top: Graphical representation of the location of early osteo-
phyte formation corresponding to the black bars depicted in
the graphs in the bottom part of the picture. Bottom: 
Incidence of osteophyte formation at various locations in the
joint, numbered 1-9 both on the medial and on the lateral side
of the joint. We evaluated spontaneous OA (STR/ort model)
(aged 8 weeks (n = 18), 6 months (n = 9) and 1 year (n = 11)),
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Figure 3
Role for BMP in TGF-β- or experimental OA-induced osteophyte formation. We scored the size of the (chondro-)osteophyte
at location nr 5 (see figure 2A) on the medial side of the joint with a computerized imaging system in 3 sections per joint.
This was averaged per joint. (A) Murine knee joints (n = 48 in total, n = 6 per group) were injected with a control virus, 
Ad-gremlin + control virus, Ad-TGF-β + control virus or Ad-TGF-β + Ad-gremlin. Knee joints were isolated for histology at
day 7 or 14 after viral injection. We found that Ad-TGF-β induced osteophyte formation, which could not be abrogated by
simultaneous expression of the BMP-inhibitor gremlin, nor could the size of the osteophyte be altered. The results of day
14 were depicted. (B) Murine knee joints (n = 16 in total, n = 8 per group) were injected with a control virus or Ad-gremlin
1 day after injection of collagenase to induce instability-induced OA. Mice were sacrificed 14 days after injection of collage-
nase. We found that during experimental-induced OA there was osteophyte formation and that blocking BMP with gremlin
during the onset of osteophyte formation did not alter the size of the osteophyte.
Comparison of osteophyte development
To compare osteophyte patterns, the incidence of osteophyte formation at all known locations
of osteophyte formation in the murine knee joint were scored regardless of developmental stage
of the osteophyte (Figure 2).
When comparing the pattern of early osteophyte formation we observed that the location of
origin of the osteophytes induced by TGF-β were very similar to those during experimental OA.
Hardly any overlap between BMP-2 and OA-induced early osteophyte formation was observed
(Figure 2). We found that at late time points almost every location showed osteophytes in some
stage of development, some in chondrophyte phase, others already turned into bone (Figure 2).
The differences that were found at early stages of osteophyte formation were no longer 
apparent at later stages. 
These data suggest that early osteophyte formation as seen during experimental OA more 
closely resembled that of TGF-β induced osteophyte formation, but is not comparable to 
BMP-2 induced osteophyte formation. This indicates that the role for BMP-2 in early osteophyte
development during OA might be very limited.
Involvement of BMP in TGF-β induced and OA-induced osteophyte formation
To further investigate the role of BMP-2, we blocked BMP activity with Ad-gremlin. As there
was overlap between TGF-β and BMP-2 osteophyte formation we first investigated whether BMP
activity plays a role in TGF-β induced osteophyte formation. Blocking BMP during TGF-β-induced
osteophyte formation by co-injection of Ad-TGF-β with Ad-gremlin did not result in changes in
the incidence of osteophyte formation (data not shown). Therefore, we decided also to inves-
tigate whether any differences were found in (chondro-)osteophyte size. We scored the size of
the (chondro-)osteophyte at location 5 (see Figure 2) on the medial side of the joint 14 days after
viral injection, but found no alterations either (Figure 3A). These data suggest that BMP did not
play a role in the initiation of TGF-β induced osteophyte formation.
To evaluate the important question whether BMP is involved in the formation of osteophytes
developing during experimental OA we blocked BMP during this process by intra-articular 
injection of Ad-gremlin. We found no alterations in incidence of osteophyte formation, nor did
we find changes in (chondro-)osteophyte size (Figure 3B). These data strongly suggest a limited
role for BMP in the early formation of OA-induced osteophytes.
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chondrocytes appear and eventually hypertrophic chondrocytes (13). We often find these 
developmental stages within one (chondro-) osteophyte extending from the outer, fibrous layer
towards the core, which is eventually turned into bone. We have shown that TGF-β expression
in chondro-osteophytes is strong in the outer fibrous layer, whereas active TGF-β signaling was
found also in the cartilaginous layer of the chondro-osteophyte, as observed by Smad-2P staining
(9). These data are comparable to those of Horner et al and Dodds et al. Horner et al show 
abundant TGF-β and TGF-β receptor staining in the proliferating layer of the chondro-
osteophyte and the staining decreases towards negative in the mineralized zone, with the 
exception of TGF-β2, which is abundantly expressed in all layers (14). Dodds et al also showed that
TGF-β1 mRNA expression in chondrocytes and that the expression was lost with the progression
towards calcifying cartilage (15). In contrast to TGF-β expression, we found that BMP-2-staining
mainly resided in the pre-hypertrophic chondrocytes. Zoricic did an extensive study of osteo-
phytes from human knee and hip joint, studying BMP-2, 3, 5 and 7 expression. They found no 
expression in proliferating and mature chondrocytes, only BMP-3 in the hypertrophic chondro-
cytes and high expression in osteoblasts. (16) Given the information from the studies mentioned
above one could speculate that both growth factors might be important for different processes
within osteophyte formation. Where TGF-β seems to be very important in the initiating process,
BMPs seems to be involved in later stages in the process of endochondral ossification. Thus, the 
osteophytes at late time points will not solely be a response to one specific growth factor stimulus.
The actual role of osteophytes during the OA process is still unknown. It seems to be a way of
compensating for instability, but apparently they can be a side effect of an elevated growth 
factor level as well. In the latter case we should focus on blocking these growth factors locally
to prevent this problem. However, we have previously shown that both TGF-β and BMPs are 
beneficial for cartilage (2;3;9;10;17-23). We demonstrated that TGF-β expression in cartilage is
correlated with healthy cartilage, and that BMP seems to play a role in cartilage repair, implicating
that the blocking should be local to prevent progression of cartilage damage.
Discussion
In this study we compared osteophyte formation induced by TGF-β and BMP-2 to OA-induced 
osteophyte formation. The ability of TGF-β to induce osteophyte formation had been demon-
strated by our own group earlier and was confirmed by others. We showed that TGF-β protein
injections resulted in osteophyte formation and no differences were found between the 3 
TGF-β isoforms. (1;2) In this paper we demonstrated that there is a significant overlap in location
of TGF-β- and experimental OA-induced osteophyte formation. This confirms our previous 
findings in which we demonstrated that TGF-β plays a role in osteophyte development during
experimental OA (10). 
In contrast to TGF-β, the pattern of osteophyte formation that is displayed upon BMP-2 exposure
is different from that during experimental OA. The pattern of Ad-BMP-2 induced osteophyte
formation was similar to that induced by protein injections (3). The role for BMP during OA-
induced osteophyte formation had not yet been studied. We showed that blocking BMP activity
did not abrogate the osteophyte formation during experimental OA, nor did it interfere with
TGF-β induced osteophyte formation. These data show that TGF-β does not need BMP to induce
osteophytes and that osteophyte formation during experimental OA do not require the presence
of BMP either. However, we blocked BMP during onset of osteophyte formation and therefore
cannot rule out involvement of BMP in osteophyte maturation. 
We could speculate that distinct cell types that are involved in osteophyte formation might cause
the differences we found in location of origin of osteophyte formation. The cells that form the
osteophytes induced by TGF-β and during OA are probably mesenchymal stem cells that reside
in the periost. These cells are thought to be the important originating cells for osteophyte 
formation during OA. Also in vitro they have the capacity to condensate and form cartilage-like
tissue. De Bari et al have shown that cells from human periost, even from aged individuals, are
still able to undergo chondrogenesis (12). In contrast a typical location of osteophyte formation
that was observed upon BMP-2 exposure is cartilage-like tissue bulging out of the growth plate
(Asterisks in Figure 1). We could speculate that BMP-2 to stimulates the cells that already have a
chondrocyte-like phenotype, like those in the growth plate whereas TGF-β stimulates the cells
that originate in the periost (Figure 3a). If this holds true, this might be an explanation for the
differences in time needed to develop an osteophyte. In this case TGF-β might require a cell to
differentiate and condensate prior to the development of cartilaginous tissue, whereas BMP 
initiates outgrowth of more mature tissue, thus requiring less time to develop.
The developmental pattern of osteophyte formation starts with chondrogenic differentiation
within fibrous, mesenchymal tissue followed by the appearance of fibrocartilagenous cells. Then
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Synovial fibrosis: role for TGF-β and CTGF
Besides being an important factor for maintaining cartilage integrity, TGF-β can induce patho-
logy. TGF-β is a major player in fibrotic disorders. One of the symptoms of OA is synovial fibrosis
and TGF-β has been shown not only to be able to induce synovial fibrosis de novo, but also plays
a role in experimental OA-induced synovial fibrosis. We showed that it is possible to isolate the
beneficial effect of TGF-β on cartilage from its fibrotic side effect on synovium by simultaneous
transfection of the synovial lining with both a TGF-β and a Smad7 adenovirus. This way the 
synovial lining was protected from TGF-β as the cells expressed Smad7 and did not respond to
TGF-β. The TGF-β that they produced was secreted into the synovial fluid and could reach the
cartilage where it induced elevation of proteoglycan content, even in a murine OA-model (6)
(Chapter 4). This shows that there are ways to overcome the problem of TGF-β side-effects in the
joint. However, Smad7 is not an easy tool to use in the clinic. Therefore we searched for secondary
mediators that could be blocked thereby abrogating TGF-β-induced fibrosis. In many fibrotic 
disorders, CTGF has been proposed as a downstream mediator of TGF-β that is involved in fibrosis.
Therefore, we investigated the potential role of CTGF in synovial fibrosis. We demonstrated that
CTGF is able to induce synovial fibrosis on its own, but it did not compare to the magnitude and
persistence of fibrosis induced by TGF-β. (9) (Chapter 5). This was most likely caused by TGF-β 
induced lysyl hydroxylase 2b, which causes cross links in collagen which are very hard to degrade.
In skin-fibrosis, Mori et al suggested that TGF-β is needed for the initial impulse to induce fibrosis
and that CTGF is important for maintenance (10). We have found that TGF-β is expressed in OA
synovium mainly in early stages, whereas in later stages of OA CTGF was more abundantly 
expressed (1) (Chapter 2). Thus although CTGF cannot induce persistent fibrosis on its own, its role
is not canceled out by our studies. One must keep in mind that during TGF-β overexpression,
there is always continuous CTGF expression. To investigate the sole contribution of TGF-β it
would be necessary to block CTGF during TGF-β induced fibrosis. 
Besides its role in fibrosis, CTGF has been found to have chondrogenic effects (11-16). In spite of
these findings, adenoviral expression of CTGF in murine knee joints resulted in reduction of 
proteoglycan content of the cartilage indicating deleterious effects (9). Moreover, CTGF over-
expression did not induce osteophyte formation (9) (Chapter 5). Although it is still possible that
CTGF can elicit chondrogenesis under explicit conditions, CTGF injection into murine knee joints
had opposite effects. This might be due to CTGF-induced fibrosis, which can result in excretion
of catabolic factors into the joint, ultimately leading to loss of proteoglycans in cartilage. If 
indeed CTGF mediates or aggravates TGF-β-induced fibrosis it would be very beneficial to block
CTGF to get rid of the TGF-β induced fibrosis while maintaining TGF-β effects on cartilage.
Concluding remarks
Osteoarthritis
Osteoarthritis is a complex disease of which the cause still has to be discovered. Nowadays several
important players in the OA process have been identified, but until now none of them have 
provided a solid target for therapy. Research has revealed that genetic defects in TGF-β or down-
stream in the TGF-β signaling cascade can lead to OA-like or OA-related phenotypes (reviewed
in chapter 1). In a contribution to unraveling the process underlying OA, we set out to investigate
the role of TGF-β in this complex disease. 
TGF-β in cartilage
We demonstrated that there is a correlation between loss of TGF-β signaling via Smad2P in 
cartilage and cartilage damage (1) (Chapter 2). Reduced TGF-β signaling is already apparent in
ageing mice, which precedes OA (2) (Chapter 3). We have shown that abrogating the TGF-β 
signal has a functional consequence: aggravation of cartilage damage (2) (Chapter 3). In other
words, lack of TGF-β makes cartilage susceptible to damage. TGF-β is a potent inducer of 
cartilage ECM synthesis and a very potent counteracting agent of IL-1 actions (3;4). Therefore,
lack of TGF-β causes a reduction in ECM deposition and suppression of catabolic stimuli is 
drastically reduced. Thus, the balance between catabolic and anabolic factors that maintains
cartilage integrity is shifted towards the catabolic side in OA. Not only through elevation of 
catabolic stimuli, but also through a dramatic decrease in anabolic stimuli, like TGF-β. 
Our new findings are in line with older observations at our laboratory in which we found that
with age the ability of TGF-β to counteract IL-1 is drastically reduced (5). This will contribute to
the progressive nature of cartilage damage. The loss of counteraction is most likely due to the
loss in TGF-β receptor expression in chondrocytes that we found during ageing, thereby making
them numb to TGF-β presence (2) (Chapter 3). When OA patients come to the clinic, they already
have cartilage damage. Thus it was important to see whether damaged cartilage still has the 
ability to respond to TGF-β supplementation. We have shown that STR/ort mice, which already
have OA, still have the ability to respond to TGF-β supplementation by up regulating their 
proteoglycan content in their cartilage (6) (Chapter 4). However, the damage that these mice had
at the time of intervention was moderate, indicating that they probably had sufficient TGF-β 
receptors present to respond. In humans, a decrease in TGF-β receptor expression in OA cartilage
was also found (7;8). It will therefore depend on the magnitude of the loss of receptors whether
TGF-β itself can be used for therapeutic purposes to treat OA in humans. 
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Final remarks
There are many questions raised by the “OA disease” that still seek an answer: what causes 
chondrocytes to lose their ability to maintain cartilage integrity? What is the factor, or are the 
combinations of factors, which force chondrocytes to respond? Does the cartilage break down
through factors secreted elsewhere in the joint or is it the chondrocyte itself that decides it needs
a change of scenery? Or maybe a combination of both? What triggers the events? Changes in
synovial tissue or changes in the cartilage? Much research has to be performed to find answers
to these questions. This thesis has contributed to understanding the mechanism underlying OA,
and will provide a stepping-stone towards the development of new OA therapies.
BMP effects in cartilage
We found that expression of BMP-2 is low in normal cartilage, but elevated staining is seen
around osteoarthritic lesions (1) (Chapter 2). We investigated what the effect of BMP-2 was on
cartilage. We found that BMP-2 induced high levels of proteoglycan synthesis, but also induced
increased levels of ECM breakdown. However, overall this resulted in an elevation of proteoglycan
content in the cartilage. Moreover, when endogenous BMP was blocked, this led to aggravation
of IL-1 induced cartilage damage. This showed that the presence of BMP-2 during OA is most 
likely an attempt to repair the damaged cartilage (Chapter 7).
Osteophyte formation: TGF-β versus BMP-2
TGF-β is a potent inducer of osteophytes, but so is BMP-2 (17;18). Our group has previously 
established that TGF-β is an important factor in OA-induced osteophyte formation (19). The role
for BMP during this process has been studied in this thesis and found to be absent during the
onset of osteophyte formation (Chapter 8). The osteophytes that were induced by BMP-2 showed
a different pattern in location of development when compared to TGF-β and OA-induced 
osteophytes. It seems that BMP induces bone formation in cells that are more differentiated 
towards a chondrocyte-like state, whereas TGF-β can already induce bone formation in a more
stem cell-like cells in the periost. We have shown that BMP is not important in the onset of 
TGF-β- or OA-induced osteophyte formation, but it might still play a role in the outgrowth of
the osteophyte towards a bone-structure (Chapter 8). However, if osteophyte formation during
human OA follows the same regimen as during experimental OA, blocking BMP is not useful as
a therapy to prevent osteophyte formation.
Conclusions
We have shown that TGF-β is important for cartilage maintenance, but also for cartilage repair
and that lack thereof predisposes cartilage to develop damage. This suggests that TGF-β is a 
potential tool for repair of OA cartilage or prevention of further degradation. However, TGF-β
application also implies side-effects like fibrosis and osteophyte formation. We have shown that
a potential solution to this problem is compartmentalized inhibition of TGF-β signaling, in 
non-articular tissues. But the application of selective inhibition is not easy. We identified 
secondary mediators of TGF-β effects on synovial fibrosis and osteophyte formation, but these
were not the sole mediators of the eventual effects and therefore blocking these mediators is
not sufficient for therapeutic applications. However, they have contributed to better understand
the underlying process. 
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Een van de belangrijkste cytokinen die in staat is kraakbeenschade te veroorzaken is Interleu-
kine-1 (IL-1). TGF-β is normaliter in staat om IL-1 tegen te werken. (5) Bij veroudering is deze 
capaciteit van TGF-β echter sterk afgenomen. (6) Aangezien veroudering een risicofactor is voor
OA zou deze afname te maken kunnen hebben met een verzwakt TGF-β signaal in ouder kraak-
been, maar mogelijk ook met een verandering in de reactie op IL-1. Om dit te onderzoeken 
hebben we bestudeerd of er bij veroudering van muizen veranderingen optreden in expressie
van TGF-β en TGF-β signaalmoleculen. (hoofdstuk 3) Hieruit bleek dat bij veroudering een 
duidelijke afname in TGF-β signaal waarneembaar was. De expressie van de TGF-β signaal-
moleculen werd niet anders beinvloed door IL-1 in oude muizen. Om uit te zoeken of de afname
van het TGF-β signaal daadwerkelijk een functionele consequentie had hebben we jonge muizen,
die wel normaal op TGF-β kunnen reageren, blootgesteld aan een TGF-β remmer terwijl we
schade induceerden met IL-1. (hoofdstuk 3) Het gebrek aan TGF-β leidde ertoe dat de IL-1 
geïnduceerde schade aan het kraakbeen ernstiger werd dan wanneer er wel endogeen TGF-β
aanwezig was. Dit toont aan dat aanwezigheid van TGF-β essentieel is voor het behoud van 
gezond kraakbeen.
Gebrek aan TGF-β maakt het kraakbeen dus gevoeliger voor schade, maar is het ook mogelijk
om hiervoor te compenseren door extra TGF-β toe te voegen? Om dit te onderzoeken werd er
TGF-β in het kniegewricht gespoten worden, maar hiervan is bekend dat dit voor ernstige bij-
werkingen zorgt. TGF-β is namelijk in staat fibrose en osteofytvorming te veroorzaken. Daarom
was het van belang eerst uit te zoeken of het mogelijk is de positieve en negatieve effecten van
TGF-β te scheiden. (hoodstuk 4) Door het synovium te transfecteren met een adenovirus dat
TGF-β tot expressie brengt, gaan de getransfecteerde cellen TGF-β produceren en uitscheiden in
de gewrichtsholte, waardoor het uiteindelijk bij het kraakbeen terecht kan komen. Door deze 
cellen tegelijk te transfecteren met een adenovirus dat de intracellulaire remmer van TGF-β,
Smad7, tot expressie brengt, gaan deze cellen tevens Smad7 produceren. Omdat dit een intra-
cellulaire remmer is blijft deze in de synoviale cellen en worden deze cellen ongevoelig voor
TGF-β en ontwikkelen geen synoviale fibrose. Door dit systeem toe te passen in muizen met OA
hebben we aangetoond dat het mogelijk is om TGF-β geïnduceerd kraakbeenherstel en fibrose
van elkaar te scheiden. (hoofdstuk 4)
Dit systeem is helaas niet direct toepasbaar in de kliniek. Daarom zou het veel voordelen hebben
als we secundaire mediatoren konden identificeren die door TGF-β aangezet worden tot het
veroorzaken van de bijwerkingen (fibrose en osteofytvorming). In andere ziektebeelden waarin
fibrose een groot probleem is, is aangetoond dat CTGF, een factor die sterk door TGF-β geïn-
duceerd wordt, een belangrijke speler is in het fibrose proces. Dit zou in synoviale fibrose ook
het geval kunnen zijn en daarom hebben we onderzocht of CTGF in staat is synoviale fibrose te
Nederlandse Samenvatting
Osteoartritis (OA), ook wel osteoartrose genoemd, is een veel voorkomende ziekte die met name
bij de oudere bevolking voorkomt. Het kan echter ook veroorzaakt worden door gewrichts-
trauma. Ouderdom en trauma zijn enkele van de bekende risicofactoren voor OA, maar de 
onderliggende oorzaak van het ontstaan van OA is nog onbekend. De belangrijkste symptomen
van OA zijn kraakbeenschade, fibrose van het synoviale weefsel en osteofytvorming (ontstaan
van nieuw bot op de botrand). De schade die aan het kraakbeen ontstaat is een groot probleem
omdat kraakbeen niet de capaciteit heeft zichzelf te herstellen. Kraakbeen bevat weinig 
kraakbeencellen en bestaat grotendeels uit het omliggende weefsel (kraakbeenmatrix). Deze
kraakbeenmatrix bestaat vooral uit collageen type II en proteoglycanen die samen voor de 
veerkrachtige en schokdempende eigenschappen van het kraakbeen zorgen. De kraakbeen-
cellen liggen geïsoleerd in de kraakbeenmatrix zonder bloedvaten en zenuwen, waardoor ze 
volledig afhankelijk zijn van hun omgeving: de kraakbeenmatrix. En juist deze matrix is beschadigd
in OA. Kraakbeencellen kunnen echter wel door groeifactoren aangezet worden tot verhoogde
productie van nieuwe kraakbeenmatrix. Een van de groeifactoren die dit kan doen is TGF-β
(Transforming Growth Factor-β). Wanneer het signaal dat TGF-β aan de chondrocyten geeft 
onderbroken wordt kan dit leiden tot OA-achtige veranderingen in het kraakbeen. (1-4) (hoofdstuk
1) TGF-β is niet alleen in staat kraakbeencellen aan te zetten tot herstel van beschadigd kraak-
been, maar is ook van belang voor het behoud van de integriteit van normaal kraakbeen. Dit
heeft geleid tot de hypothese dat de functionaliteit van het TGF-β signaal gedurende OA is aan-
getast. (hoofdstuk 2) Om deze hypothese te testen hebben wij onderzocht wat er gebeurt met
de expressie van TGF-β en de moleculen die van belang zijn voor het TGF-β signaal (TGF-β recep-
toren en de intracellulaire signaalmoleculen, Smad) gedurende het ontstaan van OA in muis-
modellen voor OA. Hierbij hebben we ontdekt dat 2 TGF-β subtypes, TGF-β2 en TGF-β3 en de
expressie van de TGF-β receptoren sterk afneemt bij progressie van kraakbeenschade gedurende
OA. Ook de fosforylatie van Smad2 (het actief doorgeven van het TGF-β signaal) nam sterk af
en was bijna niet meer aanwezig bij ernstige kraakbeenschade. De afname van het signaal kwam
niet doordat het kraakbeen nergens meer op reageerde. De groeifactor Bone Morphogenetic 
Protein 2 (BMP-2) liet namelijk het omgekeerde patroon zien: deze was vrijwel afwezig in 
normaal kraakbeen, maar kwam verhoogd tot expressie in OA kraakbeen. De afname in het
TGF-β signaal was uitsluitend in het kraakbeen waarneembaar. Elders in het gewricht, waar 
fibrose en osteofyten ontstaan, was juist een toename van TGF-β en het TGF-β signaal 
waarneembaar. Onze data laten zien dat er een duidelijke associatie is tussen kraakbeenschade
en afname van het TGF-β signaal in kraakbeencellen.
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stuk 8) TGF-β is in staat sterk BMP-2 op te reguleren. BMP-2 is dus potentieel een secundaire
mediator van TGF-β geïnduceerde osteofyten en speelt mogelijk ook een rol in OA-geïnduceerde
osteofyten. Om deze rol nader te bestuderen hebben we een vergelijking gemaakt tussen 
osteofyten zoals ze ontstaan gedurende OA in onze muismodellen, TGF-β geïnduceerde 
osteofyten en BMP-2 geïnduceerde osteofyten. Hieruit bleek dat de locaties waarop deze osteo-
fyten ontstaan verschilden tussen de verschillende condities. TGF-β en OA-geïnduceerde 
osteofyten toonden veel overlap in osteofytenpatroon, maar BMP-2-geinduceerde osteofyten
weken sterk af. Deze ontstonden op locaties waar reeds kraakbeen-achtige cellen aanwezig
waren bij de groeischijf, terwijl TGF-β en OA-geïnduceerde osteofyten vanuit het periost 
ontstonden. De verschillende groeifactoren sturen andere celsoorten aan tot het ontwikkelen
van een osteofyt. Eerder heeft ons laboratorium al aangetoond dat TGF-β een rol speelt in OA-
geïnduceerde osteofytvorming en dat wordt door deze data nog eens onderstreept. Het was
echter nog onbekend of BMP-2 een rol speelt in TGF-β geïnduceerde osteofyten en of BMP-2 een
rol speelt in OA-geïnduceerde osteofyten. Door BMP te remmen gedurende het ontstaan van
TGF-β en OA geïnduceerde osteofyten hebben we aangetoond dat in deze vroege fase geen
rol voor BMP is weggelegd. Dit neemt echter niet weg dat BMP mogelijk belangrijk is bij het om-
zetten van de vroege kraakbeenachtige-osteofyt tot bot. (hoofdstuk 8) Dit toont echter aan dat
het remmen van BMP niet kan zorgen voor het blokkeren van TGF-β geïnduceerde osteofyten
en dus niet als target gebruikt kan worden om positieve en negatieve TGF-β effecten te scheiden. 
In dit proefschrift hebben we laten zien dat TGF-β erg belangrijk is voor het beschermen van het
kraakbeen, maar ook in staat is herstel van beschadigd kraakbeen te bevorderen. Om TGF-β als
therapeutische interventie toe te kunnen passen moeten eerst de bijwerkingen hiervan (fibrose
en osteofytvorming) uitgeschakeld worden. Wij hebben aangetoond dat het mogelijk is om 
fibrose uit te schakelen en daarbij het positieve effect op het kraakbeen te behouden. Dit is
echter niet direct toepasbaar in de kliniek. Daarom is er gezocht naar secundaire mediatoren van
TGF-β die mogelijk uit te schakelen zijn om zo de negatieve effecten te voorkomen. CTGF en
BMP-2 dragen echter onvoldoende bij aan respectievelijk TGF-β geïnduceerde fibrose en osteo-
fytvorming om daarmee de negatieve bijwerkingen uit te kunnen schakelen. Onderzoek naar
deze factoren heeft echter wel bijgedragen aan een beter begrip van de onderliggende mecha-
nismen van fibrose en osteofytvorming. 
Ons onderzoek toont aan dat TGF-β een belangrijke speler is in het OA proces en dat beter 
begrip van de werking hiervan kan bijdragen tot het ontwikkelen van therapeutische interventies.
veroorzaken (hoofdstuk 5). Hoewel CTGF synoviale fibrose veroorzaakte in muizenkniëen, was
deze na 28 dagen weer verdwenen. Dit was in tegenstelling tot TGF-β, wat fibrose veroorzaakt
die na 3 maanden nog aanwezig is. Daarnaast zorgde CTGF ook voor een afname van proteo-
glycaan-inhoud van het kraakbeen, dat een essentieel bestanddeel is van de kraakbeenmatrix.
Dit kan echter veroorzaakt zijn door de fibrose die er ontstond. De fibrose kan cytokinen 
uitscheiden die op hun beurt voor de kraakbeenschade zorgen. Om uit te zoeken wat het grote
verschil was tussen TGF-β- en CTGF-geïnduceerde fibrose hebben we het fibreuze synovium 
geïsoleerd en nader bestudeerd. (hoofdstuk 6) Hierbij ontdekten we dat TGF-β zorgde voor
hoge expressie van Lysyl Hydroxylase 2 splice variant b (LH2b). Deze splice variant zorgt voor
cross links in collageen die de collageenstrengen stevig met elkaar verbindt. De door LH2b 
geïnduceerde cross links zijn moeilijker af te breken dan cross links geïnduceerd door LH2a. Dit
zal naar alle waarschijnlijkheid bijdragen aan persistentie van de fibrose. (7) Daarnaast zorgde
TGF-β ook voor hoge TIMP-1 niveau’s, wat sterk geassocieerd is met persistente fibrose (8-11).
Deze effecten werden niet gevonden in synovium dat blootgesteld was aan CTGF. Onze data
tonen aan dat CTGF niet alleen verantwoordelijk is voor de TGF-β geïnduceerde fibrose en dus
niet als target gebruikt kan worden om de fibrose te scheiden van de positieve effecten die 
TGF-β heeft op kraakbeen. Echter, wanneer TGF-β in een gewricht aanwezig was produceerde
deze ook extra CTGF (hoofdstuk 6). Het is dus nog steeds mogelijk dat CTGF wel een bijdrage
levert aan de TGF-β geïnduceerde fibrose.
In hoofdstuk 2 vonden we dat de groeifactor BMP-2 weinig voorkomt in normaal kraakbeen,
maar juist verhoogd aanwezig is in OA-kraakbeen. Wat de functie hiervan is is onbekend.
Daarom hebben wij onderzocht wat BMP-2 doet op kraakbeen. (hoofdstuk 7) BMP-2 zorgde
voor een verhoogde productie van proteoglycanen in het kraakbeen, maar daarnaast zorgde het
ook voor verhoogde afbraak van proteoglycanen. Netto bleef er een verhoging van de proteo-
glycaaninhoud van het kraakbeen over. Om uit te zoeken of dit mogelijk een poging kon zijn
van het kraakbeen tot herstellen van onstane schade hebben we schade geïnduceerd door IL-1
in muizen kniegewrichten. Vervolgens hebben we BMP geblokkeerd met een remmer of extra
BMP-2 toegevoegd. Hieruit bleek dat wanneer BMP werd geremd, de IL-1 geïnduceerde schade
aan het kraakbeen erger werd. Wanneer extra BMP-2 werd toegevoegd resulteerde dit in een
sterke bevordering van kraakbeenherstel. (hoofdstuk 7) Dit toont aan dat de aanwezigheid van
BMP-2 in het beschadigde OA kraakbeen hoogstwaarschijnlijk een poging is tot modelleren en
herstellen van het beschadigde kraakbeen. 
Behalve in OA kraakbeen was BMP-2 ook sterk verhoogd aanwezig in osteofyten. (hoofdstuk 2)
Het is zelfs in staat om nieuwe osteofyten te laten ontstaan in normale muizenkniëen. (hoofd-
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